

George N. Dalekos, MD, PhD, FEFIM, FAASLD

PROFESSOR OF MEDICINE

**PRESIDENT OF THE EUROPEAN FEDERATION OF INTERNAL
MEDICINE (EFIM), CHAIR OF THE EUROPEAN ASSOCIATION
FOR THE STUDY OF LIVER CLINICAL PRACTICE GUIDELINES
FOR AUTOIMMUNE HEPATITIS, FELLOW OF EFIM AND THE
AMERICAN ASSOCIATION FOR THE STUDY OF LIVER
DISEASES (AASLD)**

**HEAD OF THE DEPARTMENT OF
MEDICINE AND THE RESEARCH**

LABORATORY OF INTERNAL MEDICINE

**NATIONAL EXPERTISE CENTER IN AUTOIMMUNE LIVER
DISEASES AND FULL MEMBER OF THE EUROPEAN
REFERENCE NETWORK ON HEPATOLOGICAL DISEASES (ERN-
RARE LIVER), GENERAL UNIVERSITY HOSPITAL OF LARISSA
LARISSA, GREECE**

<http://www.med.uth.gr/internalmedicine/>

**CURRICULUM VITAE
(Brief Edition)**

LARISSA, December 2025

Curriculum Vitae

First name: George
Family's name: Dalekos
Father's name: Nikolaos
Mother's name: Eymorphia
Place of birth: Athens, Greece
Date of birth: November 23, 1960
Citizenship: Greek
Profession: Full Professor of Medicine, Head of the Department of Medicine and the Research Laboratory of Internal Medicine, National Expertise Center in Autoimmune Liver Diseases, Full Member of the European Reference Network on Hepatological Diseases (ERN-Rare Liver), General University Hospital of Larissa, Larissa, Greece
Marital Status: Married, father of two children
Home address: M. Dorotheou 1b, 41447 Larissa, Greece
Office address: Department of Medicine, General University Hospital of Larissa, 41110 Larissa, Greece
Telephone: 0030-241350-2285 (secretary)/ 0030-2410-685726
Fax: 0030-241350-1557
e-mail georgedalekos@gmail.com; dalekos@med.uth.gr
Languages: Greek, English

Education

1985 MD, Athens Medical School, University of Athens, Greece
 1995 Doctoral Thesis, Ioannina Medical School, University of Ioannina, Greece

Professional Experience

Oct 1985 - Nov 1987: Obligatory service in the Greek Army
 Nov 1986 - Nov 1987: House officer, Athens Navy Hospital (during my military service) (Director: Assistant Professor A. Perperas).
 Nov 1987 - May 1988: Research Fellow, Unit of Gastrointestinal Endoscopy, Athens Navy Hospital (Director: Assistant Professor N. Nikolopoulos).
 May 1988 - June 1989: Senior House officer, Division of Internal Medicine, Psychiatric Hospital of Attica (Director: Dr. A. Perrakis).
 July 1989 - Dec 1990: Obligatory medical service in rural area (Health Center of Andros Island).

- January 1991 - May 1992: Honorary Research Fellow, Laboratory of Clinical Immunology, Department of Internal Medicine, Ioannina Medical School, University of Ioannina (Director: Professor H.M. Moutsopoulos).
- May 1992 - May 1995: Chief Resident, Division of Internal Medicine, Ioannina Medical School, University of Ioannina (Directors: Professor H.M. Moutsopoulos until Nov 1993 and then Professor D. Sideris) and Research Associate, Laboratory of Clinical Immunology, Department of Internal Medicine, Ioannina Medical School, University of Ioannina (Director: Professor H.M. Moutsopoulos).
- June 1995 – April 1996: Research Associate, Department of Internal Medicine, (Hepato-Gastroenterology Division) Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos).
- May 1996 - Feb 1997: Senior Registrar in Internal Medicine, Blood Bank at the University Hospital of Ioannina. (Director: Dr. E. Zervou) and Research Associate, Department of Internal Medicine, (Hepato-Gastroenterology Division) Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos).
- March 1997 – Oct 1997: Senior Registrar in Internal Medicine, Division of Internal Medicine, Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos) and Research Associate, Department of Internal Medicine, (Hepato-Gastroenterology Division) Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos).
- Oct 1997 – Oct 1998: Post Doc Research Fellow in the Department of Gastroenterology and Hepatology, Hannover Medical School (Director: Professor M.P. Manns).
- Nov 1998 – Dec 2002: Assistant Professor of Medicine, University of Thessaly, Faculty of Health Sciences, Medical School*.
- Jan 2003 – August 2008: Associate Professor of Medicine, University of Thessaly, Faculty of Health Sciences, Medical School*.
*Chief of the Academic Liver Unit and 2nd Word of Internal Medicine Clinic, University Hospital of Larissa, Greece and Associate Director in the Research Lab of Internal Medicine, University of Thessaly, Medical School, Larissa, Greece since November 1998.
- June 2007 – June 2011: Head of the Research Group of Investigational Medicine, Institute of Biomedical Research & Technology, CERETETH, Larissa, Greece
- August 2008 – now: Full Professor of Medicine, Head of the Department of Medicine, the Academic Liver Unit and the Research Lab of Internal Medicine, University of Thessaly, Medical School, Larissa, Greece.

Licence to Practice Medicine and Speciality Certification

- 1985 Certificate of Registration, as a Medical Practitioner (Ministry of Health, Athens, Greece).
- 1995 Certificate of Internal Medicine

Member of Societies

- 1990 Society for Medical Studies (Greek)
- 1994 Hellenic Association for the Study of the Liver (Greek)
- 1996 Hellenic Society of Internal Medicine (Greek)
- 1996 The New York Academy of Sciences
- 1996 European Society for Free Radical Research

1997	European Association of Gastroenterology and Endoscopy
1997	Hellenic Association of Immunology (Greek)
1997	European Federation of Internal Medicine
1999	European Association for the Study of the Liver
2001	Hellenic Society of Systemic Autoimmune Diseases (Greek)
2001	California Blood Bank Society
2008	International Association for the Study of Liver Diseases (IASL)
2013	American Association for the Study of Liver Diseases (AASLD)
2021	Fellow of the European Federation of Internal Medicine (ID: 7316)
2023	Fellow of the American Association for the Study of Liver Diseases

Awards

1. **Second award of new scientist** by the **Hellenic Hypertension Society** for the study entitled: «*Interleukin-1 β in the systemic circulation of patients with familial hypercholesterolaemia and essential hypertension: additional risk factor for atheromatosis in hypertensive patients?*» presented in the **5th Panhellenic Congress in Hypertension** (February 29-March 2, 1996) as well as in the **16th Scientific Meeting of the International Society of Hypertension** (Glasgow, UK, June 23-27, 1996).
2. **1st Award of the Best Study** by the **Hellenic Society of Gastroenterology** for the study entitled: «*High concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptors (sIL-2Rs) in active ulcerative colitis after the development of a sensitive bioassay (IL-6 dependent mouse hybridoma clone B9)*» presented in the **10th World Congress of Gastroenterology**, Los Angeles, October 2-7, 1994 (preliminary), as well as in the **16th Panhellenic Congress of Gastroenterology**, Athens, October 12-16, 1996 (full version).
3. **First award** by the **Balkan Clinical Laboratory Federation** for the study entitled: «*Acute renal failure due to copper-induced rhabdomyolysis: Localisation of the injury by ¹H-NMR spectroscopy*» presented in the **5th Meeting of Balkan Clinical Laboratory Federation**, Ioannina, October 9-12, 1997.
4. **Second award** in the **8th Hellenic Symposium on Hepatitis C** for the study entitled: «*Anticardiolipin antibodies (a-CLAbs) are not b2-GPI-dependent (non-thrombogenic a-CLAbs): preliminary results in 107 HCV patients from central Greece*» presented in Athens, January 27, 2001.
5. **First award of Poster Session** by the **Hellenic Association for the Study of the Liver** for the study entitled: «*Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis*» presented in the **8th Panhellenic Congress of Hepatology**, Thessaloniki, May 8-11, 2003.
6. **1st Award (Symboulidio award)** by the **Medical Association of Athens** for the **Best Research and Practice** in “*Autoimmune hepatitis and virus induced phenomena*”, Athens, May 2004.
7. **Best Oral Presentation Award** by the **European Society of Hypertension** for the study entitled: «*Effect of hydroxychloroquine treatment on atherosclerosis in ApoE deficient mice*» presented in the **21st European Meeting on Hypertension & Cardiovascular Prevention**, June 17-21, 2011, Milan, Italy.
8. **1st Award for the Best Oral Presentation** in the **10th Congress of the European Federation of Internal Medicine** for the study entitled: “*Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of patients*” presented in Athens, 5-8 October, 2011.

9. **Second Award of Oral Presentation** in the **13th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *“Decreased production of hepcidin in patients with autoimmune liver diseases”* presented in Rhodes Island, May 9-12, 2013.
10. **Award of the Amphiarion Institution for Chemotherapeutic Studies by The Athens Medical Society** for the study entitled: *“Panhellenic study of resistance of Staphylococcus aureus: 2012”* presented in the **39th Annual Panhellenic Medical Congress**, Athens, May 22-25, 2013.
11. **1st Award for the Best Poster Presentation** in the **11th Panhellenic Congress of Clinical Chemistry** for the study entitled: *“Non interventional investigation of liver diseases by using caffeine test detection in urine”* presented in Volos, October 11-12, 2013.
12. **First award for the scientific work** entitled: *“Expression of HIF-1a in atherosclerotic plaques of ApoE knock-out mice under treatment with hydroxychloroquine”* presented in the **20th Congress of Greek Medical Students**, Thessaloniki, May 9-11, 2014.
13. **1st Award of Oral Presentation** in the **1st Panhellenic Congress of Continuing Education in Internal Medicine** for the study entitled: *“Long-term outcome of patients with autoimmune hepatitis (AIH) receiving Mycophenolate Mofetil (MMF) as first line treatment”* presented in Thessaloniki, February 26-28, 2015.
14. **3rd Award of Best Oral Presentation** in the **14th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *“Decrease serum DNase-I activity in patients with autoimmune liver diseases”* presented in Kos Island, May 7-10, 2015.
15. **2nd Award of Best Poster Presentation** in the **14th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *“Treatment of portal thrombosis in cirrhotic patients”* presented in Kos Island, May 7-10, 2015.
16. **1st Award of Best Poster Presentation** in the **14th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *“The role of mitogen-activated protein kinase p38 (p38MAPK) pathway on the natural history of chronic HBV infection”* presented in Kos Island, May 7-10, 2015.
17. **The work entitled:** *«Prompt initiation of intravenous corticosteroids prevents deterioration of acute/severe autoimmune hepatitis (AS-AIH) and the need for liver transplantation (LT)»* was selected for **presentation** in a **poster tour (Chair: P. Invernizzi)** during the **International Liver Congress™ 2017, 52th Annual Meeting of the European Association for the Study of the Liver**, Amsterdam, The Netherlands, April 19-23, 2017.
18. **2nd Award of the Best Case Report (Oral Presentation)** in the **Educational Two-Day Conference of the Department of Northern Greece “Macedonia” of the Hellenic Society of Gastroenterology** entitled: *“Reversion of decompensated cirrhosis in a patient with autoimmune overlap syndrome”* presented in Thessaloniki, May 12 & 13, 2017.
19. **1st Award of Best Oral Presentation** in the **15th Panhellenic Congress of the Hellenic Association for the Study of Liver** for the study entitled: *“Importance of IP10 in patients with HBeAg-negative chronic hepatitis B who interrupt long-term therapy with entecavir or tenofovir: Prospective study DARING-B”* presented in Larissa, May 25-27, 2017.
20. **1st Award of Best Oral Presentation** in the **37th Panhellenic Congress of the Hellenic Society of Gastroenterology** for the study entitled: *“DAA in the modern clinical practice for the treatment of chronic hepatitis C. HERACLIS: A Greek multicenter prospective clinical study”* presented in Thessaloniki, October 5-7, 2017.
21. **The work entitled:** *«Time trends in major hepatic complications in primary biliary cholangitis: incidence and transplant-free survival»* received the **AASLD Foundation Abstract Award**

Recipient during The Liver Meeting, 68th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, USA, October 20-24, 2017.

22. **The work entitled:** *«Time-dependent factors associated with diminished transplant-free survival in patients with primary biliary cholangitis and an optimal response to ursodeoxycholic acid after one year of treatment»* received the **AASLD Presidential Poster of Distinction** during **The Liver Meeting, 68th Annual Meeting of the American Association for the Study of Liver Diseases**, Washington, USA, October 20-24, 2017.
23. **1st Award of Best Oral Presentation** in the **16th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *“Metabonomic profile of patients with autoimmune hepatitis at diagnosis and during remission by ¹H NMR spectroscopy”* presented in Athens, May 4-6, 2018.
24. **The work entitled:** *«Impact of geographical region on death or transplantation and on malignancy in primary sclerosing cholangitis - a multicenter retrospective study of the international PSC study group (IPSCSG)»* received the **AASLD Presidential Poster of Distinction** during **The Liver Meeting, 69th Annual Meeting of the American Association for the Study of Liver Diseases**, San Francisco, USA, November 9-13, 2018.
25. **3rd Award of Best Oral Presentation** in the **17th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *“Significance of serum HBsAg levels on the prognosis of non-cirrhotic patients with chronic HBeAg negative hepatitis B who discontinue long-term antiviral therapy”* presented in Kalamata, May 9-11, 2019.
26. **The work entitled:** *«Altered expression of DNA methylation/hydroxymethylation enzymes in patients with autoimmune hepatitis»* received the **FDIME (Federation for the Development of Internal Medicine in Europe) Research Grant Award** during the **18th European Congress of Internal Medicine of the European Federation of Internal Medicine**, Lisbon, Portugal, August 29-31, 2019.
27. **The work entitled:** *«The diverse face of familial Mediterranean fever (FMF) in Greece: The importance of R202Q mutation of Mediterranean fever (MEFV) gene»* received the **FDIME (Federation for the Development of Internal Medicine in Europe) Best Research Abstract Award** during the **18th European Congress of Internal Medicine of the European Federation of Internal Medicine**, Lisbon, Portugal, August 29-31, 2019.
28. **1st Award of Best Oral Presentation** in the **18th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *“Epigenetic alterations in autoimmune hepatitis (AIH)”*, Athens, September 11-13, 2020.
29. **1st Award of Basic research** in the **9th National Congress of the Hellenic Atherosclerosis Society** for the study entitled: *“Crocic acid exerts antiatherogenic effects in apolipoprotein E knockout mice via modulation of endothelial nitric oxide synthase and hypoxia-inducible factor 1 alpha”*, Ioannina, December 3-5, 2020.
30. **1st Award of the Best Oral Presentation** in the **19th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *“Alterations of DNA methylation in isolated genes of peripheral CD4(+) T-cells of patients with autoimmune hepatitis (AIH)”*, Athens, May 6-9, 2021.
31. **3rd Award of Oral Presentation** in the **9th Panhellenic Meeting on AIDS, Hepatitis & Emerging Diseases**, for the study entitled: *“Immunomodulation and thromboembolic risk in hospitalized COVID-19 patients: Systematic review and meta-analysis of randomized trials”*, Athens, September 23-25, 2021.
32. **3rd Award of Oral Presentation** in the **24th Panhellenic Congress of Internal Medicine**, for the study entitled: *“Need for individualized combination immunotherapies in SARS-CoV-2”*

infection: Data form a large cohort of consecutive patients with COVID-19", Athens, November 3-6, 2021.

33. **Award "S. Papastamatis"** in the **48th Annual Congress of the Athens Medical Society** for the study entitled: *"Immune deregulation in SARS-CoV2 infection: A new disease entity"*, Athens, May 12-14, 2022.
34. **Award of the Best Oral Presentation** in the **20th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *"Patients with chronic liver diseases with hospitalization because of SARS-CoV-2 infection – Experience of the Infectious Disease Unit of the Department of Medicine of the General University Hospital of Larissa"*, Thessaloniki, May 26-29, 2022.
35. **The work entitled:** *"Non-invasive biomarkers for the assessment of liver fibrosis in multi-transfused patients with thalassemia major"* received the **FDIME (Federation for the Development of Internal Medicine in Europe) Best Research Abstract Award** during the **20th European Congress of Internal Medicine of the European Federation of Internal Medicine**, Malaga, Spain, June 9-11, 2022.
36. **1st Award of Best Oral Presentation** in the **25th Panhellenic Congress of Internal Medicine** for the study entitled: *"Soluble interleukin-2 receptor (SIL-2R): Prognostic factor for the development of severe respiratory failure and mortality of patients with COVID-19"*, Athens, October 5-8, 2022.
37. **1st Award of Best Oral Presentation** in the **42nd Panhellenic Congress of Gastroenterology** for the study entitled: *"Assessment of underdiagnosis and prevalence of HDV infection in HBsAg-positive patients - HERACLIS-HDV: HELLENIC MULTICENTER REAL-LIFE CLINICAL STUDY FOR HDV"*, Athens, November 10-13, 2022.
38. **First Award "S. Papastamatis"** in the **49th Annual Congress of the Athens Medical Society** for the study entitled: *"Clarithromycin positioning for early clinical response and containment of inflammatory complications in community-acquired pneumonia"*, Athens, May 11-13, 2023.
39. **Award for the Best Study** in the **21st Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *"The significance of patatin-like phospholipase domaincontaining protein-3 I148M genetic variant in autoimmune hepatitis"*, Ioannina, May 17-20, 2023.
40. **Award of Best Poster Presentation** in the **26th Panhellenic Congress of Internal Medicine** for the study entitled: *"Reversible pneumonic arterial hypertension in a patient with leptospirosis"*, Athens, October 18-21, 2023.
41. **The work entitled:** *"Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis (AIH)"* received the **First Prize Award of the session of Best Abstracts of the Young Internists** in the **22nd European Congress of Internal Medicine of the European Federation of Internal Medicine**, Istanbul, Turkey, March 6-9, 2024.
42. **Award for the Best Study** in the **22nd Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: *"Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis (AIH)"*, Chania, April 24-27, 2024.
43. **Award "S. Papastamatis"** in the **50th Annual Congress of the Athens Medical Society** for the study entitled: *"IFN- γ -driven endotypes: New perspectives in the functional classification of patients with sepsis"*, Athens, April 25-27, 2024.
44. **Third Award of the Best Oral Presentation** in the **27th Panhellenic Congress of Internal Medicine** for the study entitled: *"Characteristics of cirrhotic patients with autoimmune hepatitis: Results from the registry of the Hellenic Autoimmune Liver Diseases Study Group of the Hellenic Association for the Study of the Liver"*, Athens, October 2-5, 2024.
45. **Second Award of the Best Oral Presentation** in the **24th Panhellenic Congress of the Hellenic Association for the Study of the Liver (HASL)** for the study entitled: *"Unmet needs*

of patients with primary biliary cholangitis in Greece: Results from the Hellenic Autoimmune Liver Diseases Study Group of HASL, Thessaloniki, May 14-17, 2025.

46. **Second Award of the Best Oral Presentation** in the **28th Panhellenic Congress of Internal Medicine** for the study entitled: *“Unmet needs of patients with primary biliary cholangitis in Greece: Results from the first analysis of the Hellenic Autoimmune Liver Diseases Study Group of the Hellenic Association for the Study of the Liver”*, Athens, September 24-27, 2025.

Other activities

1. **Official Member of the International Autoimmune Hepatitis Group** (IAIHG, Decision of the Executive Committee since 2002-now).
2. **Member of the Provisional Steering Committee** of the IAIHG (Paris, April 2018).
3. **Regular and adhoc Reviewer for Research Projects in Gastroenterology and Hepatology** on behalf of *Wellcome Trust (England)*.
4. **Regular and adhoc Reviewer for Research Projects** on behalf of the *Medical Research Council, UK*.
5. **Regular and adhoc Reviewer for Research Projects** on behalf of the *Austrian Science Fund, Austria*.
6. **Member of the International PSC Study Group** (2012-now).
7. **Official peer reviewer for research projects of the University of Bologna** (2013-now).
8. **Member of the Hepatitis Delta International Network**.
9. **Principal and/or secondary Supervisor of 35 PhD students (2000-2018) who have completed efficiently their thesis (in most cases on issues on liver autoimmunity or chronic viral hepatitis B and C)**.
10. **Regular or Adhoc Reviewer for 171 journals:** Acta Parasitologica, Advances in Clinical Chemistry, Advances in Medical Sciences, African Journal of Parasitology Research, Age & Ageing, Aging Clinical and Experimental Research, Alimentary Pharmacology & Therapeutics, Annals of Gastroenterology, Annals of Gastroenterology and Digestive Disorders, Annals of Hepatology, Annals of Internal Medicine, Annals of Translational Medicine, Applied Physiology Nutrition and Metabolism, Archives of Hellenic Medicine, Archives of Organ Transplantation, Archivum Immunologiae et Therapiae Experimentalis, Arthritis Research & Therapy, Autoimmunity, Autoimmunity Highlights, Autopsy and Case Reports, BioMed Research International, Biomedical and Environmental Sciences, British Journal of Medicine and Medical Research, BMC Gastroenterology, BMC Public Health, BMJ Case Reports, BMJ Open Gastroenterology, Canadian Journal of Gastroenterology and Hepatology, Canadian Journal of Physiology and Pharmacology, Cancer Investigation, Cancer Management and Research, Case Reports in Infectious Diseases, Case Reports in Orthopedics, Cells, Cell and Tissue Research, Central European Journal of Immunology, Clinica Chemica Acta, Clinical Chemistry and Laboratory Medicine, Clinical and Experimental Immunology, Clinical and Experimental Medicine, Clinical Immunology, Clinical Infectious Diseases, Clinical Neurology and Neurosurgery, Current Clinical Pharmacology, Current Pharmaceutical Design, Digestive Diseases and Sciences, Current Oncology, Digestive and Liver Disease, Disease Markers, Epigenomics, European Journal of Clinical Investigation, European Journal of Clinical Microbiology & Infectious Diseases, European Journal of Internal Medicine, European Journal of Obstetrics & Gynecology and Reproductive Biology, European Journal of Therapeutics, European Medical Journal, Expert Opinion on Drug Metabolism and Toxicology, Expert Opinion on Pharmacotherapy, Expert Review of Anti-infective Therapy, Expert Review of Clinical Immunology, Expert Review of Gastroenterology and Hepatology, Expert Review of Molecular Diagnostics, Folia Medica,

Future Microbiology, Frontiers in Immunology, Future Virology, Gastroenterology, GERMS (Official Journal of the European HIV/AIDS and Infectious Diseases Academy), Gut, Hellenic Journal of Medicine, Hemodialysis International, Hepatic Medicine: Evidence and Research, Hepatitis Monthly, Hepatology, Hepatology International, Human Immunology, Immunological Investigations, Immunology Letters, Immunometabolism, Immunotherapy, Infection and Drug Resistance, Infection Genetics and Evolution, International Journal of Applied Microbiology and Biotechnology Research, International Journal of Artificial Organs, International Journal of Biochemical Research & Review, International Journal of Hepatology and Gastroenterology, International Journal of Immunopathology and Pharmacology, International Journal of Infectious Diseases, International Journal of Medical Sciences, International Journal of Respiratory and Pulmonary Medicine, International Journal of Tropical Disease & Health, International Research Journal of Biochemistry and Biotechnology, International Urology and Nephrology, Iranian Red Crescent Medical Journal, Journal of Autoimmune Diseases, Journal of Autoimmune Diseases and Rheumatology, Journal of Bacteriology and Parasitology, Journal of Bioenergetics and Biomembranes, Journal of Blood Disorder and Medicine, Journal of Cancer Research and Therapeutics, Journal of Cancer and Tumor International, Journal of Clinical Gastroenterology, Journal of Clinical Investigation, Journal of Clinical Laboratory Analysis, Journal of Clinical and Laboratory Medicine, Journal of Clinical Pathology, Journal of Clinical Pharmacy and Therapeutics, Journal of Clinical and Translational Hepatology, Journal of Digestive Diseases, Journal of Digestive Diseases and Hepatology, Journal of Gastroenterology and Hepatology, Journal of Gastrointestinal and Liver Diseases, Journal of Hepatitis, Journal of Hepatocellular Carcinoma, Journal of Hepatology, Journal of Hepatology Reports, Journal of Immunological Methods, Journal of Infection, Journal of Laboratory and Clinical Medicine, Journal of Laboratory Medicine, Journal of Medical Virology, Journal of Microbiology, Immunology and Infection, Journal of Microbiology and Infectious Diseases, Journal of Postgraduate Medicine, Journal of Rheumatology, Journal of Translational Internal Medicine, Journal of Veterinary Science, Journal of Viral Hepatitis, Journal of Virology and Microbiology, Journal of Zhejiang University-SCIENCE B, Lancet Global Health, Lancet Infectious Diseases, Liver International, Medical & Biological Engineering & Computing, Medical Science Monitor, Mediterranean Journal of Hematology and Infectious Diseases, Memorias do Instituto Oswaldo Cruz, Merit Research Journal of Medicine and Medical Sciences, Metabolism, Microbes and Infection, MicroRNA, Mini – Reviews in Medicinal Chemistry, Molecular and Cellular Endocrinology, Molecules, OBM Transplantation, OncoImmunology, Open Access Surgery, Open Life Sciences, Open Rheumatology Journal, Ophthalmology, Pathogens and Global Health, PEDIATRICS, QJM, Redox Report, Reviews in Medical Virology, Scandinavian Journal of Gastroenterology, Scientific Reports, SciFed Biotech and Bioengineering Journal, Stem Cells International, Therapeutic Advances in Gastroenterology, Therapeutic Advances in Infectious Diseases, Therapeutics and Clinical Risk Management, Tissue and Cell, Turkish Journal of Gastroenterology, United European Gastroenterology Journal, Viruses, World Journal of Cardiology, World Journal of Clinical Cases, World Journal of Gastroenterology, World Journal of Hepatology.

11. **Reviewer of abstracts** on behalf of the **International Liver Congress (EASL Annual meetings)**, years 2012, 2013, 2014, 2022, 2023 and 2024).
12. **Member of the Global PBC International Study Group** (2014-now).
13. **Assistant Editor and Section Editor** in Immunology for *the Hellenic Journal of Gastroenterology* (1997 – 1999; now *Annals of Gastroenterology*).
14. **Member of the Editorial Board and Section Editor** for Autoimmune Liver Diseases and Virus Induced Autoimmunity in the *Journal of Autoimmune Diseases* (2004-2009).
15. **Member of the Editorial Board** of *Journal of Hepatology* (2007-2009 and 2010-2014).

16. **Member of the Editorial Board** of *Liver International* (2008-2012).
17. **Member of the Editorial Board** of *World Journal of Gastroenterology* (2007-2009 and 2014-2017).
18. **Member of the Editorial Board** of *Autoimmune Diseases* (2009-2014).
19. **Member of the Editorial Board** of *World Journal of Gastrointestinal Pathophysiology* (2011-2015).
20. **Member of the Editorial Board** of *World Journal of Hepatology* (2013-2017).
21. **Member of the Editorial Board** of *Journal of Translational Internal Medicine* (2014-now).
22. **Member of the Editorial Board** of *Hellenic Journal of Medicine (Official Journal of the Internal Medicine Society of Greece)* (2013-2018).
23. **Academic Editor** of *Case Reports in Infectious Diseases* (2018-2021)
24. **Member of the Editorial Board** of *Journal of Autoimmune Diseases and Rheumatology* (2018-2022).
25. **Member of the Editorial Board** of *Immunity (Official Journal of the Hellenic Society of Immunology)* (2018-2022).
26. **Member of the Editorial Board** of *Cancers* (2019-now).
27. **Member of the Editorial Board** of *European Journal of Internal Medicine* (2020-now).
28. **Fellow of the European Federation of Internal Medicine** (ID: 7316), 2021.
29. **Member of the Editorial Board** of *Journal of Translational Autoimmunity* (2023-now).
30. **Fellow of the American Association for the Study of Liver Diseases (AASLD), 2023.**
31. **Participant principal investigator** in 77 clinical trials (55 international + 22 Greek) on liver, infectious, autoimmune and autoinflammatory diseases.
32. **Collaboration** with Professor D. Vergani (King's College London) and Professor J. Rodes (Barcelona, Spain) on the prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis published in *Gut* (see Original Articles No: 40), on the clinical significance of isotype specific antimitochondrial antibodies in primary biliary cirrhosis published in *Liver International* (see Original Articles No: 63) on the clinical significance of anti-gp210 antibodies published in *Hepatology* (see Letters No: 14) and on the significance and correlation of AMA detected by indirect immunofluorescence and immunoblot published in *Clin Chim Acta* (see Original Articles No: 60).
33. Sponsor and **principal investigator** along with Professor M.P. Manns (Hannover, Germany) and Professor C. Yurdaydin (Ankara, Turkey) on Investigator Protocol entitled: "A multicenter randomized study comparing the efficacy of adefovir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adefovir dipivoxil plus pegylated interferon-alfa-2a for the treatment of chronic delta hepatitis" (2004-2006), published in several journals including *Liver International*, *New England Journal of Medicine*, *Antiviral Therapy*, *Journal of Viral Hepatitis*, *Turkish Journal of Gastroenterology*, *Hepatology*, etc. (see Original Articles No: 74, 79, 82, 85, 88, 99, 100, 110, 133, 158, 251).
34. **Collaboration** with Prof. M.P. Manns (Hannover, Germany) and Prof. H. Tillmann (Leipzig, Germany) on the safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience, which is published in *Journal of Viral Hepatitis* (see Original Articles No: 49).
35. **Collaboration** with Prof. M.P. Manns (Hannover, Germany) and Prof. H. Wedemeyer (Hannover, Germany) on the cross-genotype reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073 which is published in *Vaccine* (see Original Articles No: 112).

36. **Participant principal investigator** in a multicentre study of the International Autoimmune Hepatitis Group regarding the development of the simplified criteria for the diagnosis of autoimmune hepatitis published in *Hepatology* (see Original Articles No: 65).
37. **Collaboration** with Prof. G.V. Papatheodoridis, Prof. P. Lampertico and Prof. M. Buti on the development of a prognostic score (PAGE-B) for the detection of HCC in chronic anti-HBe positive chronic HBV patients under treatment with entecavir or tenofovir which is published in *J Hepatol* (see Original Articles No: 102 and 115).
38. **Principal investigator and Co-ordinator** in a funding project by the Hellenic Association for the Study of the Liver (HASL) entitled: «Metabonomic profile of patients with autoimmune liver diseases by NMR spectroscopy: Clinical significance on the diagnosis, outcome and prognosis» (6/2015-6/2017).
39. **Participant principal investigator and Co-ordinator** in a study entitled: «Prognostic factors of sustained virological and biochemical response and immunological changes in patients with chronic HBeAg-negative hepatitis B in whom the long-term effective treatment with antivirals has been discontinued» (Sponsor: Gilead) (2015 – 2017).
40. **Participant principal investigator and Coordinator** in a national retrospective/prospective study of the Greek autoimmune hepatitis registry (Hellenic Association for the Study of the Liver, 2016 – now).
41. **Principal investigator/co-ordinator** in a retrospective study entitled: «Moving from biochemically early to advanced PBC: Are there any prognostic factors?» (Global PBC Study Group) (2016 – 2019).
42. **Participant principal investigator and Co-ordinator** in a study entitled: «Diagnostic performance of FibroMeter (ECHOSENS) in the assessment of liver fibrosis alone or in combination with Fibroscan (ECHOSENS) (2016 – 2018).
43. **Participant principal investigator and Co-ordinator** in a multicentre study entitled: «AIH and NAFLD/NASH: i) Do all NASH patients have truly only NASH? ii) NAFLD/NASH in AIH: important player or innocent bystander?» of the International AIH Group (2016-2021).
44. **Participant principal investigator and Co-ordinator** in a multicentre study entitled: «Prevalence and significance of antimitochondrial antibodies in patients with autoimmune hepatitis» of the International AIH Group (2016-2021).
45. **Collaboration** with Prof. Y. Renaudineau Brest University, France in the project entitled: «Epigenetics in autoimmune liver diseases» (2018-2020).
46. **Principal investigator and Coordinator** in a funding project by the Hellenic Association for the Study of the Liver (HASL) entitled: «DNA methylation in PBMCs of patients with autoimmune hepatitis and primary biliary cirrhosis» (6/2019-6/2021).
47. **Principal investigator/Coordinator** in a retrospective study entitled: «The significance of IgM in PBC patients» (Global PBC Study Group, 2019 – now).
48. **Principal investigator/Coordinator** in a retrospective study entitled: «Prevalence and significance of extrahepatic autoimmune diseases in PBC» (Global PBC Study Group, 2019 – now).
49. **Collaboration** with Prof. D. Bertsimas, MIT, Boston, USA in a retrospective study entitled: «COVID-19 personalized risk prediction: A machine learning approach» (2020).
50. **Participant principal investigator** in a retrospective study entitled: «Serum glycomics as diagnostic biomarkers in primary biliary cholangitis» (Global PBC Study Group, 2020-now).
51. **Collaboration** with Prof. J. Banales, San Sebastian, Spain in the project entitled: «Extracellular vesicles (EVs) and miRNAs in Patients with Primary Biliary Cholangitis (PBC)» (2020-now).

52. **Principal investigator/co-ordinator** in a prospective Greek study entitled: “Immune intervention for the management of patients with COVID-19-related pneumonia: An Open Label, Non-Randomised, Retrospective/Prospective Observational Study” (2020-2022).
53. **Collaboration** with Dr. G.N. Norman, USA, in the project entitled: “Longitudinal assessment of circulating calprotectin in newly hospitalized patients with COVID-19” (2021 – 2023).
54. **Collaboration** with Prof. G. Papatheodoridis in the multicenter study entitled “Assessment of underdiagnosis and prevalence of HDV infection in HBsAg-positive patients - HERACLIS-HDV: HELLENIC MULTICENTER REAL-LIFE CLINICAL STUDY FOR HDV” (2021 – 2022).
55. **Collaboration** with Prof. G. Papatheodoridis in the multicenter study entitled “Safety and efficacy of treatment with bulevirtide in patients with chronic hepatitis D in clinical practice in Greece (HERACLIS-BLV-D)” (2022 – now).
56. **Participant principal investigator** in a Real-World study entitled: “Second-line treatment in primary biliary cholangitis: Obeticholic acid vs. fibrates, a real-world experience in an international retrospective cohort” (Global PBC Study Group, 2022 – 2024).
57. **Participant principal investigator** in the European Reference Network-Rare Liver study entitled: “Social Determinants of Health in autoimmune liver diseases - a prospective international registry study” (ERN-Rare Liver 2024).
58. **Participant principal investigator** in a study entitled: “Data collection for GLOBAL-PBC recompensation project a retrospective international registry study in primary biliary cholangitis (Global PBC Study Group, 2024).
59. **Participant principal investigator and Coordinator** in a national retrospective/prospective study of the Greek registry of Primary Biliary Cholangitis (Hellenic Association for the Study of the Liver, 2024 – now).
60. **Reviewer for Research Projects in Gastroenterology and Hepatology on behalf of the Hellenic (Greek) Central Council of Health** (*Committee of Biomedical Research*).
61. **Reviewer for Research Projects on behalf of the Hellenic (Greek) Ministry of Education.**
62. **Member of the Scientific Committee for the Prevention, Diagnosis, Management and Treatment of Viral Hepatitis, Hellenic (Greek) Center for Disease Control and Prevention (now National Public Health Organization), Hellenic Ministry of Health** (2000-now).
63. **Associate member of the Governing Board of the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health** (2002-2005).
64. **Member of the Research Committee of the Hellenic (Greek) Association for the Study of the Liver** (2002-03, 2005-07, 2013-19 and 2023-27).
65. **Vice President of the Committee for the Control of Infectious Diseases** in the General University Hospital of Larissa, Greece (2004-2007).
66. **Member of the Advisory Board Examination for Internal Medicine Specialty, Larissa, Greece** (2008-2017).
67. **Member of the Governing Board of the Hellenic (Greek) Association for the Study of the Liver** (2001-2003).
68. **Member of many Advisory Boards (n=28) on chronic viral hepatitis B, C and D, HCC, primary biliary cholangitis, as well as on inflammatory and infectious disorders.**
69. **Member of the Data Safety Monitoring Board of the German Bundesministry of Education and Research** for the GAHB-Study.

70. **President of the Organizing Committee of the Annual or Biennial International Congress of Internal Medicine**, Larissa or Athens, Greece (2009 – 2023).
71. **President of the Organizing Committee of the Annual or Biennial Autumn Days of Internal Medicine**, Greece (2008-now).
72. **Recognition (2013)** of the Department of Medicine, the Liver Unit and the Research Laboratory of Internal Medicine, Medical School, University of Thessaly **by the Hellenic (Greek) Center for Disease Control and Prevention as a Specific Center of Rare Diseases (Autoimmune Hepatitis)**.
73. **Elected 1st Vice President of the Governing Board of the Internal Medicine Society of Northern Greece** (2011-2015).
74. **Chairman of the Advisory Board and Steering Committee for the publication of the Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis B and C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health** (2013).
75. **Chairman of the Advisory Board and Steering Committee for the publication of the Updated Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health** (2014).
76. **Member of the Clinical Practice Guideline (CPG) Committee for Autoimmune Hepatitis by the European Association for the Study of the Liver (EASL) Governing Board** (May 2014 – see Reviews-Gidelines No. 15).
77. **President** of the Institute of Internal Medicine and Hepatology, Larissa, Greece (2012-2018).
78. **Vice President** of the Institute of Internal Medicine and Hepatology, Larissa, Greece (2018-now).
79. **Elected Vice President of the Governing Board of the Hellenic (Greek) Association for the Study of the Liver** (2013-2015).
80. **Vice President (2013-2015) and President (2015-2017) of the Organizing Committee of the Annual Clinical School of Hepatology by the Hellenic (Greek) Association for the Study of the Liver**.
81. **Invited Faculty Member of the 22nd United European Gastroenterology Week**, Vienna, October 18-22, 2014.
82. **Invited Faculty Poster Reviewer and Speaker** in the 22nd United European Gastroenterology Week, Vienna, October 18-22, 2014.
83. **Member of the International Scientific Committee of the National Organization of Medicines of Greece** (October 2014).
84. **Member of the First International Quality Control for Quantification of HDV Viral Load**, October 2014.
85. **Elected 2nd Vice President of the Governing Board of the Internal Medicine Society of Northern Greece now known as Internal Medicine Society of Greece which is official member of the European Federation of Internal Medicine** (2015-2018).
86. **Chairman of the panel member of the Hellenic (Greek) Clinical Practice Guidelines of Autoimmune Hepatitis published by the Hellenic Association for the Study of the Liver** (April 2015).
87. **President of the Governing Board of the Hellenic (Greek) Association for the Study of the Liver** (2015-2017).

88. **Panel member of the Hellenic (Greek) Clinical Practice Guidelines on the Prevention and Treatment of HBV Reactivation during or after Immunosuppressive Therapy published by the Hellenic Association for the Study of the Liver (June 2015).**
89. **Member of the Scientific Committee of the Database of Autoimmune Hepatitis on behalf of the Hellenic Association for the Study of the Liver (2015-now).**
90. **Invited Member of the Scientific Committee of the 6th Southeast European Conference on Chemotherapy and Infection (SEEC) in conjunction with the 1st Congress of the Mediterranean Society of Chemotherapy and Infection (MEDSOCCHEMI) and the 16th Congress of Mediterranean Society of Chemotherapy (MSC), Thessaloniki, November 13-15, 2015.**
91. **Chairman of the Advisory Board and Steering Committee for the publication of the first revision on Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (December 2015).**
92. **Invited Expert Reviewer for the Foundation for the Development of Internal Medicine in Europe (FDIME) Research Grant Scientific Committee (1/2016-now).**
93. **Individual Collaborator of the International Consortium entitled: “European Registry on Autoimmune Hepatitis (ERA)” and Representative of the National Society Partners (Hellenic Society of Gastroenterology and Hellenic Association for the Study of the Liver) of the Consortium (This collaborative initiative 'European Registry on Autoimmune Hepatitis' was granted the UEG LINK award on January 30, 2016).**
94. **Chairman of the Advisory Board and Steering Committee for the publication of the second revision on Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (April 2016).**
95. **Chairman of the panel member of the Hellenic (Greek) Clinical Practice Guidelines of the Use of New Antivirals in Chronic Viral Hepatitis C published by the Hellenic Association for the Study of the Liver (January 2017).**
96. **Chairman of the Advisory Board and Steering Committee for the publication of the third revision on Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (February 2017).**
97. **Board member of the Committee for the Development of National Strategies for the Deletion of Viral Hepatitis Viruses in Greece (Ministry of Health, April 2017).**
98. **Faculty Member and Chairperson of the 16th European Congress of Internal Medicine, European Federation of Internal Medicine, Milan, Italy, 31 August – 2 September 2017.**
99. **Member of the Local Organizing Committee of the Stroke Summer School of ESO, Larissa/Leptokarya, September 10-15, 2017.**
100. **Member of the National Organizing and Scientific Committee of the ATHENA 2017 International Conference, Athens, November 28-30, 2017.**
101. **Board Member of the Steering Committee for the publication of the revised Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis B by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (December 2017).**
102. **Invited Expert Reviewer for the Italian Ministry of Education, Universities and Research (MIUR) (3/2018-now).**

103. **Reviewer of abstracts** on behalf of the **European Federation of Internal Medicine (EFIM, 16th, 17th, 18th, 19th, 20th, 21st, 22nd and 23rd European Congress of Internal Medicine 2017 - 2019, 2021 - 2025).**
104. **Faculty Member** of the **17th European Congress of Internal Medicine**, European Federation of Internal Medicine, Wiesbaden, Germany, 30 August – 1 September 2017.
105. **Member** of the **2nd Mackay International Meeting on PBC**, Lugano, Switzerland, September 23-25, 2018.
106. **Invited Faculty Member, Chair and Speaker** of the **26th United European Gastroenterology Week**, Vienna, October 20-24, 2018.
107. **Invited Faculty Poster Reviewer** of the **26th United European Gastroenterology Week**, Vienna, October 20-24, 2018.
108. **Member of the Working Group of IAIHG** entitled: **“Definitions on endpoints in AIH”** (December 2018).
109. **Chairman of the panel member of the Revised Clinical Practice Guidelines of Autoimmune Hepatitis of the Hellenic (Greek) Association for the Study of the Liver** (January 2019 – see Reviews-Guidelines Publication: No. 18).
110. **Member of the Advisory Board and Steering Committee for the publication of the fourth revision on Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health** (February 2019).
111. **Member of the Local Scientific Committee and Chairman of Meet the Experts in the Advanced Learning on Platelets & Thrombosis International Course (ALPIC 2019), European and Mediterranean League Against Thrombotic Diseases, Metsovo, March 22-24, 2019.**
112. **Faculty Member and Speaker** of the **18th European Congress of Internal Medicine**, European Federation of Internal Medicine, Lisbon, Portugal, August 29-31, 2019.
113. **Member of the Educational Committee of the Hellenic (Greek) Association for the Study of the Liver (6/2019-6/2025).**
114. **Official Recognition by the Ministry of Health (FEK Part B’4040/05.11.2019) of the Department of Medicine and Research Laboratory of Internal Medicine of the General University Hospital of Larissa as National Expertise Center of Greece in Autoimmune Liver Diseases (Director: Prof. G.N. Dalekos).**
115. **Faculty Member** of the **EASL International Liver Congress 2020**, European Association for the Study of the Liver, London, UK, April 14-19, 2020.
116. **Invited Faculty Member and Speaker** of the **China-International Webinar Meeting on the Management of Autoimmune Hepatitis & Liver Transplantation**, The Chinese Organ Transplant Society, NEW HORIZON Program, July 7, 2020.
117. **Meeting Chair, Faculty Member and Speaker** of the **EU-China International Webinar Meeting on the Diagnosis and Treatment of Autoimmune Hepatitis: AIH & The Variant Syndromes**, The Chinese Society of Infectious Diseases, NEW HORIZON Program, August 24, 2020.
118. **Coordinator and Chairman of the Greek Autoimmune Liver Diseases Study Group Annual Meetings (2020 – now).**
119. **Invited Faculty Member and Speaker** of the **19th European Congress of Internal Medicine**, European Federation of Internal Medicine, Virtual Congress, March 18-20, 2021.
120. **Recognition by Expertscape.com as an Expert** in the top 1% of scholars writing about Autoimmune Hepatitis over the past 10 years (July 28, 2021).

121. **Member of the Advisory Board and Steering Committee for the publication of the fifth revision on Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the National Public Health Organization, Hellenic Ministry of Health (July 2021).**
122. **Meeting Chair, Faculty Member and Speaker of the China-International Webinar Meeting on the Diagnosis and Treatment of Autoimmune Hepatitis (Vol. 2): The Guidance & Practice Worldwide, The Chinese Society of Infectious Diseases, NEW HORIZON Program, September 8, 2021.**
123. **Official Recognition by the European Commission (Decision of the Board of Member States 26.11.2021) of the Department of Medicine and Research Laboratory of Internal Medicine of the General University Hospital of Larissa as Full Member of the European Reference Network ERN-Rare Liver for Autoimmune Liver Diseases (Representative: Professor George N Dalekos).**
124. **Member of the Governing Board of the Hellenic Society of Internal Medicine (26/11/2021 - 27/09/2025).**
125. **Medical Officer Director of the General University Hospital of Larissa, Greece (2/2022-12/2024).**
126. **Member of the Scientific Committee of the Ministry of Health for the development of the National Registry of Rare Diseases (2/2022-now).**
127. **Invited Faculty Member and Chairperson of the 20th European Congress of Internal Medicine, European Federation of Internal Medicine, Malaga, Spain, June 9-11, 2022.**
128. **Invited Faculty Member, Chair and Speaker in “Meet the experts session” of the EASL International Liver Congress, European Association for the Study of the Liver (EASL), London, UK, June 22-26, 2022.**
129. **Course Organizer of the Intense Clinical Course of the Hellenic Association for the Study of the Liver entitled: “Diagnostic and therapeutic challenges in patients with autoimmune hepatitis or primary biliary cirrhosis”, Larissa, July 8-9, 2022.**
130. **Invited Faculty Member, Chair, Panelist and Expert Speaker in “Single Topic Conference on Liver Fibrosis in the era of MAFLD” of APASL, Cairo, Egypt, July 28-30, 2022.**
131. **Invited International Assessor for Academic Appointments in Internal Medicine of the Tel Aviv University (July 2022).**
132. **Course Organizer of the Two-days Educational Meeting of the Hellenic Association of Internal Medicine entitled: “Continuing Education in Internal Medicine: Evidence-based Medicine in Everyday Clinical Practice”, Larissa, December 9-10, 2022.**
133. **Invited Faculty Member and Chairperson of the 21st European Congress of Internal Medicine, European Federation of Internal Medicine, Athens, Greece, March 15-18, 2023.**
134. **President Elect, European Federation of Internal Medicine (03/2023-03/2025).**
135. **Course Organizer of the European Association for the Study of the Liver School of Hepatology entitled: “Diagnostic and treatment challenges in “difficult-to-manage” patients with autoimmune hepatitis and primary biliary cholangitis”, Larissa, Greece, June 30 – July 1, 2023.**
136. **Invited Chair of the Clinical Practice Guidelines Panel for the revised Guidelines on the Management of Autoimmune Hepatitis of EASL Governing Board, Geneva, August 4, 2023.**

137. **Editorial Board Member of the Steering Committee for the publication of the Clinical Practice Guidelines on the Diagnosis and Management of Sepsis by the Hellenic Sepsis Study Group** (Athens, 2023).
138. **Recognition as one of the top 2% of scientists** in the Global Ranking of the Stanford University (updated databases 2020, 2021, 2022, 2023, 2024).
139. **Invited Faculty Member, Chairperson and Speaker of the 22nd European Congress of Internal Medicine**, European Federation of Internal Medicine, Istanbul, Turkey, March 6-9, 2024.
140. **Acknowledgement of Exceptional Medical Activity in the field of Internal Medicine** by the Carol Davila Universitatea de Medicina si Farmacie, Bucharest, Romania, May 24, 2024.
141. **Honorary Membership of the Romanian Society of Internal Medicine** Bucharest, Romania, May 24, 2024.
142. **Invited Faculty Member and Speaker in the EASL International Liver Congress 2024**, European Association for the Study of the Liver, Milan, Italy, June 5-8, 2024.
143. **Board member of the Committee for the Development of National Strategies for the Deletion of Hepatitis B Virus in Greece** (Ministry of Health, July 2024).
144. **Member of the Advisory Board and Steering Committee for the publication of the Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis B and D by the National Public Health Organization, Hellenic Ministry of Health** (July 2024).
145. **Invited Teaching Professor** in the 5th Symposium HEPATOLOGY 2024 of the Liver Unit of the University Hospital of Bern, Bern, Switzerland, October 31, 2024.
146. **Chairman of the panel member for the Updated Clinical Practice Guidelines of Autoimmune Hepatitis of the Hellenic (Greek) Association for the Study of the Liver** (January-December 2024 – see Reviews-Guidelines Publication: No. 29).
147. **Recognition as a 2024 Top Scholar by ScholarGPS Rankings (one of the top 0.5% of all Scholars worldwide)**.
148. **Invited Faculty Member, Chairperson and Speaker of the 23rd European Congress of Internal Medicine**, European Federation of Internal Medicine, Florence, Italy, March 5-8, 2025.
149. **President, European Federation of Internal Medicine** (03/2025-03/2027).
150. **Course Chapter Organizer and Moderator of the 4th Chapter of Webinar Lessons of the Hellenic Society of Internal Medicine** on Gastrointestinal tract – Liver – Biliary – Pancreas, May-November 2025.
151. **Course Co-Organizer, Speaker, and Moderator of the European Summer School of Internal Medicine of EFIM**, Alexandroupolis, Greece, June 1-7, 2025.
152. **Honorary Fellow of the Ceylon College of Physicians (Guest of Honour at CCP 2025 - 58th Anniversary Annual Academic Sessions 2025 of CCP)**, Colombo, Sri Lanka, September 10, 2025.
153. **Specific Secretary of the Governing Board of the Hellenic Society of Internal Medicine** (28/09/2025 till now).
154. **Organizer of the 10th EFIM Day** of the European Federation of Internal Medicine, Brussels, Belgium, October 17, 2025.
155. **Invited Faculty Member, Chairperson and Speaker of the Cholestasis Academy: New Frontiers in Pediatric and Adult Hepatology**, Ipsen, Athens, Greece, November 1, 2025.

156. **Principal investigator** in a study entitled: “Real-world Evaluation of PBC Patients Transitioned from Obeticholic Acid to Elafibranor: A Retrospective / Prospective Study” (IPSEN, 2025 – now).
157. **Participant principal investigator** in a retrospective study entitled: “Differentiating isoenzymes of aspartate aminotransferase during second-line therapy with PPAR agonists in patients with primary biliary cholangitis” (Global PBC Study Group, 2025 - now).
158. **Participant principal investigator** in a multicenter study entitled “Non-interventional prospective study in a single cohort for the evaluation of adherence to the treatment with trientine tetrahydrochloride (Cuprior) in Greek patients with Wilson disease” (2025 – τώρα).
159. **Principal investigator** in a study entitled: “Primary biliary cholangitis in males: a clinical and immunological study” (IN-US-986-7961-GILEAD, 2026 – now).
160. **Participant principal investigator** in a study entitled: “A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab in Participants With Autoimmune Hepatitis (AMGEN Study 20240237, 2026 – now).
161. **Participant principal investigator** in a study entitled: “Phase III, randomized, double blind, placebo-controlled study (1:1 allocation ratio) to evaluate the efficacy and safety of Elafibranor (PPAR agonist) in adult participants with Primary Sclerosing Cholangitis”. (Primary sclerosing cholangitis-0299/0227-Ipsen Icon Study, 2026 – now).
162. **Participant principal investigator** in a study entitled: “Phase IV multicentre study to assess the effectiveness, safety and tolerability of elafibranor 80 mg/day in patients with primary biliary cholangitis receiving treatment in a real-world setting” (IPSEN ELFINITY 0299-0174 GRC 300004 CTA Dual V0.1_20240723, 2026 – now).
163. **Participant principal investigator** in a study entitled: “Understanding disease control in AIH: Analysis on how deep remission impacts clinical outcome as well as risk of a flare” (ERN, 2026 – now).

BIBLIOGRAPHY

A. Thesis

Doctoral Thesis

«*Inflammatory Bowel Disease: Immunologic abnormalities*», Ioannina, 1995.

Parts of my Doctoral Thesis have been published as full papers in *Gut*, *European Journal of Internal Medicine* and *European Journal of Gastroenterology and Hepatology* (see Original Articles No: 1,4,12 and 15).

B. Papers in International Medical Journals (Total: 402 publications)

Citation Index (31-12-2025)

ISI and/or Scopus: **22341 citations** (self-citations: 136), **h-index = 66**

Google Scholar: **30505 citations**, **h-index = 80**, **i10-index = 313**

Total impact factor: **3593.119**

B1. Original articles

1. **G.N. Dalekos**, M.N. Manoussakis, A.C. Goussia, E.V. Tsianos, H.M. Moutsopoulos. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis. *Gut* 34:658-664, 1993.
2. **G.N. Dalekos**, M.N. Manoussakis, E. Zervou, E.V. Tsianos, H.M. Moutsopoulos. Immunologic and viral markers in the circulation of anti-HIV negative heroin addicts. *Eur J Clin Invest* 23:219-225, 1993.
3. E.V. Tsianos, **G.N. Dalekos**, M. Elisaf, E. Zervou, K.C. Siamopoulos. High frequency of antibodies to Hantaan virus and hepatitis C virus in haemodialysis patients. Coincidence or cross reaction? *J Intern Med* 234:607-610, 1993.
4. E.V. Tsianos, C.N. Masalas, M. Merkouropoulos, **G.N. Dalekos**, R.F. Logan. Incidence of inflammatory bowel disease in northwest Greece: Rarity of Crohn's disease in an area where ulcerative colitis is common. *Gut* 35:369-372, 1994.
5. E.V. Tsianos, **G.N. Dalekos**, M.H. Merkouropoulos, A. Tsatsoulis, K.I. Seferiadis. Frequency of thyroid dysfunction after recombinant alpha-interferon therapy in Greek patients with chronic active hepatitis. *Eur J Gastroenterol Hepatol* 6:547-551, 1994.
6. P.G. Vlachoyiannopoulos, **G.N. Dalekos**, A. Tsatsoulis: Transient hyperthyroidism following lower respiratory tract infections. A clinical observation. *Eur J Intern Med* 6:19-22, 1995.
7. **G.N. Dalekos**, E. Zervou, F. Karabini, K. Bourantas, M. Elisaf, K.C. Siamopoulos. Prevalence of antibodies to human T-lymphotropic virus types I and II in volunteer blood donors and high-risk groups in northwestern Greece. *Transfusion* 35:503-506, 1995.
8. **G.N. Dalekos**, E. Zervou, F. Karabini, E.V. Tsianos. Prevalence of viral markers among refugees from southern Albania: increased incidence of infections with hepatitis A, B and D viruses. *Eur J Gastroenterol Hepatol* 7:553-558, 1995.
9. A. Tsatsoulis, P.G. Vlachoyiannopoulos, **G.N. Dalekos**, E.O. Johnson, H.M. Moutsopoulos. Increased serum interleukin-1 β (IL-1 β) during treatment of hyperthyroidism with antithyroid drugs. *Eur J Clin Invest* 25:654-658, 1995.
10. **G.N. Dalekos**, E. Zervou, M.H. Merkouropoulos, E.V. Tsianos. Prevalence of hepatitis B and C viruses infection in chronic alcoholics with or without liver disease in Ioannina, Greece: Low incidence of HCV infection. *Eur J Epidemiol* 12:21-25, 1996.
11. N.V. Angelopoulos, Chr. Mantas, **G.N. Dalekos**, K. Vasalos, E.V. Tsianos. Psychiatric factors in patients with ulcerative colitis according to disease activity. *Eur J Psychiat* 10:87-99, 1996.
12. **G.N. Dalekos**, E.V. Tsianos, H.M. Moutsopoulos. Immunologic markers of disease activity in the circulation of patients with ulcerative colitis: high concentrations of soluble interleukin-2 receptor molecules and interleukin-6 in active disease. *Eur J Intern Med* 7:93-98, 1996.
13. **G.N. Dalekos**, M. Elisaf, N. Papagalani, Chr. Tzallas, K.C. Siamopoulos. Elevated interleukin-1 β in the circulation of patients with essential hypertension before any drug therapy: A pilot study. *Eur J Clin Invest* 26:936-939, 1996.
14. **G.N. Dalekos**, M. Elisaf, E. Bairaktari, O. Tsolas, K.C. Siamopoulos. Increased serum levels of interleukin-1 β in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? *J Lab Clin Med (now Transl Res)* 129:300-308, 1997. **(Original article with Editorial)**.
15. **G.N. Dalekos**, J. Ringstad, J. Savaidis, K.I. Seferiadis, E.V. Tsianos. Zinc, copper, and immunologic markers in the circulation of well-nourished patients with ulcerative colitis. *Eur J Gastroenterol Hepatol* 10:331-337, 1998.

16. **G.N. Dalekos**, E. Zervou, M. Elisaf, N. Germanos, K. Bourantas, E. Galanakis, K.C. Siamopoulos, E.V. Tsianos. Antibodies to hepatitis E virus among different populations in Greece: increased prevalence in an haemodialysis unit. *Transfusion* 38:595-598, 1998.
17. **G.N. Dalekos**, D.S. Boumba, K. Katopodis, E. Zervou, G. Sferopoulos, M. Elisaf, E.V. Tsianos, K.C. Siamopoulos. Absence of viraemia due to HCV in anti-HCV negative haemodialysis patients. *Nephrol Dial Transpl* 13:1804-1806, 1998.
18. K.L. Bourantas, **G.N. Dalekos**, A. Makis, A. Chaidos, S. Tsiara, A. Mavridis. Acute phase proteins and interleukins in steady state sickle cell disease. *Eur J Haematol* 61:49-54, 1998.
19. **G.N. Dalekos**, K. Achenbach, D. Christodoulou, G.K. Liapi, E. Zervou, D. Sideris, E.V. Tsianos. Idiopathic dilated cardiomyopathy: lack of association with hepatitis C virus infection. *Heart* 80:270-275, 1998.
20. **G.N. Dalekos**, D. Christodoulou, K. G. Kistis, J. Hatzis, E.V. Tsianos. A prospective evaluation of dermatologic side effects during interferon-alpha therapy for chronic viral hepatitis. *Eur J Gastroenterol Hepatol* 10:933-939, 1998.
21. **G.N. Dalekos**, H. Wedemeyer, P. Obermayer-Straub, A. Kayser, A. Barut, H. Frank, M.P. Manns. Epitope mapping of cytochrome P450 2D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. *J Hepatol* 30:366-375, 1999.
22. M. Fatouros, **G.N. Dalekos**, E. Mylonakis, G. Vekinis, A. Kapas. Alterations in body weight, breaking strength and wound healing in Wistar rats treated pre- and postoperatively with erythropoietin or granulocyte-macrophage colony stimulating factor: Evidence of a previously unknown anabolic effect of erythropoietin? *J Lab Clin Med (now Transl Res)* 133:253-259, 1999.
23. **G.N. Dalekos**, K. Kistis, D. Boumba, E. Zervou, P. Voulgari, A.A. Drosos, E.V. Tsianos. Increased incidence of anticardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to antiphospholipid syndrome. *Eur J Gastroenterol Hepatol* 12:67-74, 2000.
24. **G.N. Dalekos**, E. Galanakis, E. Zervou, M. Tzoufi, P.L. Lapatsanis, E.V. Tsianos. Interferon-alpha treatment of children with hepatitis D virus infection: The Greek experience. *Hepatology*, 47:1072-1076, 2000.
25. E.K. Zervou, **G.N. Dalekos**, D.S. Boumba, E.V. Tsianos. Value of anti-HBc screening of blood donors for prevention of HBV infection: Results of a three-year prospective study in northwestern Greece. *Transfusion*, 41:652-658, 2001.
26. D.K. Christodoulou, **G.N. Dalekos**, M. Merkouropoulos, K.G. Kistis, G. Georgitsi, E. Zervou, K. Zachou, E.V. Tsianos. Cryoglobulinemia due to chronic viral hepatitis infections is not a major problem in clinical practice. *Eur J Intern Med*, 12:435-441, 2001.
27. P. Obermayer-Straub, S. Braun, A. Kayser, A. Barut, S. Loges, A. Harms, C. Strassburg, **G. Dalekos**, J. Perheentupa, M.P. Manns. Hepatic autoantigens in patients with autoimmune polyendocrine syndrome type 1 (APS1). *Gastroenterology* 121:668-677, 2001.
28. **G.N. Dalekos**, E. Makri, S. Loges, P. Obermayer-Straub, K. Zachou, Th. Tsirikas, E. Schmidt, G. Papadamou, M.P. Manns. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of HCV patients from central Greece. *Eur J Gastroenterol Hepatol* 14:35-42, 2002.
29. K. Zachou, C. Liaskos, D.K. Christodoulou, M. Kardasi, G. Papadamou, N. Gatselis, S.P. Georgiadou, E.V. Tsianos and **G.N. Dalekos**. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I co-factor or features of antiphospholipid syndrome. *Eur J Clin Invest* 33:161-168, 2003.

30. E. Zervou, D.S. Boumba, Ch. Liaskos, S. Georgiadou, E.V. Tsianos, **G.N. Dalekos**. Low prevalence of HCV, HIV and HTLV-I/II infection markers in northwestern Greece: Results of a three year prospective donor study. *Eur J Intern Med* 14:39-44, 2003.
31. D.S. Kyriakou, M.G. Alexandrakis, K. Zachou, F. Passam, N.E. Stathakis and **G.N. Dalekos**. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Hepatol* 39:679-685, 2003.
32. **G.N. Dalekos**, P. Obermayer-Straub, M. Bartels, T. Maeda, A. Kayser, S. Loges, S. Braun, E. Schmidt, M.E. Gershwin, M.P. Manns. Cytochrome P450 2A6: A new hepatic autoantigen in chronic hepatitis C virus infection. *J Hepatol* 39:800-806, 2003. (**Original article with Editorial**).
33. S.P. Georgiadou, K. Zachou, C. Liaskos, E. Rigopoulou, F. Gerovasilis, E. Makri, **G.N. Dalekos**. Occult hepatitis B virus (HBV) infection in Greek patients with chronic hepatitis C and diverse non-viral hepatic diseases. *J Viral Hepat* 11:358-365, 2004.
34. A.N. Moulas, A. Noulas, E. Makri, S. Bonanou-Tzedaki, and **G.N. Dalekos**. Total antioxidant status and erythrocyte superoxide dismutase activity in patients with chronic hepatitis B and C. *Eur J Inflam* 2:77-84, 2004.
35. E. E. Yiannaki, E. Zintzaras, A. Analatos, C. Theodoridou, **G.N. Dalekos**, A.E. Germenis. Evaluation of a microsphere-based flow cytometric assay for diagnosis of celiac disease. *J Immunoassay Immunochem* 25:345-357, 2004.
36. I. Stefanidis, E.K. Zervou, Ch. Rizos, Ch. Syrganis, E. Patsidis, G. Kyriakopoulos, L. Sdrakas, N. Tsianas, Rigopoulou EI, Liakopoulos V, **G.N. Dalekos**. Hepatitis E virus antibodies in hemodialysis patients: an epidemiological survey in central Greece. *Int J Artif Organs* 27:842-847, 2004.
37. E.K. Zervou, S. Georgiadou, M. Tzilianos, P. Georgitsi, V. Pournara, S. Nouis, C. Pappas, L. Daskalou, A. Vrettou, F. Karabini, and **G.N. Dalekos**. Human T-lymphotropic virus type-I/II infections in volunteer blood donors of north and west Greece. *Eur J Intern Med* 15:422-427, 2004.
38. N.K. Gatselis, S.P. Georgiadou, N. Tassopoulos, K. Zachou, C. Liaskos, A. Hatzakis, and **G.N. Dalekos**. Impact of parietal cell autoantibodies (PCA) and non-organ specific autoantibodies (NOSA) on the treatment outcome of patients with HCV infection: a pilot study. *World J Gastroenterol* 11:482-487, 2005.
39. A. Tsikrikoni, D.S. Kyriakou, E.I. Rigopoulou, M.G. Alexandrakis, K. Zachou, F. Passam, **and G.N. Dalekos**. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Hepatol* 42:393-399, 2005.
40. E.I. Rigopoulou, E.T. Davies, A. Pares, K. Zachou, C. Liaskos, D.P. Bogdanos, J. Rodes, **G.N. Dalekos**, D. Vergani. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. *Gut* 54:528-532, 2005.
41. C. Liaskos, E. Rigopoulou, K. Zachou, S. Georgiadou, N. Gatselis, **and G.N. Dalekos**. Prevalence and clinical significance of anticardiolipin antibodies in patients with autoimmune hepatitis type 1. *J Autoimmun* 24:251-260, 2005.
42. M. Satra, **G.N. Dalekos**, P. Kollia, N. Vamvakopoulos, A. Tsezou. Telomerase reverse transcriptase mRNA expression in peripheral lymphocytes of patients with chronic HBV and HCV infections. *J Viral Hepat* 12:488-493, 2005.
43. E.K. Zervou, S.P. Georgiadou, G.K. Liapi, F. Karabini, V. Giogiakas, K. Zisiadis, N.K. Gatselis, I. Goudevenos **and G.N. Dalekos**. Hepatitis viruses and human T-lymphotropic virus

type I/II infection markers in patients underwent an open-heart surgery: Evidence of increased risk for exposure to HBV and HEV. *Eur J Intern Med* 16:424-428, 2005.

44. E.K. Zervou, N.K. Gatselis, E. Xanthi, K. Ziciadis, **and G.N. Dalekos**. Intrafamilial spread of hepatitis B virus infection in Greece. *Eur J Gastroenterol Hepatol* 17:911-915, 2005.
45. E.I. Rigopoulou, I. Stefanidis, C. Liaskos, E.K. Zervou, C. Rizos, P. Mina, K. Zachou, C. Syrganis, E. Patsidis, G. Kyriakopoulos, L. Sdrakas, N. Tsianas **and G. N. Dalekos**. HCV RNA qualitative assay based on transcription-mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: Results from five hemodialysis units in central Greece. *J Clin Virol* 34:81-85, 2005.
46. A.E. Germanis, E.E. Yiannaki, K. Zachou, V. Roka, S. Barbanis, C. Liaskos, K. Adam, A.N. Kapsoritakis, S. Potamianos, **G.N. Dalekos**. Prevalence and clinical significance of IgA antibodies against tissue transglutaminase in patients with diverse chronic liver diseases. *Clin Diag Lab Immunol (now Clin Vaccine Immunol)* 12:941-948, 2005.
47. K. Zachou, E. Rigopoulou, A. Tsikrikoni, M. Alexandrakis, F. Passam, D. Kyriakou, N. Stathakis **and G.N. Dalekos**. Cytokines production is distinct in bone marrow cultures from patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Autoimmun* 25:283-288, 2005.
48. I. Nikaina, C. Pastaka, K. Zachou, **G.N. Dalekos**, K. Gourgouljanis. Sleep apnoea syndrome and early-stage cirrhosis: a pilot study. *Eur J Gastroenterol Hepatol* 18:31-35, 2006.
49. H.L. Tillmann, J. Hadem, L. Leifeld, K. Zachou, A. Canbay, C. Eisenbach, I. Graziadei, J. Encke, H. Schmidt, W. Vogel, A. Schneider, U. Spengler, G. Gerken, **G.N. Dalekos**, H. Wedemeyer, M.P. Manns. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. *J Viral Hepat* 13:256-63, 2006.
50. T.A. Zografos, E.I. Rigopoulou, C. Liaskos, E. Togousidis, K. Zachou, N. Gatselis, A. Germanis **and G. N. Dalekos**. Alterations of leptin during IFN- α therapy in patients with chronic viral hepatitis. *J Hepatol* 44:848-55, 2006.
51. Zachou K, Liaskos C, Rigopoulou E, Gabeta S, Papamichalis P, Gatselis N, Georgiadou S, **and G.N. Dalekos**. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. *Clin Immunol* 119:203-212, 2006.
52. E.I. Rigopoulou, S.P. Georgiadou, S. Barbanis, **G.N. Dalekos**. Lack of association between appendectomy and primary biliary cirrhosis (PBC). *Scand J Gastroenterol* 41:573-576, 2006.
53. K. Mimidis, V.P Papadopoulos, I. Elefsiniotis, D. Kolioukas, I. Ketikoglou, E. Paraskevas, S. Kanatakis, D. Chrysagis, **G.N Dalekos**, C. Tzathas, A. Protopapas, E. Gigi, E. Tsianos, G. Kartalis. Hepatitis C virus survival curve analysis in naïve patients treated with peg-interferon a-2b plus ribavirin. A randomized controlled trial for induction with high doses of peg-interferon and predictability of sustained viral response from early virologic data. *J Gastrointestin Liver Dis* 15:213-219, 2006.
54. N. Stefanou, M. Satra, V. Papanikolaou, F. Kalala, N. Gatselis, A. Germanis, **G.N. Dalekos**, A. Tsezou. Leptin receptor isoforms mRNA expression in peripheral blood mononuclear cells from patients with chronic viral hepatitis. *Exp Biol Med* 231:1653-1663, 2006.
55. P. Guéguen, **G. Dalekos**, J-B Nousbaum, K. Zachou, Putterman C, Youinou P, Renaudineau Y. Double reactivity against actin and α -actinin defines a severe form of autoimmune hepatitis type 1. *J Clin Immunol* 26:495-505, 2006.
56. N.K. Gatselis, S.P. Georgiadou, G.K. Koukoulis, N. Tassopoulos, K. Zachou, C. Liaskos, A. Hatzakis, **G.N. Dalekos**. Clinical significance of organ and non-organ specific autoantibodies on the response to antiviral treatment of patients with chronic hepatitis C. *Aliment Pharmacol Ther* 24:1563-1573, 2006.

57. M. Satra, N. Gatselis, D. Iliopoulos, D. Zacharoulis, **G.N. Dalekos**, A. Tsezou. Real time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis. *J Viral Hepat* 14:41-7, 2007.
58. N.K. Gatselis, E. Rigopoulou, A. Stefos, M. Kardasi, **and G.N. Dalekos**. Risk factors associated with HCV infection in semi-rural areas of central Greece. *Eur J Intern Med* 18:48-55, 2007.
59. E.I. Rigopoulou, M. Mytilinaiou, O. Romanidou, C. Liaskos, **G.N. Dalekos**. Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. *J Autoimmune Dis* 4(1): 2, 2007 (**This article has qualified as 'Highly accessed'; Accesses up to 31-12-2020: 16000; see <http://www.jautoimdis.com/content/4/1/2/about>**).
60. E.I. Rigopoulou, D-P Bogdanos, C. Liaskos, A. Koutsoumpas, H. Baum, D. Vergani, **and G.N. Dalekos**. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. *Clin Chim Acta* 380:118-21, 2007.
61. S. Gabeta, G.L. Norman, C. Liaskos, P.A. Papamichalis, T. Zografos, A. Garagounis, E.I. Rigopoulou **and G.N. Dalekos**. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. *J Clin Immunol* 27:378-387, 2007.
62. P.A. Papamichalis, K. Zachou, G.K. Koukoulis, A. Veloni, E.G. Karacosta, L. Kypri, I. Mamaloudis, S. Gabeta, E.I. Rigopoulou, A.W. Lohse **and G.N. Dalekos**. The revised international autoimmune hepatitis (AIH) score in chronic liver diseases including AIH/overlap syndromes and AIH with concurrent other liver disorders. *J Autoimmune Dis* 4:3, 2007 (**This article has qualified as 'Highly accessed'; Accesses up to 31-12-2020: 30000; see <http://www.jautoimdis.com/content/4/1/3/about>**).
63. E.I. Rigopoulou, E.T. Davies, D.P. Bogdanos, C. Liaskos, G.K. Koukoulis, **G.N. Dalekos**, P. Vergani. Anti-mitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. *Liver Int* 27:1226-1231, 2007.
64. T.A. Zografos, C. Liaskos, E.I. Rigopoulou, E. Togousidis, K. Makaritsis, A. Germenis, **and G.N. Dalekos**. Adiponectin: a new independent predictor of liver steatosis and response to IFN- α treatment in chronic hepatitis C? *Am J Gastroenterol* 103:605-614, 2008.
65. E. M. Hennes, M Zeniya, A. J. Czaja, A. Parés, **G. N. Dalekos**, E. Krawitt, P.L. Bittencourt, G. Porta, K.M. Boberg, H. Hofer, F.B. Bianchi, M Shibata, C. Schramm, B. Eisenmann de Torres, P. R. Galle, I. McFarlane, H. P. Dienes, A. W. Lohse. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology* 48:169-176, 2008.
66. Y. Renaudineau, **G.N. Dalekos**, P. Guéguen, K. Zachou, P. Youinou. Anti- α -actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. *Clin Rev Allergy Immunol* 34:321-325, 2008.
67. A. Tsikrikoni, E.I. Rigopoulou, K. Zachou, C. Liaskos, D. Kyriakou, **and GN Dalekos**. Bone marrow findings in patients with autoimmune liver diseases. *J Gastroenterol Hepatol* 23:e416-421, 2008.
68. K. Kyriakopoulou, A. Antoniou, I.V. Fezoulidis, N.L. Kelekis, **G.N. Dalekos**, M. Vlychou. The role of Doppler Perfusion Index as screening test in the characterization of focal liver lesions. *Digest Liver Dis* 40:755-760, 2008.
69. P. Fytily, **G.N. Dalekos**, M. Cornberg, V. Schlaphoff, W. Zauner, K. Zachou, M.P. Manns, C. Klade and H. Wedemeyer. Cross-genotype-reactivity of the immunodominant HCV-CD8 T-

cell epitope NS3-1073: Significance for the development of peptide-based vaccines against HCV. *Vaccine* 26:3818-3826, 2008.

70. S. Gabeta, G.L. Norman, C. Liaskos, N. Gatselis, P.A. Papamichalis, A. Garagounis, K. Zachou, E.I. Rigopoulou **and G.N. Dalekos**. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. *J Clin Immunol* 28:501-511, 2008.
71. A. Stefos, N. Gatselis, K. Zachou, E. Rigopoulou, C. Hadjichristodoulou, **and G.N. Dalekos**. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in central Greece. *Eur J Intern Med* 20:35-43, 2009.
72. S.P. Georgiadou, C. Liaskos, K. Zachou, S. Gabeta, E.I. Rigopoulou, **and G.N. Dalekos**. Occult hepatitis B virus infection in Greek patients with autoimmune liver diseases. *Liver Int* 29:434-442, 2009.
73. E. Kapsalaki, N. Gatselis, A. Stefos, K. Makaritsis, A. Vassiou, I. Fezoulidis, **G.N. Dalekos**. Spontaneous spondylodiscitis: Presentation, risk factors, diagnosis, management, and outcome *Int J Infect Dis* 13:564-569, 2009.
74. K. Zachou, C. Yurdaydin, U. Drebber, **G.N. Dalekos**, A. Erhardt, Y Cakaloglu, H. Degertekin, S. Gurel, S. Zeuzem, H. Bozkaya, V. Schlaphoff, H.P. Dienes, C.T. Bock, M.P. Manns and H. Wedemeyer for H1DT-1 Study Group. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. *Liver Int* 30:430-437, 2010.
75. P. Mina, S.P. Georgiadou, C. Rizos, **G.N. Dalekos**, E.I. Rigopoulou. Prevalence of occult HBV infection in haemodialysis patients from central Greece. *World J Gastroenterol* 16:225-231, 2010.
76. Liaskos C, Norman GL, Moulas A, Garagounis A, Goulis I, Rigopoulou EI, **Dalekos GN**. Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. *Clin Chim Acta* 411:411-415, 2010.
77. Gatselis NK, Zachou K, Papamichalis P, Koukoulis GK, Gabeta S, **Dalekos GN**, Rigopoulou EI. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score? *Digest Liver Dis* 42:807-812, 2010.
78. Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, Vergani D, Bogdanos DP, **Dalekos GN**, Milkiewicz P, Czaja AJ, Heathcote JE, Hirschfield GM, Tan EM, Miyachi K, Bignotto M, Battezzati P-M, Lleo A, Leung PS, Podda M, Gershwin ME, Invernizzi P. PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. *J Autoimmun* 35:436-442, 2010.
79. Wedemeyer H, Yurdaydin C, **Dalekos GN**, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP. Peginterferon plus adefovir versus either drug alone for hepatitis delta. *New Engl J Med* 364:322-331, 2011.
80. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, **Dalekos GN**. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. *J Hepatol* 55:636-646, 2011.
81. Argyraki CK, Gabeta S, Zachou K, Boulbou M, Polyzos A, **Dalekos GN**. Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions. *Eur J Intern Med* 22:155-157, 2011.
82. Mederacke I, Yurdaydin C, **Dalekos GN**, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H, Hep-Net/International Delta Hepatitis Study Group. Anti-HDV immunoglobulin M testing in

hepatitis delta revisited: correlations with disease activity and response to pegylated interferon- α 2a treatment. *Antivir Ther* 17:305-312, 2012.

83. Mavroidi A, Miriagou V, Malli E, Stefos A, **Dalekos GN**, Tzouvelekis LS, Petinaki E. Emergence of Escherichia coli sequence type 410 (ST410) with KPC-2 β -lactamase. *Int J Antimicrob Agents* 39:247-250, 2012.
84. Zachou K, Oikonomou K, Renaudineau Y, Chauveau A, Gatselis N, Youinou P, **Dalekos GN**. Anti- α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. *Aliment Pharmacol Ther* 35:116-125, 2012.
85. Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C, Bozkaya H, **Dalekos GN**, Manns MP, Wedemeyer H; on behalf of Hep-Net/International Delta Hepatitis Study Group. Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. *J Viral Hepat* 19:387-395, 2012.
86. Gatselis NK, Zachou K, Norman GL, Tzellas G, Speletas M, Gabeta S, Germenis A, Koukoulis GK, **Dalekos GN**. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. *Clin Chim Acta* 413:1683-1688, 2012.
87. Zografos TA, Gatselis N, Zachou K, Liaskos C, Gabeta S, Koukoulis GK, **Dalekos GN**. PBC-specific autoantibodies in first degree relatives of Greek PBC patients. *World J Gastroenterol* 18:4721-4728, 2012.
88. Kabaçam G, **Dalekos GN**, Cakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçın K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. *Turk J Gastroenterol* 23:560-568, 2012.
89. Mavroidi A, Miriagou V, Liakopoulos A, Tzelepi E, Stefos A, **Dalekos GN**, Petinaki E. Ciprofloxacin-resistant Escherichia coli in Central Greece: mechanisms of resistance and molecular identification. *BMC Infect Dis* 12:371, 2012.
90. J.Z. Liu, J.R. Hov, T. Folseraas, E. Ellinghaus, S.M. Rushbrook, N.T. Doncheva, O.A. Andreassen, R.K. Weersma, T.J. Weismüller, B. Eksteen, P. Invernizzi, G.M. Hirschfield, D.N. Gotthardt, A. Pares, D. Ellinghaus, T. Shah, B.D. Juran, P. Milkiewicz, C. Rust, C. Schramm, T. Müller, B. Srivastava, **G. Dalekos**, M.M. Nöthen, J. Winkelmann, M. Mitrovic, F. Braun, C.Y. Ponsioen, P.J.P. Croucher, M. Sterneck, A. Teufel, A.L. Mason, J. Saarela, V. Leppa, V. Pelkonen, R. Dorfman, D. Alvaro, A. Floreani, S. Onengut-Gumuscu, S.S. Rich, W.K. Thompson, A.J. Schork, S. Næss, I. Thomsen, G. Mayr, I.R. König, K. Hveem, I. Cleynen, J. Gutierrez-Achury, I. Ricaño-Ponce, D. van Heel, E. Björnsson, R.N. Sandford, P.R. Durie, E. Melum, M.H. Vatn, M. Silverberg, R.H. Duerr, L. Padyukov, S. Brand, M. Sans, V. Annese, Jean-Paul Achkar, K.M. Boberg, H-U Marschall, O. Chazouillères, C.L. Bowlus, C. Wijmenga, E. Schrumpf, S. Vermeire, M. Albrecht, The UK-PSC Consortium, The International IBD Genetics Consortium, J.D. Rioux, G. Alexander, A. Bergquist, J. Cho, S. Schreiber, M.P. Manns, M. Färkkilä, A.M. Dale, R.W. Chapman, K.N. Lazaridis, The International PSC Study Group, A. Franke, C.A. Anderson, T.H. Karlsen. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nature Genetics* 45:670-675, 2013.
91. A Mazioti, NK Gatselis, C Rountas, K Zachou, DK Filippiadis, K Tepetes, GK Koukoulis, I Fezoulidis, **GN Dalekos**. Safety and efficacy of transcatheter arterial chemoembolization in the real-life management of unresectable hepatocellular carcinoma. *Hepat Mon* 13:e7070, 2013.

92. Gatselis NK, Zachou K, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, **Dalekos GN**. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. *Autoimmunity* 46:471-479, 2013.
93. Zachou K, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, Saitis A, Boura P, **Dalekos GN**. Hepatitis B virus reactivation in HBsAg negative patients receiving immunosuppression: a hidden threat. *World J Hepatol* 5:387-392, 2013.
94. Manesis EK, Vourli G, **Dalekos G**, Vasiliadis T, Manolaki N, Hounta A, Koutsounas S, Vafiadis I, Nikolopoulou G, Giannoulis G, Germanidis G, Papatheodoridis G, Touloumi G. Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study. *J Hepatol* 59:949-956, 2013.
95. Rigopoulou EI, Zachou K, Gatselis NK, Papadamou G, Koukoulis GK, **Dalekos GN**. Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. *World J Hepatol* 5:577-583, 2013.
96. Rigopoulou EI, Zachou K, Gatselis N, Koukoulis GK, **Dalekos GN**. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. *Ann Hepatol* 13:127-135, 2014.
97. Georgiadou SP, Velegraki A, Arabatzis M, Neonakis I, Chatzipanagiotou S, **Dalekos GN**, Petinaki E. Cluster of *Fusarium verticillioides* bloodstream infections among immunocompetent patients in an internal medicine department after reconstruction works in Larissa, Central Greece. *J Hosp Infect* 86:267-271, 2014.
98. Anagnostou O, Manolakopoulos S, Bakoyannis G, Papatheodoridis G, Zisouli A, Raptopoulou-Gigi M, Manesis E, Ketikoglou I, **Dalekos G**, Gogos C, Vassiliadis T, Tzourmakliotis D, Karatapanis S, Kanatakis S, Zoumpoulis-Vafiadis I, Hounta A, Koutsounas S, Giannoulis G, Tassopoulos N, Touloumi G. Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. *Hippokratia* 18:57-64, 2014.
99. Kabaçam G, Wedemeyer H, Savaş B, Keskin O, **Dalekos G**, Tabak F, Idilman R, Erhardt A, Yalçın K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydın C; the HIDIT-1 Study Group. Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. *Liver Int* 34:1207-1215, 2014.
100. Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, **Dalekos GN**, Erhardt A, Tabak F, Yalçın K, Gurel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H. Late HDV RNA relapse after peginterferon alfa-based therapy of chronic hepatitis delta. *Hepatology* 60:87-97, 2014.
101. Kaffe ET, Rigopoulou EI, Koukoulis GK, **Dalekos GN**, Moulas AN. Oxidative stress and antioxidant status in patients with autoimmune liver diseases. *Redox Rep* 20:33-41, 2015.
102. Papatheodoridis GV, **Dalekos GN**, Yurdaydın C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. *J Hepatol* 62:363-370, 2015.
103. Zachou K, Gampeta S, Gatselis NK, Oikonomou K, Goulis J, Manoussakis MN, Renaudineau Y, Bogdanos DP, **Dalekos GN**. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. *Liver Int* 35:660-672, 2015.
104. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K,

- Ketikoglou I, Manesis E, Mela M, Hatzis G, **Dalekos GN**. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. *J Viral Hepat* 22:118-125, 2015.
- 105.Ntaios G, Melikoki V, Perifanos G, Perlepe K, Gioulekas F, Karagiannaki A, Tsantzali I, Lazarou C, Beradze N, Poulianiti E, Poulidakou M, Palantzas F, Kaditi S, Perlepe F, Sidiropoulos G, Papageorgiou K, Papavasileiou V, Vemmos K, Makaritsis K, **Dalekos GN**. Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-sectional national perception in Greece. *J Stroke Cerebrovasc Dis* 24:721-724, 2015.
- 106.Goulis I, Karatapanis S, Akriviadis E, Deutsch M, **Dalekos GN**, Raptopoulou-Gigi M, Mimidis K, Germanidis G, Drakoulis C, Triantos C, Zintzaras E, Bakalos G, Papatheodoridis G. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. *Liver Int* 35:1540-1548, 2015.
- 107.Georgiadou SP, Stefos A, Spanakos G, Skrimpas S, Makaritsis K, Sipsas NV, **Dalekos GN**. Current clinical, laboratory and treatment outcome characteristics of visceral leishmaniasis: results from a 7-year retrospective study in Greece. *Int J infect Dis* 34:e46-e50, 2015.
- 108.Sarrou S, Liakopoulos A, Chasioti M, Billinis C, Foka A, Tzanetou K, Pantelidi K, Roussaki-Schulze A, Hadjihannas L, Lachanas V, Skoulakis C, Makaritsis K, Daikos GL, **Dalekos G**, Spiliopoulou I, Petinaki E. Dissemination of methicillin-susceptible CC398 *Staphylococcus aureus* strains in a rural Greek area. *PLoS One* 10:e0122761, 2015.
- 109.Kalafateli M, Kourakli A, Gatselis NK, Lambropoulou P, Thomopoulos K, Tsamandas A, Christofidou M, Zachou K, Jelastopoulou E, Nikolopoulou V, Symeonidis A, **Dalekos GN**, Lambropoulou-Karatza C, Triantos CK. Efficacy of interferon a-2b monotherapy in b-thalassemics with chronic hepatitis C. *J Gastrointestin Liver Dis* 24:189-196, 2015.
- 110.Keskin O, Wedemeyer H, Tüzün A, Zachou K, Deda X, **Dalekos GN**, Heidrich B, Pehlivan S, Zeuzem S, Yalçın K, Gürel S, Tabak F, Idilman R, Bozkaya H, Manns M, Yurdaydin C. Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome. *Clin Gastroenterol Hepatol* 13:2342-2349, 2015.
- 111.Norman GL, Gatselis NK, Shums Z, Liaskos C, Bogdanos DP, Koukoulis GK, **Dalekos GN**. Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. *World J Hepatol* 7:1875-1883, 2015.
- 112.Lyberopoulou A, Chachami G, Gatselis NK, Kyrtzopoulou E, Saitis A, Gabeta S, Eliades P, Paraskeva E, Zachou K, Koukoulis GK, Mamalaki A, **Dalekos GN**, Simos G. Low serum hepcidin in patients with autoimmune liver diseases. *PLoS One* 10:e0135486, 2015.
- 113.Seaton RA, Menichetti F, **Dalekos G**, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K. Evaluation of effectiveness and safety of high-dose daptomycin: Results from patients included in the European Cubicin(®) Outcomes Registry and Experience. *Adv Ther* 32:1192-1205, 2015.
- 114.Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzarlis K, Zakyntinos E, **Dalekos GN**, Petinaki E. Rapid dissemination of colistin and carbapenem resistant *Acinetobacter baumannii* in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. *BMC Infect Dis* 15:559, 2015.
- 115.Papatheodoridis G, **Dalekos G**, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. *J Hepatol* 64:800-806, 2016.

116. Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, **Dalekos G**, Degertekin B, Dourakis S, Flisiak R, Goldberg D, Gore C, Goulis I, Hadziyannis S, Kalamitsis G, Kanavos P, Kautz A, Koskinas I, Leite BR, Malliori M, Manolakopoulos S, Matičić M, Papaevangelou V, Pirona A, Prati D, Raptopoulou-Gigi M, Reic T, Robaey G, Schatz E, Souliotis K, Tountas Y, Wiktor S, Wilson D, Yfantopoulos J, Hatzakis A. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. *J Viral Hepat* 23(Suppl 1):1-12, 2016.
117. Zachou K, Gatselis NK, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, **Dalekos GN**. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. *Aliment Pharmacol Ther* 43:1035-1047, 2016. **(Original article with Editorial)**.
118. Vourli G, Papatheodoridis G, Raptopoulou M, **Dalekos GN**, Hounta A, Nikolopoulou G, Zouboulis-Vafeiadis I, Manesis E, Kitis G, Gogos C, Ketikoglou I, Hatzis G, Vasiliadis T, Karatapanis S, Mimidis K, Drakoulis C, Touloumi G, The Hep-net-Greece. Association of antiviral therapy with reduced disease progression in chronic hepatitis B patients: Results from a nation-wide cohort study. *Hippokratia* 20:214-221, 2016.
119. Zachou K, Arvaniti P, Gatselis NK, Azariadi K, Papadamou G, Rigopoulou E, **Dalekos GN**. Patients with haemoglobinopathies and chronic hepatitis C: A real difficult to treat population in 2016? *Medit J Hematol Infect Dis* 9:e2017003, 2017.
120. Giamarellos-Bourboulis EJ, Tsaganos T, Tsangaris I, Lada M, Routsis C, Sinapidis D, Koupetori M, Bristianou M, Adamis G, Mandragos K, **Dalekos GN**, Kritselis I, Giannikopoulos G, Koutelidakis I, Pavlaki M, Antoniadou E, Vlachogiannis G, Koulouras V, Prekates A, Dimopoulos G, Koutsoukou A, Pnevmatikos I, Ioakeimidou A, Kotanidou A, Orfanos SE, Armaganidis A, Gogos C; Hellenic Sepsis Study Group. Validation of the new sepsis-3 definitions: proposal for improvement in early risk identification. *Clin Microbiol Infect* 23:104-109, 2017.
121. Zachou K, Gabeta S, Shums Z, Gatselis NK, Koukoulis GK, Norman GL, **Dalekos GN**. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. *Eur J Intern Med* 38:83-88, 2017.
122. Laskari K, Boura P, **Dalekos GN**, Garyfallos A, Karokis D, Pikazis D, Settas L, Skarantavos G, Tsitsami E, Sfikakis PP. Long-term beneficial effect of Canakinumab in colchicine-resistant Familial Mediterranean fever. *J Rheumatol* 44:102-109, 2017.
123. Liberal R, de Boer YS, Andrade RJ, Bouma G, **Dalekos GN**, Floreani A, Gleeson D, Hirschfield G, Invernizzi P, Lenzi M, Lohse A, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling J, Heneghan MA, on behalf of the International Autoimmune Hepatitis Group (IAIHG). Expert clinical management of autoimmune hepatitis in the real world. *Aliment Pharmacol Ther* 45:723-732, 2017.
124. Kaffe E, Katsifa A, Xylourgidis N, Ninou I, Zannikou M, Moissidou D, Foka P, Dimitriadis A, Georgopoulou U, Gorgoulis VG, **Dalekos GN** and Aidinis V. Hepatocyte autotaxin expression promotes liver fibrosis and cancer. *Hepatology* 65:1369-1383, 2017.
125. Gatselis NK, Vakrakou AG, Zachou K, Androutsakos T, Azariadi K, Hatzis G, Manoussakis MN, **Dalekos GN**. Decreased serum DNase1-activity in patients with autoimmune liver diseases. *Autoimmunity* 50:125-132, 2017.
126. Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser

- CN, **Dalekos GN**, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrupf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. *Gastroenterology* 152:1975-1984, 2017.
127. Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos Ch, Vassiliadis Th, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, **Dalekos GN**, Akriviadis E, Papatheodoridis GV. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β -thalassemia major results in high response rates with excellent safety. *Br J Haematol* 178:130-136, 2017.
128. Gatselis NK, Zachou K, Lygoura V, Azariadis K, Arvaniti P, Spyrou E, Papadamou G, Koukoulis GK, **Dalekos GN**, Rigopoulou EI. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. *Eur J Intern Med* 42:81-88, 2017.
129. Papatheodoridis GV, Idilman R, **Dalekos GN**, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavelas S, Keskin O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. *Hepatology* 66:1444-1463, 2017.
130. Skoutelis A, Pefanis A, Tsiodras S, Sipsas NV, Lelekis M, Lazanas MC, Gargalianos P, **Dalekos GN**, Roilides E, Samonis G, Maltezos E, Hatzigeorgiou D, Lada M, Metallidis S, Stoupis A, Chrysos G, Karnesis L, Symbardi S, Loupa CV, Giamarellou H, Kioumis I, Sambatakou H, Tsianos E, Kotsopoulou M, Georgopali A, Liakou K, Perlorezou S, Levidiotou S, Giotsa-Toutouza M, Tsorlini-Christoforidou H, Karaiskos I, Kouppari G, Trikka-Graphakos E, Ntrivala MA, Themeli-Digalaki K, Pangalis A, Kachrimanidou M, Martsoukou M, Karapsias S, Panopoulou M, Maraki S, Orfanou A, Petinaki E, Orfanidou M, Baka V, Stylianakis A, Spiliopoulou I, Smilakou S, Zerva L, Vogiatzakis E, Belesiotou E, Gogos CA. Point-prevalence survey of healthcare facility-onset healthcare-associated *Clostridium difficile* infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. *PLoS One* 12:e0182799, 2017.
131. Papatheodoridi M, **Dalekos GN**, Goulis J, Manolakopoulos S, Triantos C, Zachou K, Koukoulis A, Kourikou A, Zisimopoulos K, Tsoulas C, Papatheodoridis GV. Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. *Ann Gastroenterol* 30:542-549, 2017.
132. Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, **Dalekos GN**, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: Risk factors and time trends in incidence and outcome. *Am J Gastroenterol* 113:254-264, 2018.
133. Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, **Dalekos GN**, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwollegem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). *Liver Int* 38:842-850, 2018.
134. Murillo Perez F, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares

- A, Nevens F, Kowdley KV, Bruns T, **Dalekos GN**, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. *Hepatology* 67:1920-1930, 2018.
135. Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, Beuers U, Björnsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouillères O, Cheung A, **Dalekos G**, Eaton J, Eksteen B, Ellinghaus D, Färkkilä M, Festen EAM, Floreani A, Franceschet I, Gotthardt DN, Hirschfield GM, Hoek BV, Holm K, Hohenester S, Hov JR, Imhann F, Invernizzi P, Juran BD, Lenzen H, Lieb W, Liu JZ, Marschall HU, Marzioni M, Melum E, Milkiewicz P, Müller T, Pares A, Rupp C, Rust C, Sandford RN, Schramm C, Schreiber S, Schrupf E, Silverberg MS, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila AV, Vries B, Zachou K; International PSC Study Group, The UK PSC Consortium, Chapman RW, Manns MP, Pinzani M, Rushbrook SM, Lazaridis KN, Franke A, Anderson CA, Karlsen TH, Ponsioen CY, Weersma RK. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. *Gut* 67:1517-1524, 2018.
136. Papatheodoridis GV, Sypsa V, **Dalekos G**, Yurdaydin C, Van Boemmel F, Buti M, Goulis J, Luis Calleja J, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskin O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P. 8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. *J Hepatol* 68:1129-1136, 2018.
137. Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, **Dalekos GN**. DARING-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. *Antivir Ther* 23:677-685, 2018.
138. Malli E, Gatselis NK, **Dalekos GN**, Petinaki E. Combination of vial culture and broad-range PCR for the diagnosis of spontaneous bacterial peritonitis: experience in a Greek tertiary care hospital. *New Microbe and New Infect* 28:1-5, 2019.
139. Zachou K, Arvaniti P, Azariadis K, Lygoura V, Gatselis NK, Lyberopoulou A, Koukoulis GK, **Dalekos GN**. Prompt initiation of high dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. *Hepatol Res* 49:96-104, 2019.
140. Zachos I, Zachou K, **Dalekos GN**, Tzortzis V. Management of patients with liver cirrhosis and invasive bladder cancer: A case-series. *J Transl Int Med* 7:29-33, 2019.
141. Rigopoulou EI, Gyftaki S, Arvaniti P, Tsimourtou V, Koukoulis GK, Hadjigeorgiou G, **Dalekos GN**. Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. *Clin Res Hepatol Gastroenterol* 43:e25-e32, 2019.
142. Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, **Dalekos GN**, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HL, Hansen BE. Effects of age and sex of on response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis. *Clin Gastroenterol Hepatol* 17:2076-2084, 2019.

143. Murillo Perez CF, Hirschfield GM, Corpechot C, Floreani A, Mayo MJ, van der Meer A, Ponsioen CY, Lammers WJ, Parés A, Invernizzi P, Carbone M, Maria Battezzati P, Nevens F, Kowdley KV, Thorburn D, Mason AL, Trivedi PJ, Lindor KD, Bruns T, **Dalekos GN**, Gatselis NK, Verhelst X, Janssen HLA, Hansen BE, Gulamhusein A. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. *Aliment Pharmacol Ther* 50:1127-36, 2019.
144. Georgiadou S, Gatselis NK, Stefos A, Zachou K, Makaritsis K, Rigopoulou EI, **Dalekos GN**. Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ -immunoglobulin infusions. *World J Clin Cases* 7:3394-406, 2019.
145. Charras A, Arvaniti P, Le Dantec C, **Dalekos GN**, Zachou K, Bordron A, Renaudineau Y. JAK inhibitors and oxidative stress control. *Front Immunol* 10:2814, 2019.
146. Bakarozzi M, Mavropoulos A, Bogdanos DP, **Dalekos GN**, Rigopoulou EI. p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B. *J Viral Hepat* 27:52-60, 2020.
147. Papatheodoridi M, Hadziyannis E, Berby F, Zachou K, Testoni B, Rigopoulou E, Gatselis NK, Lyberopoulou A, Vlachogiannakos I, Manolakopoulos S, **Dalekos GN**, Zoulim F, Papatheodoridis GV. Predictors of HBsAg loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in non-cirrhotic HBeAg-negative chronic hepatitis B. *J Viral Hepat* 27:118-126, 2020.
148. Zachou K, Weiler-Normann C, Muratori L, Muratori P, Lohse AW, **Dalekos GN**. Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar. *Liver Int* 40:368-376, 2020.
149. Gatselis NK, Goet JC, Zachou K, Lammers WJ, Janssen HLA, Hirschfield G, Corpechot C, Lindor KD, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Lygoura V, Nevens F, Mason AL, Kowdley KV, Ponsioen CY, Bruns T, Thorburn D, Verhelst X, Harms MH, van Buuren HR, Hansen BE, **Dalekos GN**. Factors associated with progression and outcome in early-stage primary biliary cholangitis. *Clin Gastroenterol Hepatol* 18:684-692, 2020.
150. Charras A, Arvaniti P, Le Dantec Ch, **Dalekos GN**, Zachou K, Bordon A, Renaudineau Y. JAK inhibitors suppress innate epigenetic reprogramming: a promise for patients with Sjögren's syndrome. *Clin Rev Allerg Immunol* 58:182-93, 2020.
151. Hartl J, Miquel R, Zachou K, Wong G-W, Ashgar A, Pape S, Sebode M, Peiseler M, Zenouzi R, Ehken H, Krech T, Weiler-Normann C, Drenth JPH, Oo HY, **Dalekos GN**, Heneghan M, Schramm C, Lohse AW. Features and outcome of AIH patients with normal IgG. *JHEP Rep* 2:100094, 2020.
152. Arvaniti P, Le Dantec C, Charras A, Arleevskaya MA, Hedrich CM, Zachou K, **Dalekos GN**, Renaudineau Y. Linking genetic variation with epigenetic profiles in Sjögren's syndrome. *Clin Immunol* 210:108314, 2020.
153. Papatheodoridis GV, Sypsa V, **Dalekos GN**, Yurdaydin C, Van Boemmel F, Buti M, Calleja CL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Esteban R, Janssen HLA, Berg T, Lampertico P. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. *J Hepatol* 72:1088-96, 2020.
154. Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, **Dalekos GN**, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE. Goals of treatment for improved survival in primary biliary cholangitis: treatment target

should be bilirubin within the normal range and normalization of alkaline phosphatase. *Am J Gastroenterol* 115:1066-1074, 2020.

155. Deng Y, Campbell F, Han K, Theodore D, Deeg M, Huang M, Hamatake R, Lahiri S, Chen S, Horvath G, Manolakopoulos S, **Dalekos GN**, Papatheodoridis G, Goulis I, Banyai T, Jilma B, Leivers M. Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants. *J Viral Hepat* 27:699-708, 2020.
156. Arvaniti P, Giannoulis G, Gabeta S, Zachou K, Koukoulis GK, **Dalekos GN**. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. *JHEP Rep* 2:100123, 2020.
157. Tampaki M, Gatselis NK, Savvanis S, Koullias E, Saitis A, Gabeta S, Deutsch M, Manesis E, **Dalekos GN**, Koskinas J. Wilson disease: 30-year data on epidemiology, clinical presentation, treatment modalities and disease outcomes from 2 tertiary Greek centers. *Eur J Gastroenterol Hepatol* 32:1545-1552, 2020.
158. Wranke A, Hardtke S, Heidrich B, **Dalekos G**, Yalçın K, Tabak F, Gürel S, Çakaloğlu Y, Akarca US, Lammert F, Häussinger D, Müller T, Wöbse M, Manns MP, Idilman R, Cornberg M, Wedemeyer H, Yurdaydin C. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. *J Viral Hepat* 27:1359-1368, 2020.
159. Papatheodoridis GV, **Dalekos GN**, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. *J Hepatol* 73:1037-1045, 2020.
160. Gatselis NK, Tornai T, Shums Z, Zachou K, Saitis A, Gabeta S, Albesa R, Norman GL, Papp M, **Dalekos GN**. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. *World J Gastroenterol* 26:5130-5135, 2020.
161. Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, **Dalekos G**, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen H, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. *J Hepatol* 73:1368-1378, 2020.
162. Siakavellas S, Goulis J, Manolakopoulos S, Triantos C, Gatselis N, Tsentemidou E, Kranidioti H, Zisimopoulos K, Tsoulas C, **Dalekos G**, Papatheodoridis G. Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogues. *Ann Gastroenterol* 34:73-79, 2021.
163. Galaski J, Weiler-Normann C, Schakat M, Zachou K, Muratori P, Lampalzer S, Haag F, Schramm C, Lenzi M, **Dalekos GN**, Lohse AW. Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing. *J Hepatol* 74:312-320, 2021.
164. Gerussi A, Bernasconi DP, O'Donnell SE, Lammers WJ, Buuren HV, Hirschfield G, Janssen H, Corpechot C, Reig A, Pares A, Battezzati PM, Zuin MG, Cazzagon N, Floreani A, Nevens F, Gatselis N, **Dalekos G**, Mayo MJ, Thorburn D, Bruns T, Mason AL, Verhelst X, Kowdley K, van der Meer A, Niro GA, Beretta-Piccoli BT, Marzioni M, Belli LS, Marra F, Valsecchi MG, Lindor KD, Invernizzi P, Hansen BE, Carbone M. Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis. *Clin Gastroenterol Hepatol* 19:1688-1697, 2021.

165. Derben FC, Engel B, Zachou K, Hartl J, Hartleben B, Bantel H, Schramm C, **Dalekos GN**, Manns MP, Jaeckel E, Taubert R. CK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. *Liver Int* 41:123–127, 2021.
166. Zachou K, Lygoura V, Arvaniti P, Giannoulis G, Gatselis NK, Koukoulis GK, **Dalekos GN**. FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases. *Ann Hepatol* 22:100285, 2021.
167. Thair SA, He YD, Hasin-Brumshtein Y, Sakaram S, Pandya R, Toh J, Rawling D, Rimmel D, Coyle S, **Dalekos GN**, Koutsodimitropoulos I, Vlachogianni G, Gkeka E, Karakike E, Damoraki G, Antonakos N, Khatri P, Giamarellos-Bourboulis EJ, Sweeney TE. Transcriptomic similarities and differences in host response between SARS-CoV-2 and other viral infections. *iScience* 24:101947, 2021.
168. Papamichalis PA, Zachou K, Papamichali RA, Ioannou M, Gatselis NK, **Dalekos GN**, Koukoulis GK. Promyelocytic leukaemia (PML) antigen expression: a histological marker for primary biliary cholangitis diagnosis? *J Transl Int Med* 9:43-51, 2021.
169. Rigopoulou EI, Gatselis NK, Arvaniti P, Koukoulis GK, **Dalekos GN**. Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. *Eur J Intern Med* 85: 86-91, 2021.
170. Rigopoulou EI, Gatselis NK, Galanis K, Lygoura V, Gabeta S, Zachou K, **Dalekos GN**. The changing epidemiology of hepatitis B in Greece. *Ann Gastroenterol* 34:431-437, 2021.
171. Kyriazopoulou E, Panagopoulos P, Metallidis S, **Dalekos GN**, Poulakou G, Gatselis N, Karakike E, Saridaki M, Loli G, Stefos A, Prasianaki D, Georgiadou S, Tsachouridou O, Petrakis V, Tsiakos K, Kosmidou M, Lygoura V, Dareioti M, Milionis H, Papanikolaou IC, Akinosoglou K, Myrodi DM, Gravvani A, Stamou A, Gkavogianni T, Katrini K, Marantos T, Trontzas IP, Syrigos K, Chatzis L, Chatzis S, Vechlidis N, Avgoustou C, Chalvatzis S, Kyprianou M, van der Meer JW, Eugen-Olsen J, Netea MG, Giamarellos-Bourboulis EJ. An open label trial of anakinra to prevent respiratory failure in COVID-19. *Elife* 10:e66125, 2021.
172. Giannitsioti E, Pefanis A, Gogos C, Lekkou A, **Dalekos GN**, Gatselis N, Georgiadou S, Nikou P, Vrettou A, Rigopoulos A, Tryfonopoulos C, Tsaganos T, Karofilakis E, Psarrakis C, Argyriou M, Gargalianos-Kakolyris P, Adamis G, Lourida P, Kofteridis D, Andrianaki A, Loupa C, Kostis E, Sinapidis D, Sympardi S, Alexiou N, Karaikos I, Masgala A, Maltezos E, Panagopoulos P, Sachpekidis V, Evdoridis C, Sipsas NV, Daikos G, Giamarellou H. Evolution of epidemiological characteristics of infective endocarditis in Greece. *Int J Infect Dis* 106:213-220, 2021.
173. **Dalekos GN**, Stefos A, Georgiadou S, Lygoura V, Michail A, Ntaios G, Samakidou A, Giannoulis G, Gabeta S, Vlychou M, Petinaki E, Leventogiannis K, Giamarellos-Bourboulis EJ, Gatselis NK. Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. *Eur J Intern Med* 88:52-62, 2021.
174. **Dalekos GN**, Azariadis K, Lygoura V, Arvaniti P, Gampeta S, Gatselis NK. Autoimmune hepatitis in patients aged 70 years or older: disease characteristics, treatment response and outcome. *Liver Int* 41:1592-1599, 2021.
175. Goet JC, Murillo Perez CF, Harms MH, Floreani A, Cazzagon N, Bruns T, Prechter F, **Dalekos GN**, Verhelst X, Gatselis NK, Lindor KD, Lammers WJ, Gulamhusein A, Reig A, Carbone M, Nevens F, Hirschfield GM, van der Meer AJ, van Buuren HR, Hansen BE, Parés A; GLOBAL PBC Study Group. A comparison of prognostic scores (Mayo, UK-PBC, and GLOBE) in primary biliary cholangitis. *Am J Gastroenterol* 116:1514-1522, 2021.

176. Papatheodoridis GV, **Dalekos GN**, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. *JHEP Reports* 3:100290, 2021.
177. Laschtowitz A, Zachou K, Lygoura V, Pape S, Derben F, Jaeckel E, Oller-Moreno S, Weidemann S, Krech T, Piecha F, Schön G, Liebhoff AM, Al Tarrah M, Heneghan M, Drenth JPH, **Dalekos G**, Taubert R, Lohse AW, Schramm C. Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. *JHEP Reports* 3:100321, 2021.
178. Gatselis NK, Zachou K, Giannoulis G, Gabeta S, Norman GL, **Dalekos GN**. Serum cartilage oligomeric matrix protein and Golgi protein-73: New diagnostic and predictive tools for liver fibrosis and hepatocellular cancer? *Cancers* 13:3510, 2021.
179. Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, Fragkou A, Rapti A, Damoulari C, Fantoni M, Kalomenidis I, Chrysos G, Angheben A, Kainis I, Alexiou Z, Castelli F, Serino FS, Tsilika M, Bakakos P, Nicastrì E, Tzavara V, Kostis E, Dagna L, Koufargyris P, Dimakou K, Savvanis S, Tzatzagou G, Chini M, Cavalli G, Bassetti M, Katrini K, Kotsis V, Tsoukalas G, Selmi C, Bliziotis I, Samarkos M, Doumas M, Ktena S, Masgala, Papanikolaou I, Kosmidou M, Myrodi DM, Argyraki A, Cardellino CS, Koliakou K, Katsigianni EI, Rapti V, Giannitsioti E, Cingolani A, Micha S, Akinosoglou K, Liatsis-Douvitsas O, Symbardi S, Gatselis N, Mouktaroudi M, Ippolito G, Florou E, Kotsaki A, Netea MG, Eugen-Olsen J, Kyprianou M, Panagopoulos P, **Dalekos GN**, Giamarellos-Bourboulis EJ. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomised controlled phase 3 trial. *Nat Med* 27:1752-1760, 2021.
180. Gatselis N, Azariadis K, Lyberopoulou A, **Dalekos GN**. Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. *J Transl Autoimmun* 4:100126, 2021.
181. Sagris D, Florentin M, Tasoudis P, Korompoki E, Gatselis N, Giamarellos-Bourboulis EJ, Milionis H, Douketis J, Spyropoulos AC, **Dalekos G**, Ntaios G. Immunomodulation and reduction of thromboembolic risk in hospitalized COVID-19 patients: Systematic review and meta-analysis of randomized trials. *J Clin Med* 10:5366, 2021.
182. Speletas M, Dadouli A, Gatselis N, Syrakouli A, Germanidis G, Mouchtouri B, Koulas I, Samakidou A, Stefanos A, Hatzianastasiou S, Koureas M, Anagnostopoulou L, Tseroni M, Tsintzi G, Metallidis S, **Dalekos GN**, Hadjichristodoulou C. MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19. *Immunobiology* 226:152136, 2021.
183. Murillo Perez CF, Gulamhusein A, Carbone M, Trivedi PJ, van der Meer AJ, Corpechot C, Battezzati PM, Lammers WJ, Cazzagon N, Floreani A, Parés A, Nevens F, Lleo A, Mayo MJ, Kowdley KV, Ponsioen CY, **Dalekos GN**, Gatselis NK, Thorburn D, Mason AL, Janssen H, Verhelst X, Bruns T, Lindor KD, Chazouillères O, Invernizzi P, Hansen BE, Hirschfield GM. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis study group age, bilirubin, alkaline phosphatase risk assessment tool. *Eur J Gastroenterol Hepatol* 33(1S Suppl 1):e266-e273, 2021.
184. Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdisen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B; CREATE study group. Prediction of sustained response after

- nucleo(s)tide analogue cessation using hbsag and hbcrag levels - a multicenter study (CREATE). *Clin Gastroenterol Hepatol* 20:e784-e793, 2022.
185. Speletas M, Raftopoulou S, Farmaki E, Gatselis N, Germanidis G, Mouchtouri V, Hatzianastasiou S, Georgiadou S, Tsinti G, Tsachouridou O, Tseroni M, Metallidis S, **Dalekos G**, Eibel H, Hadjichristodoulou C. B cells and COVID-19: Lessons from agammaglobulinemia patients and the study of functional B cell polymorphisms. *J Investig Allergol Clin Immunol* 32:53-55, 2022.
 186. Samonakis DN, Gatselis N, Bellou A, Sifaki-Pistolla D, Mela M, Demetriou G, Thalassinos E, Rigopoulou EI, Kevrekidou P, Tziortziotis I, Azariadi K, Kavousanaki M, Digenakis E, Vassiliadis T, Kouroumalis EA, **Dalekos GN**. Spontaneous bacterial peritonitis: A prospective Greek multicenter study of its epidemiology, microbiology and outcome. *Ann Gastroenterol* 35:80-87, 2022.
 187. Taubert R, Engel B, Diestelhorst J, Hupa-Breier KL, Behrendt P, Baerlecken NT, Sühs KW, Janik MK, Zachou K, Sebode M, Schramm C, Londoño MC, Habes S; UK-AIH Consortium, Oo YH, Lalanne C, Pape S, Schubert M, Hust M, Dübel S, Thevis M, Jonigk D, Beimdiek J, Buettner FFR, Drenth JP, Muratori L, Adams DH, Dyson JK, Renand A, Graupera I, Lohse AW, **Dalekos GN**, Milkiewicz P, Stangel M, Maasoumy B, Witte T, Wedemeyer H, Manns MP, Jaeckel E. Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. *Hepatology* 75:13-27, 2022.
 188. **Dalekos GN**, Arvaniti P, Gatselis NK, Samakidou A, Gabeta S, Rigopoulou E, Koukoulis GK, Zachou K. First results from a propensity matching trial of mycophenolate mofetil vs. azathioprine in treatment-naïve AIH patients. *Front Immunol* 12:798602, 2022.
 189. Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Nam JY, Lee YB, Kim YJ, Yoon JH, Zoulim F, Lampertico P, **Dalekos GN**, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Papatheodoridis GV, Lee JH. Impact of HB_eAg on hepatocellular carcinoma risk during oral antiviral treatment in patients with chronic hepatitis B. *Clin Gastroenterol Hepatol* 20:1343-1353, 2022.
 190. Kim HY, Lampertico P, Nam JY, Lee H-C, Kim SU, Seo YS, Lee HA, Park SY, Lim Y-S, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim J-J, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, **Dalekos GN**, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen HLA, Jang M-J, Lee YB, Kim YJ, Yoon J-H, Papatheodoridis GV, Lee J-H. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. *J Hepatol* 76:311-318, 2022.
 191. Moon AM, Webb GJ, García-Juárez I, Kulkarni AV, Adali G, Wong DK, Lusina B, **Dalekos GN**, Masson S, Shore BM, Barnes E, Barritt AS 4th, Marjot T. SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination. *Hepatol Commun* 6:889-897, 2022.
 192. Makaritsis KP, Kotidis C, Papacharalampous K, Kouvaras E, Poulakida E, Tarantilis P, Asproдини E, Ntaios G, Koukoulis GK, **Dalekos GN**, Ioannou M. Mechanistic insights on the effect of crocin, an active ingredient of saffron on atherosclerosis in Apolipoprotein E knockout mice. *Coronary Artery Dis* 33:394-402, 2022.
 193. Shiha G, Soliman R, Mikhail NNH, Alswat K, Abdo A, Sanai F, Derbala MF, Örmeci N, **Dalekos GN**, Al-Busafi S, Hamoudi W, Sharara AI, Zaky S, El-Raey F, Mabrouk M, Marzouk S, Toyoda H. Development and multicenter validation of FIB-6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C. *Hepatol Res* 52:165-175, 2022.

194. Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Çalışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua A, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagioli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, **Dalekos GN**, N Assis D, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. *Liver Int* 42:607-614, 2022.
195. Karakike E, **Dalekos GN**, Koutsodimitropoulos I, Saridaki M, Pourzitaki C, Papatheodoros G, Kotsaki A, Chalvatzis S, Dimakopoulou V, Vechlidis N, Paramythiotou E, Avgoustou C, Ioakeimidou A, Kouriannidi E, Komnos A, Neou E, Rovina N, Stefanatou E, Milionis H, Nikolaidis G, Koutsoukou A, Damoraki G, Dimopoulos G, Zoumpos V, Eugen-Olsen J, Akinosoglou K, Gatselis NK, Koulouras V, Gkeka E, Markou N, Netea MG, Giamarellos-Bourboulis EJ. ESCAPE: An open-label trial of personalized immunotherapy in critically ill COVID-19 patients. *J Innate Immun* 14:218-228, 2022.
196. Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou A, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, **Dalekos G**, Kao JH, Hadziyannis S, Papatheodoridis G. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBsAg-negative chronic hepatitis B: A multicenter cohort study. *Liver Int* 42:541-550, 2022.
197. Pape S, Snijders RJALM, Gevers TJG, Chazouilleres O, **Dalekos GN**, Hirschfield GM, Lenzi M, Trauner M, Manns MP, Vierling JM, Montano-Loza AJ, Lohse AW, Schramm C, Drenth JPH, Heneghan MA, on behalf of the International Autoimmune Hepatitis Group (IAIHG) collaborators. International Autoimmune Hepatitis Group Report* Systematic review of response criteria and endpoints in autoimmune hepatitis. *J Hepatol* 76:841-849, 2022.
198. Tsilipounidaki K, Athanasakopoulou Z, Müller E, Burgold-Voigt S, Florou Z, Braun SD, Monecke S, Gatselis NK, Zachou K, Stefanos A, Tsagalas I, Sofia M, Spyrou V, Billinis C, **Dalekos GN**, Ehrlich R, Petinaki E. Plethora of resistance genes in carbapenem-resistant Gram-negative bacteria in Greece: no end to a continuous genetic evolution. *Microorganisms* 10:159, 2022.
199. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, **Dalekos GN**, Erler NS, Höner zu Siederdisen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B. Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels. *J Hepatol* 76:1042-1050, 2022.
200. Zachou K, Arvaniti P, Lyberopoulou A, Sevdali E, Speletas M, Ioannou M, Koukoulis GK, Renaudineau Y, **Dalekos GN**. Altered DNA methylation pattern characterizes the peripheral immune cells of patients with autoimmune hepatitis. *Liver Int* 42:1355-1368, 2022.
201. Giamarellos-Bourboulis EJ, Poulakou G, de Nooijer A, Milionis H, Metallidis S, Ploumidis M, Grigoropoulou P, Rapti A, Segala FV, Balis E, Giannitsioti E, Rodari P, Kainis I, Alexiou Z, Focà E, Lucio B, Rovina N, Scorzolini L, Dafni M, Ioannou S, Tomelleri A, Dimakou K, Tzatzagou G, Chini M, Bassetti M, Traketelli C, Tsoukalas G, Selmi C, Samaras C, Saridaki M, Pyrpassopoulou A, Kaldara E, Papanikolaou I, Argyraki A, Akinosoglou K, Koupetori M, Panagopoulos P, **Dalekos GN**, Netea MG. Development and validation of SCOPE score: a

clinical score to predict progression of COVID-19 pneumonia to severe respiratory failure. *Cell Rep Med* 3:100560, 2022.

202. Tasoudis PT, Arvaniti CK, Adamou AT, Belios I, Stone JH, Horick N, Sagrais D, **Dalekos GN**, Ntaios G. Interleukin-6 inhibitors reduce mortality in COVID-19: An individual patient data meta-analysis from randomized controlled trials. *Eur J Intern Med* 101:41-48, 2022.
203. Gatselis NK, Lygoura V, Lyberopoulou A, Giannoulis G, Samakidou A, Vaiou A, Vavidis G, Antoniou K, Stefanos A, Georgiadou S, Sagrais D, Sveroni D, Stergioula D, Gabeta S, Ntaios G, and **Dalekos GN**. Soluble IL-2R levels at baseline predict the development of severe respiratory failure and mortality in COVID-19 patients. *Viruses* 14:787, 2022.
204. Kassianidis G, Siampanos A, Poulakou G, Adamis G, Rapti A, Milionis H, **Dalekos GN**, Petrakis V, Sympardi S, Metallidis S, Alexiou Z, Gkavogianni T, Giamarellos-Bourboulis EJ, Theoharides TC. Calprotectin and imbalances between acute-phase mediators are associated with critical illness in COVID-19. *Int J Mol Sci* 23:4894, 2022.
205. Efe C, Kulkarni AV, Beretta-Piccoli BT, Magro B, Stättermayer AF, Cengiz M, Clayton-Chubb D, Lammert C, Bernsmeier C, Gül Ö, la Tijera FH, Anders M, Lytvyak E, Akin M, Purnak T, Liberal R, Peralta M, Ebik B, Duman S, Demir N, Balaban Y, Urzua Á, Contreras F, Venturelli MG, Bilgiç Y, Medina A, Giralda M, Günşar F, Londoño MC, Androutsakos T, Kisch A, Yurci A, Güzelbult F, Çağın YF, Avcı E, Akyıldız M, Dindar-Demiray EK, Harputluoğlu M, Kumar R, Satapathy SK, Mendizabal M, Silva M, Fagiuoli S, Roberts SK, Soyly NK, Idilman R, Yoshida EM, Montano-Loza AJ, **Dalekos GN**, Ridruejo E, Schiano TD, Wahlin S. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. *Hepatology* 76:1576-1586, 2022.
206. Papatheodoridis GV, Mimidis K, Manolakopoulos S, Gatselis N, Goulis J, Kapatais A, Manesis E, Vasiliadis T, Triantos C, Samonakis D, Sevastianos V, Karatapanis S, Elefsiniotis I, Deutsch M, Mylopoulou T, Papatheodoridi M, Kranidioti H, Agorastou P, Karaoulani T, Kyriazidou A, Zisimopoulos K, **Dalekos GN**. HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks. *Aliment Pharmacol Ther* 56:702-712, 2022.
207. Koukoulas K, Lygoura V, Kartalidis P, Gatselis NK, Petinaki E, **Dalekos GN**, Simos G. Hepcidin as a sensitive and treatment-responsive acute-phase marker in patients with bacteremia: A pilot study. *Diagnostics (Basel)* 12:1404, 2022.
208. Zachou K, Azariadis K, Sofia M, Lyberopoulou A, Arvaniti P, Gatselis N, Spyrou V, Billinis C, **Dalekos GN**. Acute non-A, non-B, non-C hepatitis differences and similarities between hepatitis E virus infection and autoimmune hepatitis, with phylogenetic analysis of hepatitis E virus in humans and wild boars. *Ann Gastroenterol* 35:532-540, 2022.
209. Skendros P, Germanidis G, Mastellos DC, Antoniadou C, Gavriilidis E, Kalopitas G, Samakidou A, Lontos A, Chrysanthopoulou A, Ntinopoulou M, Kogias D, Karanika I, Smyrlis A, Cepaityte D, Fotiadou I, Zioga N, Mitroulis I, Gatselis NK, Papagoras C, Metallidis S, Milionis H, **Dalekos GN**, Willems L, Persson B, Manivel VA, Nilsson B, Connolly ES, Iacobelli S, Papadopoulos V, Calado RT, Huber-Lang M, Risitano AM, Yancopoulou D, Ritis K, Lambris JD. Complement C3 inhibition in severe COVID-19 using compstatin AMY-101. *Sci Adv* 8:eabo2341, 2022.
210. Corpechot C, Carrat F, Gaouar F, Chau F, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Schramm C, Pares A, Olivas I, Eaton JE, Osman KT, **Dalekos G**, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmund E, Yehezkel E, Kremer AE, Deibel A, Dumortier J, Bruns T, Große K, Pageaux

- GP, Wetten A, Dyson J, Jones D, Chazouilleres O, Hansen B, de Lédighen V; Global & ERN Rare-Liver PBC Study Groups. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. *J Hepatol* 77:1545-1553, 2022.
211. Papatheodoridi M, Papachristou E, Moschidis Z, Hadziyannis E, Rigopoulou E, Zachou K, Villeret F, Magiorkinis G, Lyberopoulou A, Gatselis N, Vlachogiannakos I, Manolakopoulos S, **Dalekos GN**, Zoulim F, Paraskevis D, Papatheodoridis GV. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy. *J Viral Hepat* 29:948-957, 2022.
212. de Veer RC, van Hooff MC, Corpechot C, Thorburn D, Invernizzi P, Lammers WJ, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Parés A, Mason AL, Kowdley KV, Trivedi PJ, Hirschfield GM, Goet JC, Bruns T, **Dalekos GN**, Gatselis NK, Verhelst X, van Buuren HR, Hansen BE, Harms MH, van der Meer AJ - on behalf of the Global PBC Study Group. Liver-transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid. *Aliment Pharmacol Ther* 56:1408-1418, 2022.
213. Efe C, Taşçılar K, Bolis F, Lammert C, Ebik B, Stättermayer AF, Cengiz M, Gökçe DT, Gerussi A, Peralta M, Massoumi H, Montes P, Cerda E, Rigamonti C, Yapalı S, Adalı G, Çalışkan AR, Balaban Y, Eren F, Eşkazan T, Barutçu S, Lytvyak E, Zazueta GM, Aksoy-Kayhan M, Heurgue-Berlot A, De Martin E, Yavuz A, Bıyık M, Narro GC, Hernandez N, Gatselis NK, Aguirre J, Duman S, Idilman R, Silva M, Mendizabal M, Atay K, Güzelbulut F, Dhanasekaran R, Montano-Loza AJ, Ridruejo E, **Dalekos GN**, Invernizzi P, Wahlin S. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. *J Autoimmun* 132:102906, 2022.
214. Leventogiannis K, Kyriazopoulou E, Antonakos N, Kotsaki A, Tsangaris I, Markopoulou D, Grondman I, Rovina N, Theodorou V, Antoniadou E, Koutsodimitropoulos I, **Dalekos G**, Vlachogianni G, Akinosoglou K, Koulouras V, Komnos A, Kontopoulou T, Prekates A, Koutsoukou A, van der Meer JWM, Dimopoulos G, Kyprianou M, Netea MG, Giamarellos-Bourboulis EJ. Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial. *Cell Rep Med* 3:100817, 2022.
215. Murillo Perez F, Fisher H, Hiu S, Kareithi D, Adekunle F, Mayne T, Malecha E, Ness E, van der Meer AJ, Lammers WJ, Trivedi PJ, Battezzati PM, Nevens F, Kowdley KV, Bruns T, Cazzagon N, Floreani A, Mason AL, Ponsioen CY, Parés A, Londoño MC, Invernizzi P, Carbone M, Lleo A, Mayo MJ, **Dalekos GN**, Gatselis NK, Thorburn D, Verhelst X, Gulamhusein A, Janssen HLA, Trauner M, Bowlus CL, Lindor KD, Corpechot C, Jones D, Mells G, Hirschfield GM, Wason J, Hansen BE. Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. *Gastroenterology* 163:1630-1642.e3, 2022.
216. **Dalekos GN**, Arvaniti P, Gatselis NK, Gabeta S, Samakidou A, Giannoulis G, Rigopoulou E, Koukoulis GK, Zachou K. Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis. *JHEP Rep* 4:100601, 2022.
217. Chochlakis D, **Dalekos G**, Yachnakis E, Makridaki E, Psaroulaki A. Spotted Fever Group Rickettsiae in Greece: The Outcomes of a 15 Years Survey from the National Reference Centre. *Biomed J Sci Tech Res* 47:38063-38073, 2022.
218. Samaras C, Kyriazopoulou E, Poulakou G, Reiner E, Kosmidou M, Karanika I, Petrakis V, Adamis G, Gatselis NK, Fragkou A, Rapti A, Taddei E, Kalomenidis I, Chrysos G, Bertoli G, Kainis I, Alexiou Z, Castelli F, Saverio Serino F, Bakakos P, Nicastrì E, Tzavara V, Kostis E, Dagna L, Koukidou S, Tzatzagou G, Chini M, Bassetti M, Trakatelli C, Tsoukalas G, Selmi C, Samarkos M, Pyrpasopoulou A, Masgala A, Antonakis E, Argyraki A, Akinosoglou K,

- Sympardi S, Panagopoulos P, Milionis H, Metallidis S, Syrigos KN, Angel A, **Dalekos GN**, Netea MG, Giamarellos-Bourboulis EJ. Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia. *Cytokine* 162:156111, 2023.
219. Murillo Perez CF, Gerussi A, Trivedi PJ, Corpechot C, van der Meer AJ, Maria Battezzati P, Lindor KD, Nevens F, Kowdley KV, Bruns T, Cazzagon N, Floreani A, Tanaka A, Ma X, Mason AL, Gulamhusein A, Ponsioen CY, Carbone M, Lleo A, Mayo MJ, **Dalekos GN**, Gatselis NK, Thorburn D, Verhelst X, Parés A, Janssen HLA, Hirschfield GM, Hansen BE, Invernizzi P, Lammers WJ. Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe. *Eur J Gastroenterol Hepatol* 35:112-119, 2023.
220. Bergquist A, Weismüller TJ, Levy C, Rupp C, Joshi D, Nayagam JS, Montano-Loza AJ, Lytvyak E, Wunsch E, Milkiewicz P, Zenouzi R, Schramm C, Cazzagon N, Floreani A, Liby IF, Wiestler M, Wedemeyer H, Zhou T, Strassburg CP, Rigopoulou E, **Dalekos G**, Narasimman M, Verhelst X, Degroote H, Vesterhus M, Kremer AE, Bündgens B, Rorsman F, Nilsson E, Jørgensen KK, von Seth E, Cornillet Jeannin M, Nyhlin N, Martin H, Kechagias S, Wiencke K, Werner M, Beretta-Piccoli BT, Marzioni M, Isoniemi H, Arola J, Wefer A, Söderling J, Färkkilä M, Lenzen H; International PSC Study Group. Impact on follow-up strategies in patients with primary sclerosing cholangitis. *Liver Int* 43:127-138, 2023.
221. Akinosoglou K, Kotsaki A, Poulakou G, Metallidis S, Adamis G, Fragkou A, Fantoni M, Rapti A, Kalomenidis I, Chrysos G, Angheben A, Kainis I, Alexiou Z, Castelli F, Serino FS, Bakakos P, Nicastrì E, Tzavara V, Safarika A, Kostis E, Dagna L, Dimakou K, Tzatzagou G, Chini M, Bassetti M, Kotsis V, Tsoukalas G, Selmi C, Bliziotis I, Samarkos M, Doumas M, Damoraki G, Masgala A, Papanikolaou I, Argyraki A, Leventogiannis K, Symbardi S, Gatselis NK, Netea MG, Panagopoulos P, Milionis H, **Dalekos GN**, Giamarellos-Bourboulis EJ. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial. *eClinicalMedicine* 56:101785, 2023.
222. Mantaka A, Gatselis N, Triantos CK, Thalheimer U, Leandro G, Zachou K, Konstantakis C, Saitis A, Thomopoulos K, Kouroumalis EA, **Dalekos GN**, Samonakis DN. Treatment of portal vein thrombosis in cirrhosis: a multicenter real life cohort study. *Minerva Gastroenterol* 69:107-113, 2023.
223. de Veer RC, van Hooff MC, Corpechot C, Thorburn D, Invernizzi P, Lammers WJ, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Parés A, Mason AL, Kowdley KV, Trivedi PJ, Hirschfield GM, Goet JC, Bruns T, **Dalekos GN**, Gatselis NK, Verhelst X, Hansen BE, Harms MH, van der Meer AJ. Ursodeoxycholic acid treatment-induced GLOBE score changes are associated with liver transplantation-free survival in patients with primary biliary cholangitis. *Am J Gastroenterol* 118:1196-1203, 2023.
224. Zachou K, Azariadis K, Lytvyak E, Snijders RJALM, Takahashi A, Gatselis NK, Robles M, Andrade RJ, Schramm C, Lohse AW, Tanaka A, Drenth JPH, Montano-Loza AJ, **Dalekos GN**. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease. *JHEP Rep* 5:100778, 2023.
225. Sonneveld MJ, Chiu S-M, Park JY, Brakenhoff SM, Kaewdech A, Seto W-K, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bömmel F, Berg T, Zoulim F, Ahn AH, **Dalekos GN**, Erler NS, Brunetto M, Wedemeyer H, Cornberg M, Yuen M-F, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen C-H, Maasoumy B, for the CREATE study group. Lower pre-treatment hbv dna levels are associated with better off-treatment outcomes after Nucleo(S)Tide analogue withdrawal in patients with hbeag negative chronic hepatitis B: A multicenter cohort study. *JHEP Rep* 5:100790, 2023.

226. Murillo Perez CF, Ioannou S, Hassanally I, Trivedi PJ, Corpechot C, van der Meer AJ, Lammers WJ, Battezzati PM, Lindor KD, Nevens F, Kowdley KV, Bruns T, Cazzagon N, Floreani A, Mason AL, Gulamhusein A, Ponsioen CY, Carbone M, Lleo A, Mayo MJ, **Dalekos GN**, Gatselis NK, Thorburn D, Verhelst X, Parés A, Londoño MC, Janssen HLA, Invernizzi P, Vuppalanchi R, Hirschfield GM, Hansen BE, Levy C. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival. *Liver Int* 43:1497-1506, 2023.
227. Papatheodoridis G, Mimidis K, Manolakopoulos S, Triantos C, Vlachogiannakos I, Veretanos C, Deutsch M, Karatapanis S, Goulis I, Elefsiniotis I, Cholongitas E, Sevastianos V, Christodoulou D, Samonakis D, Manesis E, Kapatais A, Papadopoulos N, Ioannidou P, Germanidis G, Giannoulis G, Lakiotaki D, Kogias D, Kranidioti H, Zisimopoulos K, Mela M, Kontos G, Fytili P, Manolaka C, Agorastou P, Pantzios SI, Papatheodoridi M, Karagiannakis D, Geladari E, Psychos N, Zachou K, Chalkidou A, Spanoudaki A, Thomopoulos K, **Dalekos G**. HERACLIS-HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg-positive patients. *Liver Int* 43:1879-1889, 2023.
228. Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmund E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, **Dalekos GN**, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. *Hepatology* 78:397-415, 2023.
229. Schinas G, Dimakopoulou V, Dionysopoulos K, Fezoulidi G, Vlychou M, Vassiou K, Gatselis NK, Samakidou A, Giannoulis G, Tzouvelekis A, Marangos M, Gogos C, **Dalekos GN**, Kalogeropoulou C, Akinosoglou K. Radiologic Features of T10 Paravertebral Muscle Sarcopenia: Prognostic Factors in COVID-19. *J Clin Med Res* 15:368-376, 2023.
230. Bakaros E, Voulgaridi I, Paliatsa V, Gatselis N, Germanidis G, Asvestopoulou E, Alexiou S, Botsfari E, Lygoura V, Tsachouridou O, Mimitsoudis I, Tseroni M, Sarrou S, Mouchtouri VA, Dadouli K, Kalala F, Metallidis S, **Dalekos G**, Hadjichristodoulou C, Speletas M. Innate immune gene polymorphisms and COVID-19 prognosis. *Viruses* 15:1784, 2023.
231. Gatselis NK, Zachou K, Loza AJM, Cañado ELR, Arinaga-Hino T, Muratori P, Efe C, Floreani A, Invernizzi P, Takahashi A, Takaki A, Beretta-Piccoli BT, van Hoek B, Lytvyak E, Guedes LV, Purnak T, Cazzagon N, Lygoura V, Arvaniti P, Rigopoulou EI, Muratori L, **Dalekos GN**. Prevalence and significance of antimitochondrial antibodies in autoimmune hepatitis (AIH): Results from a large multicentre study of the International AIH Group. *Eur J Intern Med* 116:43-50, 2023. (Original article with Commentary).
232. Rigopoulou EI, Bakarozi M, Dimas I, Galanis K, Lygoura V, Gatselis NK, Koulentaki M, **Dalekos GN**. Total and individual PBC-40 scores are reliable for the assessment of health-related quality of life in Greek patients with primary biliary cholangitis. *J Transl Int Med* 11:246-254, 2023.
233. Terziroli Beretta-Piccoli B, Buescher G, **Dalekos G**, Zachou K, Geerts A, Semmo N, Kolev M, De Martin E, Janik MK, Madaleno J, Lalosevic Stojkovic M, Dumortier J, Vanwollegghem T, Schregel I, Steinmann S, Lacaille F, Sebode M. Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis. *J Autoimmun* 140:103113, 2023.
234. Arvaniti P, Giannoulis G, Lygoura V, Gatselis NK, Gabeta S, Rigopoulou E, Koukoulis GK, Zachou K, **Dalekos GN**. FibroMeter scores are predictive noninvasive markers of advanced

and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease. *Ann Gastroenterol* 36:661-669, 2023.

235. Anushiravani A, Alswat K, **Dalekos GN**, Zachou K, Örmeci N, Al-Busafi S, Abdo A, Sanai F, Mikhail NN, Soliman R, Shiha G. Multicenter validation of FIB-6 as a novel machine learning noninvasive score to rule out liver cirrhosis in biopsy proven MAFLD. *Eur J Gastroenterol Hepatol* 35:1284-1288, 2023.
236. Nayagam JS, Weismüller TJ, Milkiewicz P, Wronka KM, Bik E, Schramm C, Fuessel K, Zhou T, Chang J, Färkkilä M, Carlsson Y, Lundman A, Cazzagon N, Corrà G, Rigopoulou E, **Dalekos GN**, Båve AL, Bergquist A, Belkacem KB, Marzioni M, Mancinelli M, Verhelst X, Marschall H-U, Heneghan MA, Joshi D. Maternal liver-related symptoms during pregnancy in primary sclerosing cholangitis. *JHEP Rep* 6:100951, 2024
237. Gatselis NK, Lyberopoulou A, Lygoura V, Giannoulis G, Samakidou A, Vaiou A, Antoniou K, Triantafyllou K, Stefos A, Georgiadou S, Sagris D, Sveroni D, Gabeta S, Ntaios G, Norman GL, **Dalekos GN**. Calprotectin serum levels on admission and during follow-up predict severity and outcome of patients with COVID-19: A prospective study. *Eur J Intern Med* 122:78-85, 2024.
238. Corpechot C, Lemoine S, Soret PA, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Pares A, Olivas I, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, **Dalekos G**, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Dumortier J, Pageaux GP, de Lédinghen V, Chazouillères O, Carrat F. Adequate vs. deep response to UDCA in PBC: To what extent and under what conditions is normal ALP level associated with complication-free survival gain? *Hepatology* 79:39-48, 2024.
239. Slooter CD, van den Brand FF; Lleo A, Colapietro F, Lenzi M, Muratori P, Kerkar N, **Dalekos GN**, Zachou K, Lucena MI, Robles M, Di Zeo D, Andrade RJ, Montano-Loza AJ, Lytvyak E, Lissenberg-Witte BI, Bouma G, Dutch AIH Study Group, Liberal R, de Boer YS. Lack of complete biochemical response leads to adverse outcome in autoimmune hepatitis: first report of the IAIHG Retrospective Registry. *Hepatology* 79:538–550, 2024.
240. Chun HS, Papatheodoridis GV, Lee M, Lee HA, Kim YH, Kim SH, Oh YS, Park SJ, Kim J, Lee HA, Kim HY, Kim TH, Yoon EL, Jun DW, Ahn SH, Sypsa V, Yurdaydin C, Lampertico P, Calleja JL, Janssen H, **Dalekos GN**, Goulis J, Berg T, Buti M, Kim SU, Kim YJ. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B. *J Hepatol* 80:20-30, 2024.
241. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bömmel F, Janssen HL, Berg T, Zoulim F, Ahn SH, **Dalekos GN**, Erler NS, Brunetto M, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B. HBV DNA and HBsAg levels at 24 weeks off-treatment predict clinical relapse and HBsAg loss in HBeAg-negative patients who discontinued antiviral therapy. *Gastroenterology* 166:168-177.e8, 2024.
242. Colapietro F, Maisonneuve P, Lytvyak E, Beuers U, Verdonk RC, van der Meer AJ, van Hoek B, Kuiken SD, Brouwer JT, Muratori P, Aghemo A, Carella F, van den Berg AP, Zachou K, **Dalekos GN**, Di Zeo-Sánchez DE, Robles M, Andrade RJ, Montano-Loza AJ, van den Brand FF, Slooter CD, Macedo G, Liberal R, de Boer YS, Lleo A. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis. *J Hepatol* 80:53-61, 2024.

243. Dimou A, Zachou K, Kostara C, Azariadis K, Giannoulis G, Lyberopoulou A, Bairaktari E, **Dalekos GN**. NMR-based metabolomic signature: An important tool for the diagnosis and to study pathogenesis of autoimmune hepatitis. *Hepatology* 80:266-277, 2024.
244. Iliopoulou K, Koufargyris P, Doulou S, Tasouli E, Katopodis S, Chachali SP, Schinas G, Karachalios C, Astriti M, Katsaounou P, Chrysos G, Seferlis T, Dimopoulou E, Kollia M, Poulakou G, Gerakari S, Papanikolaou IC, Milionis H, **Dalekos GN**, Tzavara V, Kontopoulou T, Giamarellos-Bourboulis EJ. Developing a tool for differentiation between bacterial and viral respiratory infections using myxovirus resistance protein A and C-reactive protein. *Infect Dis Ther* 13:105-119, 2024.
245. Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, Doulou S, Kakavoulis N, Tsiakos K, Katopodis S, Schinas G, Skorda L, Alexiou Z, Armenis K, Katsaounou P, Chrysos G, Masgala A, Poulakou G, Antonakos N, Safarika A, Kyprianou M, Dakou K, Gerakari S, Papanikolaou IC, Milionis H, Marangos M, **Dalekos GN**, Tzavara V, Akinosoglou K, Hatziaggelaki E, Sympardi S, Kontopoulou T, Mouktaroudi M, Papadopoulos A, Niederman MS. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. *Lancet Respir Med* 12:294-304, 2024.
246. Koutalos AA, Koskinitis A, Rountas C, Konstantinou E, Georgiadou S, Stefos A, Gatselis NK, **Dalekos GN**, Malizos KN. Osteonecrosis risk after steroids-related treatment of COVID-19 is not negligible: A cross sectional study. *Eur J Intern Med* 123:127-131, 2024.
247. Kyriazopoulou E, Hasin-Brumshtein Y, Midic U, Poulakou G, Milionis H, Metallidis S, Astriti M, Fragkou A, Rapti A, Taddei E, Kalomenidis I, Chrysos G, Angheben A, Kainis I, Alexiou Z, Castelli F, Serino FS, Bakakos P, Nicastrì E, Tzavara V, Ioannou S, Dagna L, Dimakou K, Tzatzagou G, Chini M, Bassetti M, Kotsis V, Tsoukalas DG, Selmi C, Konstantinou A, Samarkos M, Dumas M, Masgala A, Pagkratis K, Argyraki A, Akinosoglou K, Symbardi S, Netea MG, Panagopoulos P, **Dalekos GN**, Liesenfeld O, Sweeney TE, Khatri P, Giamarellos-Bourboulis EJ. Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial. *Crit Care* 28:73, 2024.
248. Alswat K, Soliman R, Mikhail NNH, Örmeci N, **Dalekos GN**, Derbala MFM, Al-Busafi SA, Hamoudi W, Shiha G. Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B. *Saudi J Gastroenterol* 30:138-144, 2024.
249. Kyriazopoulou E, **Dalekos GN**, Metallidis S, Poulakou G, Papanikolaou IC, Tzavara V, Argyraki K, Alexiou Z, Panagopoulos P, Samarkos M, Chrysos G, Tseliou A, Milionis H, Sympardi S, Vasishta A, Giamarellos-Bourboulis EJ. Heparin-binding protein levels predict unfavorable outcome in COVID-19 pneumonia: A post-hoc analysis of the SAVE trial. *Shock* 61:395-399, 2024.
250. Engel B, Diestelhorst J, Hupa-Breier KL, Kirchner T, Henjes N, Loges S, Yuksel M, Janczyk W, Lalanne C, Zachou K, Oo YH, Gournay J, Pape S, Drenth JPH, Renand A, **Dalekos GN**, Muratori L, Socha P, Ma Y, Arian C, Baumann U, Manns MP, Wedemeyer H, Junge N, Jaeckel E, Taubert R. Detection of polyreactive immunoglobulin G facilitates diagnosis in children with autoimmune hepatitis. *Hepatol Int* 18:1214-1226, 2024.
251. Azariadis K, Gatselis NK, Lyberopoulou A, Arvaniti P, Zachou K, Gabeta S, **Dalekos GN**. PNPLA3 I148 M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality. *J Transl Autoimmun* 9:100243, 2024.
252. Wranke A, Lobato C, Ceausu E, **Dalekos GN**, Rizzetto M, Turcanu A, Niro GA, Keskin O, Gherlan G, Abbas M, Ingiliz P, Muche M, Buti M, Jachs M, Vanwolleghem T, Cornberg M,

- Abbas Z, Yurdaydin C, Dörge P, Wedemeyer H on behalf of the Hepatitis Delta International Network. Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International Network (HDIN). *Liver Int* 44:2442-2457, 2024.
253. Lam L, Soret PA, Lemoine S, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Parés A, Olivás I, Londono MC, Rodríguez-Tajes S, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, **Dalekos G**, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristofori L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Levy C, Tanaka A, Dumortier J, Pageaux GP, de Lédighen V, Carrat F, Chazouillères O, Corpechot C; Global & ERN Rare-Liver PBC Study Groups. Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis. *Clin Gastroenterol Hepatol* 22:2432-2441.e2, 2024.
254. Schregel I, Papp M, Sipeki N, Kovats PJ, Taubert R, Engel B, Campos-Murguía A, **Dalekos GN**, Gatselis N, Zachou K, Milkiewicz P, Janik M, Raszeja-Wyszomirska J, Ytting H, Braun Felix, Casar C, Sebode M, Lohse AW, Schramm C on behalf of the European Reference Network (ERN) RARE-LIVER. Unmet needs in autoimmune hepatitis: results of the prospective multicentre European Reference Network Registry (R-LIVER). *Liver Int* 44:2687-2699, 2024.
255. Gómez-Huelgas R, **Dalekos GN**, Dicker D, Montano N. Internal medicine in the 21st century: Back to the future. *Eur J Intern Med* 128:26-29, 2024.
256. Stern L, Schmidt C, Kocheise L, Joerg V, Casar C, Walter A, Drenth JPH, Papp M, Gatselis NK, Zachou K, Pinter M, Scheiner B, Vogel A, Kirstein MM, Finkelmeier F, Waidmann O, Weinmann A, Milkiewicz P, Thorburn D, Halliday N, Lleo A, Huber S, **Dalekos GN**, Lohse AW, Wege H, von Felden J, Schulze K. Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma. *Ann Hepatol* 29:101534, 2024.
257. Kranidioti E, Ricaño-Ponce I, Antonakos N, Kyriazopoulou E, Kotsaki A, Tsangaris I, Markopoulou D, Rovina N, Antoniadou E, Koutsodimitropoulos I, **Dalekos GN**, Vlachogianni G, Akinosoglou K, Koulouras V, Komnos A, Kontopoulou T, Dimopoulos G, Netea MG, Kumar V, Giamarellos-Bourboulis EJ. Modulation of metabolomic profile in sepsis according to the state of immune activation. *Crit Care Med* 52:e536-e544, 2024.
258. Karakike E, Metallidis S, Poulakou G, Kosmidou M, Gatselis NK, Petrakis V, Rovina N, Gkeka E, Sympardi S, Papanikolaou I, Koutsodimitropoulos I, Tzavara V, Adamis G, Tsiakos K, Koulouras V, Mouloudi E, Antoniadou E, Vlachogianni G, Anisoglou S, Markou N, Koutsoukou A, Panagopoulos P, Milionis H, **Dalekos GN**, Kyprianou M, Giamarellos-Bourboulis EJ. Clinical phenotyping for prognosis and immunotherapy guidance in bacterial sepsis and COVID-19. *Crit Care Explor* 6:e1153, 2024.
259. Roberts SB, Choi WJ, Worobetz L, Vincent C, Flemming JA, Cheung A, Qumosani K, Swain M, Grbic D, Ko HH, Peltekian KM, Abrahamyan L, Saini M, Tirona K, Aziz B, Lytvyak E, Invernizzi P, Ponsioen CY, Bruns T, Cazzagon N, Lindor K, **Dalekos GN**, Gatselis NK, Verhelst X, Floreani A, Corpechot C, Mayo MJ, Levy C, Londoño MC, Battezzati PM, Pares A, Nevens F, van der Meer A, Kowdley KV, Trivedi PJ, Lleo A, Thorburn D, Carbone M, Selzner N, Gulamhusein AF, Janssen H, Montano-Loza AJ, Mason AL, Hirschfield GM, Hansen BE; Canadian Network for Autoimmune Liver disease (CaNAL). Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis. *JHEP Rep* 6:101168, 2024.

260. Olivas I, Arvaniti P, Gabeta S, Torres S, Del Barrio M, Díaz-González A, Esteban P, Riveiro-Barciela M, Mauro E, Rodríguez-Tajes S, Zachou K, **Dalekos GN**, Londoño M-C. Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis. *JHEP Rep* 6:101213, 2024.
261. Brandes-Leibovitz R, Riza A, Yankovitz G, Pirvu A, Dorobantu S, Dragos A, Streata I, Ricaño-Ponce I, de Nooijer A, Dumitrescu F, Antonakos N, Antoniadou E, Dimopoulos G, Koutsodimitropoulos I, Kontopoulou T, Markopoulou D, Aimoniotou E, Komnos A, **Dalekos GN**, Ioana M, Giamarellos-Bourboulis EJ, Gat-Viks I, Netea MG. Sepsis pathogenesis and outcome are shaped by the balance between the transcriptional states of systemic inflammation and antimicrobial response. *Cell Rep Med* 5:101829, 2024.
262. Papaefthymiou A, Sarrou S, Pateras K, Vachliotis ID, Agrotis G, Sgantzu IK, Perifanos G, Kapsoritakis A, Speletas M, Vlychou M, **Dalekos GN**, Potamianos S, Goulas A, Kountouras J, Polyzos SA. The effect of biologic agents on steatotic liver disease in patients with inflammatory bowel disease: A prospective, open-label comparative trial. *Pharmaceuticals (Basel)* 17:1432, 2024.
263. Kyriazopoulou E, Akinosoglou K, Florou E, Kouriannidi E, Bogosian A, Tsachouridou O, Syrigos KN, Gatselis N, Milionis H, Papanikolaou IC, Sympardi S, Dafni M, Alevizou A, Amvrazi AV, Alexandrou E, Archontoulis K, Argyraki K, Alexiou Z, Georgiou Y, Gkogka D, Kyrailidi F, Kalyva V, Nikolopoulou T, Ioannou S, Bakakos P, Karathanassiou G, Koklanos K, Miletis DN, Tili AM, Vakkas L, Vila I, Panagopoulos P, Samarkos M, Chrysos G, **Dalekos GN**, Poulakou G, Metallidis S, Giamarellos-Bourboulis EJ. Anakinra efficacy in COVID-19 pneumonia guided by soluble urokinase plasminogen activator receptor: association with the inflammatory burden of the host. *Int J Antimicrob Agents* 65:107405, 2025.
264. Giannitsioti E, Stefanos A, Damoraki G, Georgiadou S, Pavlaki M, Giamarellos-Bourboulis EJ, **Dalekos G**. TLR4 and TNF- α single nucleotide polymorphisms in patients with brucellosis: Association with infection complications. *Eur J Intern Med* 131:121-124, 2025.
265. Kyriazopoulou E, Kotsaki A, Safarika A, Poulakou G, Milionis H, Metallidis S, Adamis G, Fragkou A, Rapti A, Del Vecchio P, Kalomenidis I, Kitzoglou D, Angheben A, Kainis I, Iliopoulou K, Serino FS, Bakakos P, Tzavara V, Ioannou S, Dagna L, Dimakou K, Tzatzagou G, Chini M, Bassetti M, Kotsis V, Tsoukalas G, Selmi C, Nikolakopoulou S, Samarkos M, Doumas M, Masgala A, Papanikolaou I, Argyraki A, Akinosoglou K, Symbardi S, Panagopoulos P, **Dalekos GN**, Liesenfeld O, Sweeney TE, Khatri P, Giamarellos-Bourboulis EJ. 29-mRNA host response signatures for classification of bacterial infection, viral infection and disease progression in COVID-19 pneumonia: a post hoc analysis of the SAVE-MORE randomized clinical trial. *Intensive Care Med Exp* 13:67, 2025.
266. Rigopoulou EI, Lygoura V, Gabeta S, Gatselis N, Giannoulis G, **Dalekos GN**. Increased IgG levels at diagnosis are associated with worse prognosis of patients with primary biliary cholangitis. *Liver Int* 45:e70074, 2025.
267. Sagris D, Antoniadou C, Gatselis NK, Gavriilidis E, Papadopoulos V, Georgiadou S, Gabeta S, Tsironidou V, Makaritsis KP, Skendros P, Rigopoulou EI, Ritis K, **Dalekos GN**. R202Q homozygosity of Mediterranean fever gene is associated with atypical clinical phenotype of familial Mediterranean fever. *Eur J Intern Med* 138:69-75, 2025.
268. Werner E, van Hooff MCB, Weijsters GHX, Abbas N, Gerussi A, Willemse JA, Mitchell-Thain R, Leburgue A, Hirschfield GM, Corpechot C, Schramm C, Levy C, Nevens F, Verbeek J, Mason AL, **Dalekos G**, Cazzagon N, Mells GF, Kowdley KV, Carbone M, Jones DE, Hansen BE, Trivedi PJ, van der Meer AJ; Global PBC Study Group/ERN RARE-LIVER/Question Prompt List. Development of a question prompt list for people living with primary biliary cholangitis - A Delphi Study. *Clin Gastroenterol Hepatol* 23:1935-1942.e5., 2025.

269. Papatheodoridi M, Sevastianos V, Zachou K, Christodoulou D, Koskinas J, Deutsch M, Alexopoulou A, Elefsiniotis I, Triantos C, Gigi E, Androutsakos T, Karagiannakis D, Mani I, Dimitroulopoulos D, Mela M, Sinakos E, Michopoulos S, Mimidis K, Papadopoulos N, Kontos A, Veretanos C, Lymperopoulos D, Giannoulis G, Papadimitropoulos V, Avramopoulou E, Papatheodoridi A, Pantzios S, Vasilieva L, Kranidioti H, Koullias E, Psychos N, Fytili P, Vlachogiannakos J, Cholongitas E, Manolakopoulos S, Goulis I, **Dalekos G**, Papatheodoridis G. HERACLIS_BLV_D: Increasing Response Rates During 2-Year Bulevirtide Real-Life Therapy in Chronic Hepatitis D. *Liver Int* 45:e70151, 2025.
270. Gerussi A, Nofit E, Bernasconi DP, Kroll C, Groß F, Schregel I, Marini A, Cristoferi L, Malinverno F, Papp M, **Dalekos G**, Rigopoulou E, Janik MK, Milkiewicz P, Ytting H, Leburgue A, Braun F, Casar C, Sebode M, Lohse A, Hansen B, Carbone M, Schramm C, Invernizzi P. Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER). *United European Gastroenterol J* 13:1955-1963, 2025.
271. Arvaniti P, Zachou K, Lyberopoulou A, Sevdali E, Gabeta S, Speletas M, Renaudineau Y, **Dalekos GN**. Cell-specific epigenome-wide DNA methylation in peripheral CD4(+) lymphocytes from patients with primary biliary cholangitis. *J Transl Autoimmun* 11:100314, 2025.
272. Kirchner T, Junge N, Henjes N, Loges S, Yuksel M, Janczyk W, Lalanne C, Zachou K, Oo YH, Gournay J, Pape S, Drenth JPH, Renand A, **Dalekos GN**, Muratori L, Socha P, Arikan C, Ma Y, Wedemeyer H, Baumann U, Engel B, Taubert R. Complementary use of autoantibody detection methods facilitates diagnosis of juvenile autoimmune hepatitis and autoimmune sclerosing cholangitis. *JHEP Rep* 8:101706, 2026.
273. Arvaniti P, Rodríguez-Tajes S, Padilla M, Olivás I, Mauro E, Maimouni CE, Lytvyak E, Verhelst X, Engel B, Taubert R, Lorente-Pérez S, Conde I, Riveiro-Barciela M, Ruiz-Cobo JC, Álvarez-Navascués C, Salcedo M, Gómez J, Janik MK, Mateos B, Efe C, Granito A, Datji E, Azzaroli F, Horta D, Vila C, Castello I, Pérez-Medrano I, Arencibia A, Gerussi A, Bruns T, Colapierto F, Lleo A, Van den Ende N, Verbeek J, Díaz-González Á, Morillas RM, Torner-Simó M, Bernal V, Fernández EM, Gevers TJ, Beretta-Piccoli BT, Gómez E, Cuenca P, de Boer YS, Kerkar N, Assis DN, Liberal R, Drenth JP, Tana MM, Sebode M, Schregel I, Schramm C, Lohse AW, Montano-Loza AJ, Zachou K, Villamil A, **Dalekos GN**, Londoño MC; International Autoimmune Hepatitis Group (IAIHG), ERN-Liver, ColHai Registry. Hepatic encephalopathy and MELD-Na predict treatment benefit in autoimmune hepatitis-related decompensated cirrhosis. *Clin Gastroenterol Hepatol* 2026 (in press).
274. Wong YJ, Lam L, Soret PA, Lemoine S, Hansen B, Hirschfield G, Gulamhusein A, Lytvyak E, Pares A, Olivás I, Londoño MC, Rogriguez-Tajes S, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, **Dalekos G**, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmund E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Levy C, Tanaka A, Dumortier J, Pageaux GP, de Lédinghen V, Carrat F, Chazouillères O, Corpechot C, Montano-Loza AJ; Global & ERN Rare-Liver PBC Study Groups. Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis. *J Hepatol* 2026 (in press).
275. Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, Efthymiou A, Koutsoukou V, Ehler J, Paridou A, Frantzeskaki F, Müller MCA, Pickkers P, Meylan S, Nikolopoulos I, Lupse M, Gavala A, Vlachogianni G, Solomonidi N, Alevizou A, Kondili E, Antoniadou E, Nakou M, Markou N, Hatziagelaki E, Prekates A, Komnos A, Bakkerus L, Slim MA, **Dalekos GN**, Karapanagiotou A, Ktena S, De Pascale G, Koulouras V, Psarrakis C, Massa E, Dakou K,

Pazvanti C, Ioakeimidou A, Tsangaris I, Antonakos N, Vlaar APJ, Anisoglou S, Calandra T, Papaioannou V, Myrianthefs P, Patrani M, Alamanos I, Antonelli M, van der Meer JWM, van der Poll T, Wiersinga WJ, Ntaganou M, Gkeka E, Bauer M, Mouloudi E, Netea MG; ImmunoSep Study Group. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. *JAMA* 2026 (in press).

B2. Reviews - Guidelines

1. **G.N. Dalekos**, K. Zachou, Ch. Liaskos. The antiphospholipid syndrome and infection. **(Invited review)**. *Curr Rheumatol Reports*, 3:277-285, 2001.
2. **G.N. Dalekos**, K. Zachou, C. Liaskos, N. Gatselis. Autoantibodies and defined target-autoantigens in autoimmune hepatitis: An overview. *Eur J Intern Med* 13:293-303, 2002.
3. K. Zachou, E. Rigopoulou, and **G.N. Dalekos**. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. *J Autoim Dis* 1:2, 2004 (15 October 2004) **(Invited Review; this article has qualified as 'Highly accessed'; Accesses 43000 up to 31-12-2020)**.
4. E.I. Rigopoulou **and G.N. Dalekos**. Molecular diagnostics of primary biliary cirrhosis. *Expert Opin Med Diagn (now Expert Rev Mol Diagn)* 2:621-634, 2008. **(Invited review)**.
5. D.P. Bogdanos **and G.N. Dalekos**. Enzymes as autoantigens of liver-specific autoimmunity. *Curr Med Chem* 15:2285-2292, 2008. **(Invited review)**.
6. I. Goulis **and G.N. Dalekos**. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. *Expert Rev Anti-Infect Ther* 6:855-859, 2008. **(Invited review)**.
7. Oikonomou KG, Zachou K, **Dalekos GN**. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. *Autoimmun Rev* 10:389-396, 2011.
8. Tillmann HL, Zachou K, **Dalekos GN**. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? *Liver Int* 32:544-553, 2012.
9. Ntaios G, Gatselis NK, Makaritsis K, **Dalekos GN**. Adipokines as mediators of endothelial function and atherosclerosis. *Atherosclerosis* 227:216-221, 2013.
10. Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, **Dalekos GN**, Muratori L. Review article: Autoimmune hepatitis – current management and challenges. *Aliment Pharmacol Ther* 38:887-913, 2013.
11. Gatselis NK, Ntaios G, Makaritsis K, **Dalekos GN**. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. *Clin Exp Med* 14:121-131, 2014.
12. Gatselis NK, Zachou K, Saitis A, Samara M, **Dalekos GN**. Individualization of chronic hepatitis C treatment according to the host characteristics. *World J Gastroenterol* 20:2839-2853, 2014 **(Invited review)**.
13. Gatselis N, Zachou K, Koukoulis GK, **Dalekos GN**. Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics. *World J Gastroenterol* 21:60-83, 2015. **(Invited review)**.
14. Georgiadou SP, Makaritsis KP, **Dalekos GN**. Leishmaniasis revisited: Current aspects on epidemiology, diagnosis, and treatment. *J Transl Int Med* 3:43-50, 2015. **(Invited review)**.
15. **European Association for the Study of the Liver***. EASL Clinical Practice Guidelines: Autoimmune hepatitis. *J Hepatol* 63:971-1004, 2015. *Chairman: Ansgar W. Lohse. Panel members: Olivier Chazouillures, **George Dalekos**, Joost Drenth, Michael Heneghan, Harald Hofer, Frank Lammert, Marco Lenzi.

16. Gatselis NK, **Dalekos GN**. Molecular diagnostic testing for primary biliary cholangitis. *Expert Rev Mol Diagn* 16:1001-1010, 2016. **(Invited review)**.
17. **Dalekos GN**, Lygoura V, Gatselis NK. Variants of primary biliary cholangitis: An updated mini review. *J Autoimmune Dis Rheumatol* 6:21-28, 2018. **(Invited review)**.
18. **Dalekos GN**, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver (HASL) Clinical Practice Guidelines: Autoimmune Hepatitis. *Ann Gastroenterol* 32:1-23, 2019.
19. Dyson JK, De Martin E, **Dalekos GN**, Drenth JPH, Herkel J, Hubscher SG, Kelly D, Lenzi M, Milkiewicz P, Oo YH, Heneghan MA, Lohse AW, on behalf of the IAIHG Consortium. Review article: unanswered clinical and research questions in autoimmune hepatitis- conclusions of the International Autoimmune Hepatitis Group Research Workshop. *Aliment Pharmacol Ther* 49:528-536, 2019.
20. Papatheodoridis GV, Goulis J, Sypsa V, Lionis C, Manolakopoulos S, Elefsiniotis I, Anagnostou O, Tsoulas C, Hatzakis A, **Dalekos GN**. Aiming towards hepatitis C virus elimination in Greece. *Ann Gastroenterol* 32:321-329, 2019.
21. **Dalekos GN**, Gatselis NK. Variant and specific forms of autoimmune cholestatic liver diseases: A short review. *Arch Immunol Ther Exp (Warsz)* 67:197-211, 2019. **(Invited review)**.
22. Arvaniti P, Zachou K, Lyberopoulou A, Gatselis NK, Brooks WH, **Dalekos GN**, Renaudineau Y. Epigenetic modifications in generalized autoimmune epithelitis: Sjögren's syndrome and primary biliary cholangitis. *Epigenomes* 3,15, 2019.
23. Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, **Dalekos G**, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. *J Autoimmun* 105:102328, 2019.
24. **Dalekos GN**, Gatselis NK, Zachou K, Koukoulis GK. NAFLD and autoimmune hepatitis: Do not judge a book by its cover. *Eur J Intern Med* 75:1-9, 2020. **(Invited review)**.
25. Rigopoulou EI, **Dalekos GN**. Current trends and characteristics of hepatocellular carcinoma in patients with autoimmune liver diseases. *Cancers* 13:1023, 2021 **(Invited review)**.
26. Zachou K, Arvaniti P, Lyberopoulou A, **Dalekos GN**. Impact of genetic and environmental factors on autoimmune hepatitis. *J Transl Autoimmun* 4:100125, 2021. **(Invited review)**.
27. **Dalekos GN**, Samakidou A, Lyberopoulou A, Banakou E, Gatselis NK. Recent advances in the diagnosis and management of autoimmune hepatitis. *Pol Arch Intern Med* 132:16334, 2022. **(Invited review)**.
28. **Dalekos GN**, Gatselis NK. Autoimmune serology testing in clinical practice: An updated roadmap for the diagnosis of autoimmune hepatitis. *Eur J Intern Med* 108:9-17, 2023. **(Invited review)**.
29. **Dalekos GN**, Papatheodoridis GV, Koskinas J, Goulis I, Rigopoulou EI, Tiniakos D on behalf of the Hellenic Study Group for Autoimmune Liver Diseases of HASL. Hellenic Association for the Study of the Liver (HASL): Revised Clinical Practice Guidelines of Autoimmune Hepatitis. *Ann Gastroenterol* 37:623-654, 2024.
30. **European Association for the Study of the Liver***. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. ***Chairman: George N. Dalekos**. Panel members: Nikolaos Gatselis, Joost P Drenth, Michael Heneghan, Marianne Jørgensen, Ansgar W Lohse,

Maria Londoño, Luigi Muratori, Maria Papp, Marianne Samyn, Dina Tiniakos, Ana Lleo. *J Hepatol* 83:453-501, 2025.

31. Gabeta S, **Dalekos GN**, Gatselis NK. Management of asymptomatic patients with abnormal liver function tests. *Eur J Intern Med* 141:106429, 2025.

B3. Editorials – Perspectives - Commentaries

1. **G.N. Dalekos**, D.P. Bogdanos and J. Neuberger. Celiac disease-related autoantibodies in end-stage autoimmune liver diseases: What is the message? *Liver Int* 28:426-428, 2008.
2. E.I. Rigopoulou, **G.N. Dalekos**. Can mathematical models be useful in clinical hepatology? *Liver Int* 30:637-638, 2010.
3. Zachou K, **Dalekos GN**. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. *Liver Int* 31:277-279, 2011.
4. Georgiadou SP, Giamarellos-Bourboulis EJ, **Dalekos GN**. Monkeypox: A real new warning or just a sign of times? *J Transl Int Med* 11:15-18, 2023.
5. van Erpecum KJ, **Dalekos GN**. New horizons in the diagnosis and management of patients with MASLD. *Eur J Intern Med* 122:1-2, 2024.
6. Gabeta S, Rigopoulou EI, **Dalekos GN**. Artificial intelligence supported ultrasonography: Can it be the solution for early and accurate diagnosis of steatotic liver disease? *Eur J Intern Med* 125:41-43, 2024.
7. von Wowern F, **Dalekos GN**, Gómez-Huelgas R. Intermediate care units in internal medicine - From concept to consolidation. *Eur J Intern Med* 137:35-36, 2025.

B4. Case Reports

1. **G.N. Dalekos**, G.C. Liapi, P. Dallas, D. Stefanou, M. Elisaf: Stauffer's syndrome as first manifestation of renal cell carcinoma. A case report. *Eur J Intern Med* 5:319-320, 1994.
2. E.V. Tsianos, **G.N. Dalekos**, C. Tzermias, M.H. Merkouropoulos, J. Hatzis. Hidradenitis suppurativa in Crohn's disease. A further support to this association. *J Clin Gastroenterol* 20:151-153, 1995.
3. **G.N. Dalekos**, F.N. Skopouli, E.V. Tsianos. Primary biliary cirrhosis associated with anticardiolipin syndrome. *Eur J Intern Med* 6:179-181, 1995.
4. **G.N. Dalekos**, C. Papas, L.G. Christou, J. Pneumáticos, G. Nakos. Severe erysipelas in a previously healthy man: possible link with Epstein-Barr virus infection. *Eur J Intern Med* 7:53-56, 1996.
5. K.L. Bourantas, L.G. Christou, **G.N. Dalekos**, K. Barbati, E.V. Tsianos. A 54-year-old stockbreeder with ascites. *Lancet* 349:994, 1997.
6. A. Polyzos, C. Sinani, N. Kelekis, G. Papadamou, K. Patsiaoura, and **G.N. Dalekos**. Advanced intrahepatic cholangiocarcinoma in a patient with end-stage HCV-associated liver disease. *Eur J Gastroenterol Hepatol* 15:331-334, 2003.
7. K. Zachou, E. Rigopoulou, C. Liaskos, K. Patsiaoura, E. Makri, N. Stathakis, and **G.N. Dalekos**. Primary biliary cirrhosis presented as peripheral eosinophilia in asymptomatic women with or without elevated alkaline phosphatase. *Eur J Gastroenterol Hepatol* 16:425-428, 2004.
8. N. Kelekis, E. Makri, A. Vasiou, K. Patsiaoura, M. Spiridakis and **G.N. Dalekos**. Confluent hepatic fibrosis as the presenting imaging sign in non-advanced alcoholic cirrhosis. *Clin Imaging* 28:124-127, 2004.

9. A. Stefos, S.P. Georgiadou, C. Gioti, A. Loukopoulos, M. Ioannou, S. Pournaras, **and G.N. Dalekos**. Leptospirosis and pancytopenia: Two case reports and review of the literature. *J Infection* 51:e277-280, 2005.
10. N. Gatselis, E. Malli, G. Papadamou, E. Petinaki, **and G.N. Dalekos**. Direct detection of *Cardiobacterium hominis* in serum from a patient with infective endocarditis by broad-range bacterial PCR. *J Clin Microbiol* 44:669-672, 2006.
11. N. Tzovaras, A. Stefos, S.P. Georgiadou, N. Gatselis, G. Papadamou, E. Rigopoulou, M. Ioannou, I. Skoularigis **and G.N. Dalekos**. Reversion of severe hepatopulmonary syndrome in a non-cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: A case report and review of the literature. *World J Gastroenterol* 12:336-339, 2006.
12. E. Tsironi, N. Gatselis, M.G. Kotoula, D. Z. Chatzoulis, **G.N. Dalekos**. Unexplained choroidal embolization: Remember the antiphospholipid syndrome. *Lancet* 368:1936, 2006.
13. N.K. Gatselis, A. Stefos, C. Gioti, E.I. Rigopoulou and **G.N. Dalekos**. Primary biliary cirrhosis and Henoch-Schonlein purpura: Report of two cases and review of the literature. *Liver Int* 27:280-283, 2007.
14. A. Daponte, M. Ioannou, C. Gioti, A. Kallitsaris, **G.N. Dalekos**, I.E. Messinis. Primary retroperitoneal non-Hodgkin lymphoma presenting with torturous generalized pruritus in an elderly. *Arch Gynecol Obstet* 275:287-289, 2007.
15. N.K. Gatselis, K. Tepetes, A. Loukopoulos, K. Vasiou, A. Zafiriou, C. Gioti, and **G.N. Dalekos**. Hepatitis B virus and intrahepatic cholangiocarcinoma: report of two cases and review of the literature. *Cancer Investigation* 25:55-58, 2007.
16. K. Zachou, P. Papamichalis, **and G.N. Dalekos**. Severe pharyngitis in stockbreeders: an unusual presentation of brucellosis. *Occup Med* 58:305-307, 2008.
17. N.K. Gatselis, S. Barbanis, F. Karasavidou, **G.N. Dalekos**. Could the 90s be a second childhood period? The case of Henoch-Schonlein purpura. *Age & Ageing* 37:483, 2008.
18. Stefanidis I, Giannopoulou M, Liakopoulos V, Dovas S, Karasavvidou F, Zachou K, Koukoulis GK, **Dalekos GN**. A case of membranous nephropathy associated with Sjogren syndrome, polymyositis, and autoimmune hepatitis. *Clin Nephrol* 70:245-250, 2008.
19. Makaritsis KP, Gatselis NK, Ioannou M, Petinaki E, **Dalekos GN**. Polyclonal hypergammaglobulinaemia and high smooth muscle autoantibodies titres with specificity against filamentous actin: Consider visceral leishmaniasis, not just autoimmune hepatitis. *Int J Infect Dis* 13:e157-160, 2009.
20. KP Makaritsis, Ch Neocleous, N Gatselis, E Petinaki **and GN Dalekos**. An immunocompetent patient presenting with severe septic arthritis due to *Ralstonia pickettii* identified by molecular-based assays: a case report. *Cases J* 2:8125, 2009.
21. E. Tsironi, N. Gatselis, M.G. Kotoula, K. Zachou, M. Pefkianaki, F. Zacharaki, D.Z. Chatzoulis **and G.N. Dalekos**. Ocular disorders as the prevailing manifestations of the antiphospholipid syndrome: three case reports. *Cases J* 2:159, 2009.
22. Gatselis NK, Zachou K, **Dalekos GN**. Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. *Gastroenterol Res Pract* 2010. pii:121620, 2010.
23. Gatselis NK and **Dalekos GN**. Education and imaging. Hepatobiliary and pancreatic: Primary hepatic lymphoma. *J Gastroenterol Hepatol* 26:210, 2011.
24. Gatselis NK, Makaritsis KP, Gabranis I, Karanikas K and **Dalekos GN**. Unusual cardiovascular complications of brucellosis presenting in two men: two case reports and a review of the literature. *J Med Case Reports* 5:22, 2011.

25. Papamichalis P, Argyraki K, Papamichalis M, Loukopoulos A, **Dalekos GN**, Rigopoulou EI. Salmonella enteritidis infection complicated by acute myocarditis: a case report and review of the literature. *Cardiol Res Pract* 2011:574230, 2011.
26. Koumati E, Palassopoulou M, Matsouka P, Polyzos A, **Dalekos GN**, Zachou K. Multiple autoimmune propensity and B-non-hodgkin lymphoma: cause or effect? *Autoimmune Dis* 2011:841325, 2011.
27. Papamichalis P, Alexiou A, Boulbou M, **Dalekos GN**, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? *Clin Res Hepatol Gastroenterol (previous Gastroentérologie Clinique et Biologique)* 36:84-93, 2012.
28. Gatselis NK, Liamis G, Makaritsis KP, **Dalekos GN**. Metabolic acidosis during treatment of mushroom poisoning: a diagnostic pitfall. *Intern Med* 51:1077-1080, 2012.
29. Stefos A, Gatselis N, Goudelas A, Mpakarosi M, Papaparaskevas J, **Dalekos G**, Petinaki E. Cutaneous infection caused by Bacillus anthracis in Larissa, Thessaly, Central Greece, July 2012. *Euro Surveill* 17(32). pii:20245, 2012.
30. Skrimpas S, Polyzos A, **Dalekos GN**, Zachou K. Quiz: Sternoclavicular joint swelling in a previously healthy adult. *Internal Med: Open Access* 2:2, 2012.
31. Saitis A, Gatselis NK, **Dalekos GN**. Leishmaniasis-associated haemophagocytic syndrome revisited: not an uncommon clinical presentation of leishmaniasis. *J Med Cases* 3:315-318, 2012.
32. Zellos A, Spoulou V, Roma-Giannikou E, Karentzou O, **Dalekos GN**, Theodoridou M. Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact? *Ann Hepatol* 12:147-151, 2013.
33. Makaritsis KP, Liaskos C, Papadamou G, **Dalekos GN**. Spontaneous bacterial peritonitis: an unusual manifestation of brucellosis in a previous healthy male patient. *BMJ Case Reports* pii: bcr2015209387, 2015.
34. Kalafateli M, Triantos C, Tsamandas A, **Dalekos GN**. Spontaneous cirrhosis regression in an IFN-beta-induced AIH-like syndrome following drug withdrawal: Art of facts or artifacts? *Eur J Case Rep Intern Med* 3:doi:10.12890/2016_000396, 2016.
35. Gatselis NK, Skendros P, Ritis K, **Dalekos GN**. Severe liver involvement in two patients with long-term history of fever: remember familial Mediterranean fever. *BMJ Case Rep* pii: bcr2016216941, 2016.
36. Rigopoulou EI, Ioannou M, Papadamou G, **Dalekos GN**. Ascites in a patient with episodic angio-oedema and eosinophilia: thinking outside the box. *BMJ Case Rep* pii: bcr-2017-219467, 2017.
37. Polychronopoulou E, Lygoura V, Gatselis NK, **Dalekos GN**. Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. *BMJ Case Rep* pii: bcr-2017-220824, 2017.
38. Doumstis P, Oikonomou T, Goulis I, Zachou K, **Dalekos G**, Cholongitas E. Type 1 autoimmune hepatitis presenting with severe autoimmune neutropenia. *Ann Gastroenterol* 31:123-126, 2018.
39. Arvaniti P, Zachou K, Koukoulis GK, **Dalekos GN**. Postinfantile giant cell hepatitis with features of acute severe autoimmune hepatitis probably triggered by diclofenac in a patient with primary myelofibrosis. *Case Rep Hepatol* 2018:9793868, 2018.

40. Georgiadou SP, Manoulakas E, Makaritsis K, **Dalekos GN**. A chronic alcoholic man with high fever, neck rigidity and loss of consciousness: Remember the Austrian syndrome a commonly unrecognized invasive pneumococcus triad. *BMJ Case Reports pii: bcr-2018-225010*, 2018.
41. Sveroni D, Stefos A, Rigopoulou EI, **Dalekos GN**. Rifampicin: not always an innocent drug. *BMJ Case Reports pii: e227356*, 2018.
42. Azariadis K, Gatselis NK, Koukoulis GK, **Dalekos GN**. Glycogenic hepatopathy as a cause of severe deranged liver enzymes in a young patient with type 1 diabetes mellitus. *BMJ Case Rep pii: e228524*, 2019.
43. Azariadis K, Giannoulis G, Gabeta S, Michail A, Zachou K, **Dalekos GN**. Severe pharyngodynia followed by migratory polyarthritis and high fever in young immigrants: remember that rheumatic fever is still relevant in 2020! *Case Rep Infect Dis doi: 10.1155/2020/8854868 eCollection*, 2020.
44. Vatidis G, Rigopoulou EI, Tepetes K, **Dalekos GN**. Hepatic brucellosis: a rare complication of a common zoonotic disease. *BMJ Case Rep 13:e237076*, 2020.
45. **Dalekos GN**, Gatselis NK, Koukoulis GK. Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. *BMJ Case Reports 13:e238400*, 2020.
46. Azariadis K, Ioannou M, Zachou K, **Dalekos GN**. An immunocompetent HIV-negative elderly patient with low-grade fever, generalized lymphadenopathy, splenomegaly, and acute phase response: Do not forget Castleman disease. *Case Rep Infect Dis doi: 10.1155/2021/6614208 eCollection*, 2021.
47. Pervanidou D, Georgiadou S, Stavropoulou E, Stefos A, Tsioka K, Kefaloudi CN, Gatselis N, Makaritsis K, Makris D, Kyriaki P, Chatzianastasiou S, Maragkos A, Georgakopoulou T, Paraskeva D, Paraskevis D, Papachristou O, Papatheodorou S, Damaskou S, Kaouna V, Sotiraki S, Saratsis A, Liakata A, Papasteriou D, Kartsoulis E, Bogogiannidou Z, Kokkali S, Voulgaridi I, Sarrou S, Stoikou K, Pappa S, Tsakalidou O, Mouchtouri V, Marinou K, Fragkou IA, Hatzigeorgiou D, Papa A, **Dalekos GN**, Hadjichristodoulou C. Two autochthonous cases of Crimean-Congo haemorrhagic fever and the One Health response, Thessaly, Greece, 2025. *Euro Surveill 30:2500717*, 2025.

B5. Letters

1. **G.N. Dalekos**, E.V. Tsianos: Antineutrophil antibodies in chronic viral hepatitis. *J Hepatol 20:561*, 1994.
2. **G.N. Dalekos**, E. Zervou, E.V. Tsianos. IgM antibodies to HCV in chronic active hepatitis in NW Greece. Solution or more questions? *J Hepatol 22:509*, 1995.
3. C. Tzermias, **G.N. Dalekos**, J. Hatzis, E.V. Tsianos: Pyoderma gangrenosum: successful treatment with intralesional injections of corticosteroids. *J Eur Acad Dermatol Venerol 5:197-199*, 1995.
4. **G.N. Dalekos**, E. Zervou, K. Bourantas, E.V. Tsianos. Viral hepatitis and idiopathic (autoimmune) thrombocytopenic purpura. Is there any relationship? *J Hepatol, 25:1000-1001*, 1996.
5. **G.N. Dalekos**, J. Hatzis, E.V. Tsianos. Dermatologic disease during interferon-alpha therapy for chronic viral hepatitis. *Ann Intern Med 128:409-410*, 1998.
6. **G.N. Dalekos**, E. Zervou, M. Elisaf, D.S. Boumba, K. Katopodis, G. Sferopoulos, K.C. Siamopoulos, E.V. Tsianos. Increased prevalence of markers of GBV-C/HGV infection in a

selected cohort of haemodialysis patients negative for other blood-borne viruses. *Nephrol Dial Transpl* 14:255-256, 1999.

7. E. Rigopoulou, **G.N. Dalekos**. Anti-sp100 antibodies in primary biliary cirrhosis. *Scand J Gastroenterol* 39:406-407, 2004.
8. I. Stefanidis, V. Liakopoulos, E.I. Rigopoulou, **G.N. Dalekos**. Diagnostic discordance for hepatitis C virus infection in hemodialysis: correlations with clinical and laboratory features. *Am J Kidney Dis* 46:992-993, 2005.
9. D.P. Bogdanos, C. Liaskos, E.I. Rigopoulou, **G.N. Dalekos**. Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen. *Clin Chim Acta (Letter)* 373:183-184, 2006.
10. **G.N. Dalekos**, K. Makaritsis, E.I. Rigopoulou. Redesigning training for internal medicine. What needs to be done? *Ann Intern Med* 145:865, 2006.
11. C. Liaskos, D.P. Bogdanos, E.T. Davies, **G.N. Dalekos**. Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. *J Clin Pathol* 60:107-108, 2007.
12. C. Liaskos, D.P. Bogdanos, E.I. Rigopoulou, **G.N. Dalekos**. Development of anti-mitochondrial antibodies in patients with autoimmune hepatitis: an art of facts or an artifact? *J Gastroenterol Hepatol* 22:454-455, 2007.
13. E.I. Rigopoulou, **G. Dalekos**, D.P. Bogdanos. How common are connective tissue disorders in patients with autoimmune hepatitis? *Sem Arthritis Rheum* 36:332, 2007.
14. D.P. Bogdanos, C. Liaskos, A. Pares, G. Norman, E.I. Rigopoulou, L. Caballeria, **G.N. Dalekos**, J. Rodes, D. Vergani. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. *Hepatology* 45:1583, 2007.
15. E.I. Rigopoulou **and GN Dalekos**. Autoimmune hepatitis: of host and pathogen. *Hepatology* 47:2147-2148, 2008.
16. S.P. Georgiadou **and G.N. Dalekos**. Which level of immunosuppression is harmful for occult hepatitis B virus infection? 'A million dollar's answer. *Liver Int* 29:1127-1128, 2009.
17. A. Koutsoumpas, M. Mytilinaiou, D. Polymeros, **G.N. Dalekos**, D.P. Bogdanos. Anti-*Helicobacter pylori* antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific anti-mitochondrial antibodies. *Eur J Gastroenterol Hepatol* 21:1220, 2009.
18. Saitis A, Gatselis N, Zachou K, **Dalekos GN**. Use of TNF α antagonists in refractory AIH: revealing the unforeseen. *J Hepatol* 59:197-198, 2013.
19. Lohse AW, Chazouilleres O, **Dalekos G**, Drenth JP, Heneghan M, Hofer H, Lammert F, Lenzi M; EASL Clinical Practice Guidelines: Autoimmune hepatitis panel. Reply to "Further considerations in autoimmune hepatitis". *J Hepatol* 64:1458-1459, 2016.
20. **Dalekos GN**, Zachou K. Editorial: autoimmune hepatitis - identifying options for treatment. Authors' reply. *Aliment Pharmacol Ther* 43:1237-1238, 2016.
21. Zachou K, Gabeta S, Gatselis NK, Norman GL, **Dalekos GN**. Cartilage oligomeric matrix protein on the spot for liver fibrosis evaluation: Too early or too late? *Eur J Intern Med* 43:e48-e49, 2017.
22. **Dalekos GN**, Gatselis NK, Zachou K. Acute severe autoimmune hepatitis: corticosteroids or liver transplantation? The importance of the absence of any sign of encephalopathy. *Liver Transpl* 25:1588-1589, 2019.
23. Rigopoulou EI, Gabeta S, Lygoura V, **Dalekos GN**. IgG baseline serum levels and prognosis of primary biliary cholangitis. *Liver Int* 45:e70229, 2025.

24. **Dalekos GN**, Gatselis N, Tiniakos D; EASL CPG panel members. EASL CPG: Liver biopsy cannot be skipped for the diagnosis of autoimmune hepatitis. *J Hepatol* 83:e278-e279, 2025.

B6. Collaborative papers

1. S. Shivananda, J Lennard-Jones, R. Logan, N. Fear, A. Price, L. Carpenter, M. van Blankenstein, S. Shivananda, J Lennard-Jones, R. Logan, N. Fear, A. Price, L. Carpenter, M. van Blankenstein, S. Bjornsson, J.H. Johansson, E. Oddsson, B. Moum, M. Vatn, E. Aadland, O. Fausa, I. Lygren, J. Sauar, T. Schulz, N. Stray, R. Stave, E. Langholz, V. Binder, P. Vedtofte, J. Sonne, R. Collins, C. Omorain, J. Mayberry, I. Carr, M. Russel, R. Stockbrugger, H. Goebell, B. Katschinski-Breuer, J.L. Dupas, P. Bianchi, T. Ranzi, M.C. Campannini, M. Curzio, R. Gullotta, P. Bodoni, P. Politi, G. Lupinacci, A. Zambelli, G. Fornaciari, M. Beltrami, M.G. Mortilla, F. Nicoli, L. Serra, G. Trallori, A. Bonanomi, G. dAlbasio, F. Pacini, V.R. Ochoa, A. delaFuente, F. Tardaguila, D.D. Rodriguez, S. Pereira, D.M. Butron, D.M. Cueto, L. Alvarez Cervea, J. Clofent, J.R. Pineda, E. Brullet, X. Bonfill, G. Urrutia, F.T. Veloso, R. Noronha, E. Tsianos, **G. Dalekos**, E. Monteiro, J. Freitas, P. Borralho, F.C. Leal, C. Soares, P. Martins, M. Dupond, M. Cottone, G. Filippazzo, R. Ayala, J. Mouzas, O. Manousos, S. Odes, R. Brower, J. Campbell, R. Doll, A. Ekbom. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative study on Inflammatory Bowel Disease (EC-IBD). *Gut* 39:690-697, 1996.
2. J. E. Lennard-Jones, S. Shivananda, N. Fear, L. Carpenter, M. van Blankenstein, S. Bjornsson, J.H. Johansson, E. Oddsson, B. Moum, M. Vatn, E. Aadland, O. Fausa, I. Lygren, J. Sauar, T. Schulz, N. Stray, R. Stave, E. Langholz, V. Binder, P. Vedtofte, J. Sonne, R. Collins, C. Omorain, J. Mayberry, I. Carr, M.G.V.M. Russel, R. Stockbrugger, H. Goebell, B. Katschinski-Breuer, J.L. Dupas, P. Bianchi, T. Ranzi, M.C. Campannini, M. Curzio, R. Gullotta, P. Bodoni, P. Politi, G. Lupinacci, A. Zambelli, G. Fornaciari, M. Beltrami, M.G. Mortilla, F. Nicoli, L. Serra, G. Trallori, A. Bonanomi, G. dAlbasio, F. Pacini, V.R. Ochoa, A. delaFuente, F. Tardaguila, D.D. Rodriguez, S. Pereira, D.M. Butron, D.M. Cueto, L. Alvarez Cervea, J. Clofent, J.R. Pineda, E. Brullet, X. Bonfill, G. Urrutia, F.T. Veloso, R. Noronha, E. Tsianos, **G. Dalekos**, E. Monteiro, J. Freitas, P. Borralho, F.C. Leal, C. Soares, P. Martins, M. Dupond, M. Cottone, G. Filippazzo, R. Ayala, J. Mouzas, O. Manousos, S. Odes, R. Brower, J. Campbell, R. Doll, A. Ekbom, Logan RF, Price AB. Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe. *Eur J Gastroenterol Hepatol* 9:353-359, 1997.
3. M.G.V.M. Russel, A. Volovics, E.J. Schoon, E.H.J. van Wijlick, R.F. Logan, S. Shivananda, R. Stockbrugger, E. Langholz, V. Binder, J.L. Dupas, H. Goebell, B. Katschinski-Breuer, E. Tsianos, **G. Dalekos**, J. Mouzas, O. Manousos, S. Bjornsson, E. Oddsson, S. Odes, C. O'Morain, R. Collins, P. Bianchi, T. Ranzi, P. Bodoni, P. Politi, M. Cottone, G. Fornaciari, M. Beltrami, G. Trallori, A. Bonanomi, M. Vatn, B. Moum, F.T. Veloso, R. Noronha, E. Monteiro, J. Freitas, E. Brullet, X. Bonfill, V.R. Ochoa, A. de la Fuente, J. Mayberry, I. Carr. Inflammatory bowel disease: Is there any relation between smoking status and disease presentation? *Inflamm Bowel Dis* 4:182-186, 1998.
4. Wiegand J, Wedemeyer H, Franke A, Röbber S, Zeuzem S, Teuber G, Wächter M, Römmele U, Ruf B, Spengler U, Trautwein C, Bock CT, Fiedler GM, Thiery J, Manns MP, Brosteanu O, Tillmann HL; **German Hep-Net Acute Hepatitis B (GAHB) Study Group**. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. *J Viral Hepat* 21:744-750, 2014.
5. Mangia A, Foster GR, Berg CP, Curescu M, De Ledingham V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S on behalf of **the PegBase Group Investigators**. Efficacy and safety profile of boceprevir- or telaprevir-based

triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. *Ann Gastroenterol* 30:327-343, 2017.

6. Gutiérrez-Gutiérrez B, Sojo-Dorado J, Bravo-Ferrer J, Cuperus N, de Kraker M, Kostyanov T, Raka L, Daikos G, Feifel J, Folgiori L, Pascual A, Goossens H, O'Brien S, Bonten MJ, Rodríguez-Baño J; **EURECA project team**. European prospective cohort study on Enterobacteriaceae showing RESistance to CARbapenems (EURECA): a protocol of a European multicentre observational study. *BMJ Open* 7:e015365, 2017.
7. Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; **Hepatitis Delta International Network (HDIN)**. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. *J Hepatol* 70:1008-1015, 2019.
8. Freire M, Sopeña B, Carballo I, Diaz-Peromingo JA, Vazquez-Agra N, Gonzalez-Quintela A and **Collaborators**. Being an internist throughout the world - same name, different training curricula. *Intern Med J* 50:235-238, 2020.
9. Bertsimas D, Lukin G, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B, Wiberg H, Gonzalez-Garcia S, Parra-Calderón CL, Robinson K, Schneider M, Stein B, Estirado A, A Beccara L, Canino R, Dal Bello M, Pezzetti F, Pan A; **Hellenic COVID-19 Study Group**. COVID-19 mortality risk assessment: An international multi-center study. *PLoS One* 15:e0243262, 2020.
10. Kausik K Ray, Bart Molemans, W Marieke Schoonen, Periklis Giovas, Sarah Bray, Gaia Kiru, Jennifer Murphy, Maciej Banach, Stefano De Servi, Dan Gaita, Ioanna Gouni-Berthold, G Kees Hovingh, Jacek J Jozwiak, J Wouter Jukema, Robert Gabor Kiss, Serge Kownator, Helle K Iversen, Vincent Maher, Luis Masana, Alexander Parkhomenko, André Peeters, Piers Clifford, Katarina Raslova, Peter Siostrzonek, Stefano Romeo, Dimitrios Tousoulis, Charalambos Vlachopoulos, Michal Vrablik, Alberico L Catapano, Neil R Poulter, Robert Kiss, Vincent MG Maher, Johan W Jukema, Jacek Jozwiak, Luis Masana, Oleksander Parkhomenko, Klaus Distelmaier, Thomas M Stulnig, Heinz Drexel, Christoph Ebenbichler, Robert Zweiker, Helmut Brath, Gudrun Zweiker, Luc Janssens, Philippe van de Borne, Attilio Leone, Robin Lemmens, Ann A Verhaegen, Marc De Meulemeester, Yohan Balthazar, Stéphane Heijmans, Yvan Calozet, Nicolas Paquot, Stéphane G Carlier, Dimitri Hemelsoet, Tomáš Velimský, Pavel Kolečkář, Ivana Kellnerová, Vladimír Cech, Jan Machač, Norbert Kral, Bohumil Seifert, Janka Škrobáková, Jiří Krupička, Jes S Lindholt, Christina Kruuse, Emmanuel Touzé, Joel Constans, JF Renucci, Philippe G Steg, Nabil Chakfe, Michel Farnier, Franck Bocarra, Grit Faulmann, Frank Schaper, Burkhard Manfras, Andreas Schäfer, Norbert Weiss, Frank Dellanna, Ulrike Schatz, Moses Elisaf, **George N Dalekos**, Daniel Berezki, Katalin Farkas, Martyin Tibor, Laszlo Fehér, Verica Kiss, Robert G Kiss, Laszlo Mark, Peter Harrington, Brendan McAdam, Brian PO O'Doherty, Patricia M O'Connor, David Molony, Maurizio Averna, Roberto Cemin, Fabio Verzini, Giuseppe Derosa, Salvatore Novo, Francesco Giorgino, Frank-Erik de Leeuw, Gerard K Hovingh, Pim van der Harst, Frank LJ Visseren, Jacek J Józwiak, Grzegorz Gajos, Monika Lukaszewicz, Jaroslaw D Kasprzak, Sławomir Kasperczyk, Jaroslaw Krawczyk, Anca Cerghizan, Noemi Pletea, Mircea I Popescu, Ionut Donoiu, Ion Ionescu, Boris Raska, Peter Bojcik, Jaime Masjuán-Vallejo, Esteban Jodar, Francisco Gomez-Delgado, Francisco J Tinahones, Alfonso Soto González, Jaime Garcia de Tena, Carlos Brotons, Anders Gottsäter, Ann Charlotte Laska, Åke Olsson, Carl-Johan Lindholm, Niclas Abrahamsson, Paul Ainsworth, Colin Bicknell, Ian C Chetter, Patrick Eavis, Paul Guyler, Timothy Hall, Robert J Hinchliffe, Peter Holt, Wayne M Turner, David Weston, David MacFarlane, Keith W Muir, David Julian A Scott, Matt Bown, Oleksandr Karpenko, Igor P Vakaliuk, Iurii Rudyk, Oleksii Korzh, Larysa M Yena, Kopytsya Mykola Pavlovych, Halyna Myshanych. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. *Eur J Prev Cardiol* 28:1279-1289, 2021.

11. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoué T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; **NN9931-4296 Investigators**. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. *N Engl J Med* 384:1113-1124, 2021.
12. Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, Eugen-Olsen J, Clerici M, Veas F, Chatellier G, Kaplanski G, Netea MG, Pontali E, Gattorno M, Cauchois R, Kooistra E, Kox M, Bandera A, Beaussier H, Mangioni D, Dagna L, van der Meer JWM, Giamarellos-Bourboulis EJ, Hayem G; **International Collaborative Group for Anakinra in COVID-19**. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. *Lancet Rheumatol* 3:e690-e697, 2021.
13. Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; **Global multi-stakeholder consensus on the redefinition of fatty liver disease**. Global multi-stakeholder endorsement of the MAFLD definition. *Lancet Gastroenterol Hepatol* 7:388-390, 2022.
14. Pérez-Galera S, Bravo-Ferrer JM, Paniagua M, Kostyanév T, de Kraker MEA, Feifel J, Sojo-Dorado J, Schotsman J, Cantón R, Daikos GL, Carevic B, Dragovac G, Tan LK, Raka L, Hristea A, Viale P, Akova M, Reguera JM, Valiente de Santis L, Torre-Cisneros J, Cano Á, Roilides E, Radulovic L, Kirakli C, Shaw E, Falagas ME, Pintado V, Goossens H, Bonten MJ, Gutiérrez-Gutiérrez B, Rodríguez-Baño J; **COMBACTE-CARE-EURECA Team**. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA). *EClinicalMedicine* 57:101871, 2023.
15. Paniagua-García M, Bravo-Ferrer JM, Pérez-Galera S, Kostyanév T, de Kraker MEA, Feifel J, Palacios-Baena ZR, Schotsman J, Cantón R, Daikos GL, Carevic B, Dragovac G, Tan LK, Raka L, Hristea A, Viale P, Akova M, Cano Á, Reguera JM, Bartoloni A, Florescu SA, Benea S, Bukarica L, Asensio Á, Korten V, Grundmann H, Goossens H, Bonten MJ, Gutiérrez-Gutiérrez B, Rodríguez-Baño J; **COMBACTE-CARE-EURECA team**. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA). *Clin Microbiol Infect* 30:223-230, 2024.
16. Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladrón de Guevara Cetina AL, Janczewska E, Zigmund E, Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londoño Hurtado MC, Bergheanu S, Yang K, Choi YJ, Crittenden DB, McWherter CA; **RESPONSE Study Group**. A phase 3 trial of seladelpar in primary biliary cholangitis. *N Engl J Med* 390:783-794, 2024.
17. Zhou H, Buetti N, Pérez-Galera S, Bravo-Ferrer J, Gutiérrez-Gutiérrez B, Paniagua-García M, Feifel J, Sauser J, Kostyanév T, Canton R, Tan LK, Basoulis D, Pintado V, Roilides E, Dragovac G, Torre-Cisneros J, Mediç D, Akova M, Goossens H, Bonten M, Harbarth S, Rodríguez-Baño J, De Kraker MEA; **COMBACTE- EURECA project team**. Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study. *J Antimicrob Chemother* 79:2132-2141, 2024.
18. Levy C, Trivedi PJ, Kowdley KV, Gordon SC, Bowlus CL, Londoño MC, Hirschfield GM, Gulamhusein A, Lawitz EJ, Vierling JM, Mayo MJ, Jacobson IM, Kremer AE, Corpechot C, Jones D, Buggisch P, Zhuo S, Proehl S, Heusner C, McWherter CA, Crittenden DB; ASSURE Investigators. Long-Term Efficacy and Safety of Selective PPAR δ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. *Am J Gastroenterol* 2026 (in press).

C. Chapters in Books and/or electronic publications

1. **G.N. Dalekos**. *Infections of Hepatotropic Viruses in Multitransfused Patients-Therapeutic approaches*. Syllabuses of the Meeting (Sickle Cell Disease and Thalassaemia), University of Ioannina, Medical School, Child Health Department, Ioannina, Greece, October 8-9, 1994, S-15.
2. E.V. Tsianos, **G.N. Dalekos**. *Primary Sclerosing Cholangitis*. In: Postgraduate Courses in Gastroenterology. University Studio Press, Thessaloniki, Greece, 1996, p. 203-212.
3. **G.N. Dalekos**, E.V. Tsianos. *Aetiopathogenesis of Inflammatory Bowel Disease*. In: Proceedings of the XVI Panhellenic Congress in Gastroenterology. Athens, Greece, 1996, p. 65-83.
4. E.V. Tsianos, **G.N. Dalekos**. *The Liver in Autoimmune Rheumatic Diseases*. In: Postgraduate Courses in Hepatology, Volume IV, Athens, Greece, 1996, p. 71-89.
5. **G.N. Dalekos**. *Immunologic Mechanisms in Inflammatory Bowel Disease*. In: Proceedings of the IIIrd Panhellenic Symposium on Inflammatory Bowel Disease. University Studio Press, Thessaloniki, Greece, 1997, p. 34-53.
6. E.V. Tsianos, **G.N. Dalekos**. *The Gastrointestinal Tract and the Liver in Pregnancy*. In: Textbook of Gynecology and Obstetrics by D. Lolis (Ed), G. Parisianos, Athens, Greece, 1998, p. 519-536.
7. **G.N. Dalekos**. *Laboratory Evaluation in the Diagnosis and Differential Diagnosis of Primary Biliary Cirrhosis and Autoimmune Hepatitis*. In: Proceedings of the 6th Panhellenic Congress of the Hellenic Association for the Study of the Liver, Thessaloniki, Greece, 1999, p. 124-135.
8. **G.N. Dalekos**. *Nucleoside Analogues in the Treatment of Chronic HBeAg (+) Hepatitis B*. In: Proceedings of the 25th Panhellenic Congress of Medicine, Athens, Greece, 1999, p. 57-65.
9. **G.N. Dalekos**. *Famciclovir for the Treatment of Chronic Hepatitis B*. In: Proceedings of the 1st Symposium in Hepatitis B, Athens, Greece, 2000, p. 122-128.
10. P. Obermayer-Straub, J. Perheentupa, S. Braun, A. Kayser, A. Barut, S. Loges, A. Harms, **G. Dalekos**, C.P. Strassburg, M.P. Manns. *Hepatic Autoantigens in Patients with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy*. In: Autoantigens and Autoantibodies: Diagnostic Tools and Clues to Understanding Autoimmunity, Conrad K, Humbel R-L, Meurer M, Shoenfeld, Tan EM (Eds.), Pabst Science Publishers, 2000.
11. **G.N. Dalekos**, E. Makri. *Epidemiological, Clinical and Laboratory Characteristics – Diagnostic Criteria of Autoimmune Hepatitis*. In: Proceedings of the Postgraduate Course in Hepatology, Athens, Greece, 2000, p. 68-82.
12. **G.N. Dalekos**. *Current Aspects in Autoimmune Hepatitis*. In: Proceedings of the 7th Panhellenic Congress of the Hellenic Association for the Study of the Liver, Athens, Greece, 2001, p. 78-92.
13. **G.N. Dalekos**. *Portal Hypertension: Pathophysiology and Pathogenesis*. In: Postgraduate Courses in Gastroenterology, University Studio Press, Thessaloniki, Greece, 2001, p. 46-55.
14. **G.N. Dalekos**, C. Liaskos, K. Zachou, E. Makri, M. Venizelos. *Management of asymptomatic patients with elevated liver function tests*. Hellenic Center for the Control of Infectious Diseases (Ed), Hellenic Ministry of Health, 2001.
15. **G.N. Dalekos**. *Autoimmune hepatitis: Pathogenesis, Diagnosis, clinical manifestations and treatment*. In: Postgraduate Courses in Pathology, Volcano press, Athens, 2001, p. 42-49.
16. **G.N. Dalekos**. *Cytokines in Inflammatory Bowel Disease*. In: Inflammatory Bowel Disease: The Greek Experience, edited by the Heraklion (Creta) Medical School, Heraklion, Greece, 2001, p.87-100.

17. **G.N. Dalekos.** *Liver and lung.* In: Proceedings of the Postgraduate Course in Hepatology, University Studio Press, Thessaloniki, Greece, 2001, p. 24-39.
18. **G.N. Dalekos,** G. Papadamou. *Treatment of chronic hepatitis C.* In: Proceedings of the Postgraduate Course in Hepatology, University Studio Press, Athens, 2002, p. 133-146.
19. **G.N. Dalekos.** *Autoantibodies in the diagnosis of the diseases of the gastrointestinal tract and the liver.* In: Proceedings of the 28th Panhellenic Congress of Medicine, Athens, Greece, 2002, p. 1-14.
20. **G.N. Dalekos.** *Cytokines in Medicine: From Bench to Bedside.* In: Postgraduate Courses in Surgery. Athens, Greece, 2002, p. 35-51.
21. **G.N. Dalekos.** *Decision Making in the Treatment of Difficult Cases of Chronic Hepatitis C Virus Infection.* In: Proceedings of the 8th Symposium on Hepatitis C, by S.I. Hatziyannis (Ed), P.C. Paschalidis, Athens, Greece, 2003, p. 365-382.
22. **G.N. Dalekos.** *Autoantibodies in diseases of the liver and the alimentary tract.* In: Diagnostic Immunology edited by A.E. Germanis, Larissa, Greece, 2002, p. 1-13.
23. **G.N. Dalekos.** *Hepatitis B and C in Greece: an update from the Hellenic Center for Disease Control and Prevention.* In: Proceedings of the 9th Symposium on Hepatitis C, by S.I. Hatziyannis (Ed), P.C. Paschalidis, Athens, Greece, 2004, p. 18-26.
24. **G.N. Dalekos.** *Contribution of molecular virology in diagnosis and treatment of viral hepatitis.* In: Proceedings of the Symposium of the Hellenic Association for the Study of the Liver on Viral Hepatitis, Nicosia, Cyprus, Syllabuses of the Meeting, May 7-8, 2004, p. 18-24.
25. **G.N. Dalekos.** *The utility of molecular virology in the clinical management of chronic hepatitis C.* In: Proceedings of the 24th Panhellenic Congress of Gastroenterology, November 6-9, 2004, p.23-27.
26. G. Kitis, E. Manesis, M. Deutsch, B. Papadimitropoulos, S. Savas, G. Germanidis, J. Goulis, and **G.N. Dalekos.** *Decision making in hepatitis C.* In: Proceedings of the 9th Symposium on Hepatitis B and C, by S.I. Hatziyannis (Ed), ALFAPAK Ltd, Athens, 2005, p. 129-138.
27. **G.N. Dalekos.** *Autoimmune hepatitis: Impact of symptoms and cirrhosis on the natural history and outcome of the disease.* In: News in Rheumatology, October/November/December 2005, p. 29-30.
28. **G.N. Dalekos.** *Autoimmune liver diseases: Differential diagnosis and treatment.* In: Proceedings of the Educational Seminar of the Hellenic Association of Research and Education in Primary Care, Plastira lake, Karditsa, 2005, p. 85-102.
29. **G.N. Dalekos.** *Autoimmune liver diseases.* In: Proceedings of the 20th Postgraduate course of the Hellenic Association of Immunology, Athens, October 13-15, 2005, p.13-27.
30. E. Petinaki and **G.N. Dalekos.** *Molecular methods as tools for the diagnosis of bacterial infections: useful or useless?* In: R.M. Mohan (Ed). *Research Advances in Microbiology*, Global Research Network, 2006, p. 23-31.
31. **G.N. Dalekos.** «*Hereditary and Metabolic Diseases of the Liver*». Chapter 154, Cecil, Internal Medicine, 18th Greek edition, Mendor Editions, Athens, 2010, p. 1122-1128.
32. **G.N. Dalekos.** «*Bacterial, Parasitic, Fungal and Granulomatous Diseases of the Liver*». Chapter 155, Cecil, Internal Medicine, 18th Greek edition, Mendor Editions, Athens, 2010, p. 1128-1135.
33. **G.N. Dalekos.** «*Alcoholic and non-Alcoholic Steatohepatitis*». Chapter 156, Cecil, Internal Medicine, 18th Greek edition, Mendor Editions, Athens, 2010, p. 1135-1139.

34. **G.N. Dalekos**. « *Diseases of the Gall Bladder and Biliary Tract*». Chapter 159, Cecil, Internal Medicine, 18th Greek edition, Mendor Editions, Athens, 2010, p. 1152-1161.
35. E. Petinaki and **G.N. Dalekos**. *Cardiobacterium*. In: Dongyou Liu (Ed). Molecular detection of human bacterial pathogens, Taylor & Francis CRC Press, Chapter 70, 2011, p.811-814.
36. **G.N. Dalekos**. *Autoimmune hepatitis: Clinical and laboratory aspects*. In: Hellenic Association for the Study of Liver (Ed). Clinical Hepatology, University Studio Press, Thessaloniki, 2011, p. 303-314.
37. **G.N. Dalekos**. *Liver and autoimmunity*. In: Proceedings of the 22th Year of Internal Medicine Days, Third Department of Internal Medicine of the Medical School of the University of Athens, Athens, April 5-6, 2013, chapter of invited speakers on CD (7 pages).
38. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Clinical Practice Guidelines for the Management of Hepatitis B Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, 2013 (*online edition, www.keelpno.gr*).
39. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, 2013 (*online edition, www.keelpno.gr*).
40. **G.N. Dalekos**. *Autoimmune hepatitis and primary biliary cirrhosis: Models of clinical and laboratory challenges for the discovery of amazing diseases*. In: GM Chatzigeorgiou and Medical Editions Konstantaras (Eds). Honorary Volume to Prof. A. Papadimitriou, Athens, Chapter 32, 2013, p. 181-187.
41. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Updated Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, November 2014 (*online edition, www.keelpno.gr*).
42. **G.N. Dalekos**, K. Zachou, N.K. Gatselis, G.K. Koukoulis, J. Koskinas. *Clinical Practice Guidelines of the Hellenic Association for the Study of the Liver (HASL) on the Diagnosis and Management of Autoimmune Hepatitis*. HASL (ed.), Athens, April 2015 (*online edition, www.eemh.gr*).
43. J. Vlachogiannakos, G.V. Papatheodoridis, **G.N. Dalekos**, A. Alexopoulou, Ch. Triantos, E. Chologitas, J. Koskinas. *Clinical Practice Guidelines of the Hellenic Association for the Study of the Liver (HASL) for the Prevention and Treatment of HBV Reactivation during or after Immunosuppressive Therapy*. HASL (ed.), Athens, June 2015 (*online edition, www.eemh.gr*).
44. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *First revision on Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, December 2015 (*online edition, www.keelpno.gr*).
45. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Second revision on Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, April 2016 (*online edition, www.keelpno.gr*).

46. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Clinical Practice Guidelines of the Hellenic Association for the Study of the Liver (HASL) on the Use of New Antivirals in Chronic Viral Hepatitis C*. HASL (ed.), Athens, January 2017 (online edition, www.eemh.gr).
47. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Third revision on Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, February 2017 (online edition, www.keelpno.gr).
48. **G.N. Dalekos**, E.I. Rigopoulou. “Gastrointestinal, Liver and Biliary Tract System” (Chapter 9, Chamberlain’s Clinical Examination and Diagnosis, Greek Edition, P.C. Paschalidis Editions, Athens, 2017, p. 166-205).
49. **G.N. Dalekos**, E.I. Rigopoulou. “Cirrhosis of the Liver and its Complications” (Chapter 43, Greek Edition Andreoli & Carpenter’s Cecil Essentials of Medicine, P.C. Paschalidis Editions, Athens, 2017, p. 427-436).
50. **G.N. Dalekos**, E.I. Rigopoulou. “Diseases of the gallbladder and the biliary tree” (Chapter 44, Greek Edition Andreoli & Carpenter’s Cecil Essentials of Medicine, P.C. Paschalidis Editions, Athens, 2017, p. 437-442).
51. **G.N. Dalekos**, K. Makaritsis. “Vascular diseases of the brain” (Chapter 116, Greek Edition Andreoli & Carpenter’s Cecil Essentials of Medicine, P.C. Paschalidis Editions, Athens, 2017, p. 941-952).
52. **G.N. Dalekos**, K. Makaritsis. “Traumatic injury of brain and spinal cord” (Chapter 117, Greek Edition Andreoli & Carpenter’s Cecil Essentials of Medicine, P.C. Paschalidis Editions, Athens, 2017, p. 953-957).
53. **G.N. Dalekos**, I. Goulis, S. Manolakopoulos, V. Papaevangelou, G. Papatheodoridis. *Clinical Practice Guidelines for the Management of Hepatitis B Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, December 2017 (online edition, www.keelpno.gr).
54. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Forth revision on Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, February 2019 (online edition, www.keelpno.gr).
55. **G.N. Dalekos**. *Autoimmune hepatitis*. In: Hellenic Association for the Study of Liver (Ed). *Clinical Hepatology, Focus on Health Ltd*, Athens, 2019, p. 465-477.
56. **G.N. Dalekos** and N.K. Gatselis. Primary sclerosing cholangitis – Autoimmune hepatitis overlap. In: M. Eric Gershwin, John M. Vierling, Atsushi Tanaka, and Michael P. Manns (Eds). *Liver Immunology: Principles and Practice, Springer International Publishing, Cham, Chapter 23, pp. 359-373, 2020*.
57. G. Papatheodoridis, **G.N. Dalekos**. *Fifth revision on Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the National Public Health Organization, Athens, July 2021 (online edition, www.eody.gov.gr).
58. **G.N. Dalekos** and N.K. Gatselis: Autoimmune hepatitis. In: *Modern Gastroenterology, Athens, Medical Editions ‘Neon’ (Ed.), 2022, p. 563-572*.
59. **G.N. Dalekos** and K. Zachou: Primary biliary cholangitis. In: *Modern Gastroenterology, Athens, Medical Editions ‘Neon’ (Ed.), 2022, p. 573-582*.

60. **Editorial Committee.** Guidelines for the Diagnosis and Management of Sepsis, Hellenic Study Group of Sepsis, *Manual of the Hellenic Institute for the Study of Sepsis, Athens, 2023* (online edition, <https://hssg.sepsis.gr/el/bulletins-on-sepsis-2/>).
61. **G.N. Dalekos.** “Abdomen” (Chapter 19, 6th Greek Edition Bates’ Guide to Physical Examination and History Taking, P.C. Paschalidis Editions, Broken Hill Publishers Ltd, Nicosia, Cyprus, 2024, p. 491-538).
62. **G.N. Dalekos.** “Nervous System” (Chapter 24, 6th Greek Edition Bates’ Guide to Physical Examination and History Taking, P.C. Paschalidis Editions, Broken Hill Publishers Ltd, Nicosia, Cyprus, 2024, p. 661-728).
63. **G.N. Dalekos.** “Older Adult” (Chapter 27, 6th Greek Edition Bates’ Guide to Physical Examination and History Taking, P.C. Paschalidis Editions, Broken Hill Publishers Ltd, Nicosia, Cyprus, 2024, p. 871-905).
64. G. Papatheodoridis, I. Goulis, S. Manolakopoulos, **G.N. Dalekos.** *Clinical Practice Guidelines for the Management of patients with Hepatitis B and D Virus Infection.* Special edition by the National Public Health Organization, Athens, July 2024 (online edition, www.eody.gov.gr).
65. **G.N. Dalekos.** “Managing clinical encounters with patients” (Chapter 1, 14th Greek Edition Macleod’s Clinical examination, Scientific Publications Parisianou AE, Athens, 2024, p. 3-9).
66. **G.N. Dalekos.** “General aspects of history taking” (Chapter 2, 14th Greek Edition Macleod’s Clinical examination, Scientific Publications Parisianou AE, Athens, 2024, p. 11-23).
67. **G.N. Dalekos.** “General aspects of examination” (Chapter 3, 14th Greek Edition Macleod’s Clinical examination, Scientific Publications Parisianou AE, Athens, 2024, p. 25-47).
68. **General Editing of the 2nd Greek Edition Step-Up to Medicine, Konstantaras Ed, Athens, 2025.**

D. Papers in Greek Medical Journals

1. **G.N. Dalekos,** P. Aggelis, K. Papadopoulos, D. Perakis. Fatal acute renal failure due to acute rhabdomyolysis in an heroin addict. *Psychiatry Letters* 24: 108-111, 1988.
2. **G.N. Dalekos,** K. Papadopoulos. Heatstroke: Current aspects of its pathophysiology, complications, treatment and prevention. *Iatriki* 56: 426-436, 1989.
3. **G.N. Dalekos,** P. Aggelis, D. Christodoulou, K. Katsikis. Dermatomyositis as first manifestation of pancreatic cancer. *Iatriki* 57: 74-77, 1990.
4. **G.N. Dalekos,** D. Kairis, E. Drimilis. Concentrations of magnesium in the sera of patients with delirium tremens due to alcohol withdrawal. *Psychiatry Letters* 33: 144-148, 1991.
5. **G.N. Dalekos.** Prostaglandins: Their role in cytoprotection and in cirrhosis of the liver. *Iatriki* 60: 231-242, 1991.
6. **G.N. Dalekos,** D. Kairis, P. Aggelis, K. Papadopoulos. Concentrations of selenium in the sera of patients with delirium tremens due to alcohol withdrawal. *Arch Hell Med* 8: 120-123, 1991.
7. **G.N. Dalekos,** C.N. Masalas, M. Merkouropoulos, E.V. Tsianos. Epidemiology of ulcerative colitis in the area of Epirus, Greece. *Hell J Gastroenterol* 4: 283-288, 1991.
8. K. Masalas, **G.N. Dalekos,** M. Merkouropoulos, E.V. Tsianos. The constipation as a presenting symptom at the first attack of ulcerative colitis. *Arch Hell Med* 9: 201-204, 1992.

9. **G.N. Dalekos**, M. Merkouropoulos, A. Mavridis, E. Zervou, K. Masalas, E.V. Tsianos. Frequency of hepatitis C in heroin addicts. *Iatriki* 63: 51-54, 1993.
10. **G.N. Dalekos**, E.V. Tsianos. Hepato-pulmonary syndrome: Is this a functional lung failure in liver cirrhosis? *Iatriki* 63: 449-458, 1993.
11. **G.N. Dalekos**, M. Stamouli, P. Aggelis. The glycosylated haemoglobin A₁ (HbA₁) in chronic heroin addicts during the withdrawal stage. *Psychiatry Letters* 42: 140-142, 1993.
12. **G.N. Dalekos**, M.N. Manoussakis, M.C. Merkouropoulos. E.V. Tsianos. Autoimmunity and cellular immune activation before and after α -interferon administration in Greek patients with chronic viral hepatitis. A preliminary study. *Hell J Gastroenterol* 6: 166-171, 1993.
13. **G.N. Dalekos**, M. Stamouli, E. Drimilis, G. Solias. Heroin as a cause of high mean cell volume. *Iatriki* 64: 637-640, 1993.
14. **G.N. Dalekos**, G.C. Liapi, P. Dallas, D. Stefanou, M. Elisaf. Hepatic dysfunction as first manifestation of renal cell carcinoma. A case report and review of the literature. *Hell J Gastroenterol* 6: 267-271, 1993.
15. L. Christou, **G.N. Dalekos**, E.V. Tsianos, K. Bourantas. Brucellosis and ascites. *Iatriki* 67: 77-79, 1995.
16. **G.N. Dalekos**, D.I. Anastasopoulos, M.H. Merkouropoulos, E.V. Tsianos. Choreic movements as neurologic manifestation of ulcerative colitis. Reality or coincidence? *Hell J Gastroenterol* 8: 75-77, 1995.
17. **G.N. Dalekos**, M. Elisaf, E. Bairaktari, N. Papagalani, K.C. Siamopoulos. Interleukin-1 β in the systemic circulation of patients with familial hypercholesterolemia and essential hypertension: Additional risk factor for atherogenesis in hypertensive patients? *Arterial Hypertension* 4: 53-62, 1995.
18. **G.N. Dalekos**, E. Zervou, F. Karabini, H. Liapis, K. Ziciadis, E.V. Tsianos. Frequency of chronic hepatitis C virus (HCV) infection among individuals with indeterminate results after RIBA-II HCV test: A prospective study. Proceedings of the Second Symposium on Hepatitis C, by S.I. Hadziyannis (Ed), Athens, P. Paschalides (Pub.), 1995, p. 175-179.
19. **G.N. Dalekos**, E. Zervou, E.V. Tsianos. IgM antibodies to HCV in chronic active hepatitis C in north-western Greece. Solution or more questions? Proceedings of the Second Symposium on Hepatitis C, by S.I. Hadziyannis (Ed), Athens, P. Paschalides (Pub.), 1995, p. 180-183.
20. **G.N. Dalekos**, E.V. Tsianos. High concentrations of soluble interleukin-2 receptors and interleukin-6 in active ulcerative colitis. *Hell J Gastroenterol* 8: 319-327, 1995.
21. **G.N. Dalekos**, A. Vlachopoulos, E.V. Tsianos. The epidemiology of inflammatory bowel disease in Ioannina. *Iatriki* 69: 66-74, 1996.
22. **G.N. Dalekos**, E.V. Tsianos. Cytokines in inflammatory bowel disease. *Hell J Gastroenterol (Letter)*, 9: 75-76, 1996.
23. **G.N. Dalekos**, E. Zervou, E.V. Tsianos. Prevalence of anti-HCV antibodies in healthy individuals, chronic alcoholics and refugees from Albania in Epirus region-Greece Proceedings of the Third Symposium on Hepatitis C, by S.I. Hadziyannis (Ed), Athens, Paschalides, 1996, p. 157-163.
24. **G.N. Dalekos**, E. Zervou, D.S. Boumba, A. Gerolymatou, E.V. Tsianos. Frequency of viraemia due to hepatitis C virus (HCV) among individuals with indeterminate results after RIBA-II HCV test: A preliminary study. *Hell J Gastroenterol* 9: 160-166, 1996.
25. E. Ioachim, **G.N. Dalekos**, E.V. Tsianos, E. Demou, A.C. Goussia, N.J. Agnantis. Aberrant HLA-DR expression and lymphocyte subsets in inflammatory bowel disease: an

- immunohistological study on frozen and paraffin sections. *Hell J Gastroenterol* 9: 332-338, 1996.
26. E.V. Tsianos, **G.N. Dalekos**. Inflammatory bowel disease (I). Genetic factors and inflammatory mediators. *Iatriki* 71: 25-30, 1997.
 27. **G.N. Dalekos**, E.V. Tsianos. Inflammatory bowel disease (II). Immunologic factors. *Iatriki* 71: 134-142, 1997.
 28. **G.N. Dalekos**, M. Elisaf, E. Bairaktari, N. Papagalanis, O. Tsolas, K.C. Siamopoulos. Interleukin-1 β and essential hypertension. *Iatriki* 71: 573-580, 1997.
 29. **G.N. Dalekos**, D. Boumba, E. Zervou, D. Christodoulou, K. Kistis, E.V. Tsianos. Equivalence (correlation) and clinical significance of serotypes and genotypes of hepatitis C virus: A preliminary study. Proceedings of the Fourth Symposium on Hepatitis C, by S.I. Hatziyannis (Ed), PRESS CONCEPT N. Heraklion, Athens, 1997, p. 183-188.
 30. **G.N. Dalekos**, D. Christodoulou, K.G. Kistis, A. Gerolymatou, E.V. Tsianos. The role of interleukin-7 in the induction of the inflammatory cascade in ulcerative colitis patients. More questions than evidence. *Hell J Gastroenterol* 10: 51-53, 1997.
 31. E. Zervou, **G.N. Dalekos**, D. Christodoulou, E.V. Tsianos. Prevalence of HCV serotype in Epirus by using an enzyme immunoassay. *Acta Microbiologica Hellenica* 42: 206-209, 1997.
 32. E. Zervou, **G.N. Dalekos**, S. Alfantaki, E. Galanakis, P. Lapatsanis, E.V. Tsianos. Prevalence of anti-HAV IgG antibodies in pediatric population and blood donors in N.W. Greece. *Acta Microbiologica Hellenica* 42: 218-222, 1997.
 33. **G.N. Dalekos**, E. Zervou, M. Elisaf, D.S. Boumba, K. Katopodis, G. Sferopoulos, K.C. Siamopoulos, E.V. Tsianos. Increased frequency of HGV-RNA detection in hemodialysis patients negative for other blood-borne viruses. *Hell J Gastroenterol* 10: 203-209, 1997.
 34. E. Zervou, **G.N. Dalekos**, D. Christodoulou, A. Gerodemou, E.V. Tsianos. Correlation between anti-HBc positivity and HBV viraemia. *Iatriki*, 74: 400-403, 1998
 35. E. Zervou, **G.N. Dalekos**, A. Gerolymatou, D. Boumba, E.V. Tsianos. Prevalence of hepatitis B and C markers in blood donors in Epirus. *Acta Microbiologica Hellenica* 43: 482-489, 1998
 36. **G.N. Dalekos**. Molecularly defined target-autoantigens as tools for the diagnosis, differential diagnosis and the study of aetiopathogenesis of autoimmune liver diseases. *Iatriki* 75: 408-418, 1999.
 37. Ch. Liaskos, **G.N. Dalekos**. New concepts on the epidemiology and the clinical and laboratory markers for the diagnosis and differential diagnosis of autoimmune hepatitis. *Iatriki* 78: 233-243, 2000.
 38. E. Zervou, P. Georgitsi, M. Tzoufi, G.N. Dalekos, M. Pontikaki, K. Zisiadis, E.V. Tsianos. Prevalence and clinical characteristics of HGV infection in blood donors and patients with thalassemia major. *Acta Microbiologica Hellenica* 46: 167-171, 2001.
 39. K. Zachou, Ch. Liaskos, E. Makri, G. Papadamou, M. Kardasi, A. Pliaka, F. Gerovasilis, **G.N. Dalekos**. Anticardiolipin antibodies (a-CLAbs) are not b2-GPI-dependent (non-thrombogenic a-CLAbs): preliminary results in 107 HCV patients from central Greece. In: Proceedings of the 1st Symposium on Hepatitis B and C 2001-02, by S.I. Hatziyannis (Ed), Medical press P.C. Paschalidis, Athens, 2003, p. 392-402.
 40. S. Georgiadou, K. Zachou, Ch. Liaskos, N. Gatselis, A. Tsikrikoni, F. Gerovasilis, M. Kardasi, E. Makri, G. Papadamou and **G.N. Dalekos**. Increased prevalence of occult hepatitis B virus infection in patients with chronic hepatitis C: absence of association with more severe liver disease. In: Proceedings of the 2nd Symposium on Hepatitis B and C 2003, by S.I. Hatziyannis (Ed), Medical press P.C. Paschalidis, Athens, 2004, σ . 304-315.

41. **G.N. Dalekos**. Autoantibodies and autoantigens associated with autoimmune hepatitis and viruses-induced autoimmune response: significant tools in clinical practice and in the study of pathogenesis of autoimmune hepatic diseases. *Archives of Hellenic Medicine* 21:502-527, 2004
42. E.I. Rigopoulou **and G.N. Dalekos**. Current treatment of HBV and HCV infections. *Drugs & Prescription* 11:16-24, 2005.
43. M. Speletas, F. Kalala, **G. Dalekos**. Continuing medical education. Clinical Immunology quiz- Case 1. *Archives of Hellenic Medicine* 24:398, 2007.
44. **G. Dalekos**. Autoimmune liver diseases: Aetiopathogenesis and diagnosis. *Anosia* 8:59-65, 2012.
45. N. Gatselis, **G.N. Dalekos**. Autoimmune hepatitis, one disease with many faces: Part I. *Hell J Med* 101:4-30, 2014.
46. K. Zachou, **G.N. Dalekos**. Autoimmune hepatitis, one disease with many faces: Part II. *Hell J Med* 102:58-73, 2014.
47. P. Arvaniti, Koukoulis GK, **Dalekos GN**, Zachou K. Postinfantile giant cell hepatitis with features of acute severe autoimmune hepatitis probably triggered by diclofenac in a patient with primary myelofibrosis. *Hell J Med* 120:238-245, 2018.

Note

1. I have also presented/participated 347 and 485 abstracts in Greek and International Congresses, respectively.
2. I have acted as faculty member, chairperson, moderator and/or speaker in several local (Greek) and International Congresses like EASL, UEGW, AASLD, APASL, EFIM, IAIHG, European Society of Hypertension, European and Mediterranean League Against Thrombotic Diseases, and International Immunology Congresses (n=646 in total).